



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Board Meeting

August 14, 2013

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Board Meeting

August 14, 2013

0.	Agenda	002
1 – A.	Meeting Notice & Arrangements	004
1 – B.	Acronyms	005
2.	Invocation & Pledge of Allegiance	
3.	Quorum Call	
4.	Call for Additional Agenda Items	
5.	Consideration of Minutes from Previous Meetings ~ May 29, 2013	009
6.	Report on Action Items	
7.	Confirmation of Acts	
8.	Opportunity for Public Comment	
9.	Committee Reports	
A.	Finance – Mr. Pitre	026
	• Final Report for Fiscal Year 2012-2013	027
	• Proposed Budget Amendment No. 1 for Fiscal Year 2013-2014	049
B.	Application Review – Ms. Melancon	
	• Case No. 13-0147 – Fred’s Pharmacy No. 2679	058
C.	Reciprocity – Ms. Hall	061
D.	Violations – Mr. Bond	
E.	Impairment – Mr. Rabb	063
F.	Reinstatement – Ms. Melancon	064
G.	Tripartite – Mr. Burch	
H.	Regulation Revision – Mr. McKay	
	• Consideration of Comments & Testimony from May 30 Public Hearing Re <u>Regulatory Project 2013-1 ~ Compounding for Prescriber Use</u>	069
I.	Executive Committee – Mr. Aron	082
	• Consideration of Committee Recommendations re Policies & Procedures	
	> P&P II.B.7 – Dress Code	083
	> P&P II.C.2 – Employment	085
	> P&P II.C.3 – Employment Benefits	088
	> P&P II.C.5 – Office Hours	091
	> P&P II.C.6 – Attendance	093
	> P&P II.C.7 – Performance Planning & Review	096
	> P&P II.C.9 – Holidays	101
	> P&P II.C.10 – Layoffs & Layoff Avoidance Measures	103
	> P&P III.B – Document Depository Program	104
	• Consideration of Proposed Amendment to Existing Contract with NexLearn	106
10.	Staff Reports	
J.	Prescription Monitoring Program – Mr. Fontenot	
	• Quarterly Report	107
	• Requests for Waivers from Reporting to PMP	118
K.	General Counsel – Mr. Finalet	
L.	Executive Director – Mr. Broussard	
	• Narrative Report	123
	• Census Report – Compliance Division	128
	• Census Report – Credentials Division	129

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

	• Credentials Division – New Licensure Activity Report	134
	• Credentials Division – Pending Applications Report	135
	• Credentials Division – Exceptions Report	136
	• Annual Statistical Report for Compliance Division	139
	• Annual Report for 2013	141
	• Examination Report – MPJE	151
	• Examination Report – NAPLEX	175
	• Examination Report – PTCB	199
	• Louisiana Compliance Questionnaire for 2013	204
	• Roster & Inventory of Agency Publications	213
	• Final Legislative Brief for 2013 Legislature	217
	• Roster of Accredited Schools of Pharmacy	220
11.	Request for Opinion: Addition of Medications by Non-Pharmacy Practitioners to Parenteral Preparations Previously Compounded by Pharmacies (BioScrip®)	225
12.	Announcements	238
13.	Recess	

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



MEMORANDUM

To: Board Members & Staff
From: Malcolm Broussard
Date: August 7, 2013
Re: Board Meeting Schedule & Arrangements

The next quarterly meeting of the Board and certain of its committees will be held at the Board office on August 13-15, 2013. The schedule of events is as follows:

Tuesday, August 13, 2013

0800	Finance Committee	<i>Boardroom</i>
0900	Reinstatement Committee	<i>Boardroom</i>
1200	Committee Luncheon	<i>Boardroom</i>
1300	Impairment Committee	<i>Boardroom</i>
1700 (est.)	Executive Committee	<i>Boardroom</i>

Wednesday, August 14, 2013

0700	Reciprocity Committee	<i>Boardroom</i>
1000	Board Meeting	<i>Boardroom</i>
1200	Board Luncheon	<i>Boardroom</i>

Thursday, August 15, 2013

0830	Administrative Hearing	<i>Boardroom</i>
------	------------------------	------------------

You should have already received your hotel reservation confirmations from Ms. Kelley Villeneuve via email. If you have any questions about those arrangements, please contact her directly at kvilleneuve@pharmacy.la.gov or 225.925.6498.

Most of your meeting materials have been posted in the *Boardroom Library*. You may enter the library by visiting our website at www.pharmacy.la.gov, selecting the *Login* link on the horizontal menu bar, and entering your log-in and password information. At the *Boardroom Library Lobby*, select the link for the *Main Reading Room*, and then the 08-14-2013 link for the board meeting. For those of you with committee meetings that week, your meeting materials will be posted in the applicable committee reading room, also accessible from the *Boardroom Library Lobby*. As we update the files in the reading rooms, we will advise you accordingly.

In the event you experience any difficulty accessing this material, please let me know so that we can arrange delivery of these documents to you by some other means. During the meetings, we plan to use the electronic meeting binders instead of the printed binders.

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals
DME	durable medical equipment

DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners
LSBN	Louisiana State Board of Nursing

LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDPCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America
PCMA	Pharmaceutical Care Management Association

PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
WHO	World Health Organization



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Minutes

Regular Meeting

Wednesday, May 29, 2013 at 10:00 a.m.

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i>Wednesday, May 29, 2013</i>		
1.	Call to Order	3
2.	Invocation & Pledge of Allegiance	3
3.	Quorum Call	3
4.	Call for Additional Agenda Items	4
5.	Consideration of Minutes	4
6.	Report on Action Items	4
7.	Confirmation of Acts	4
8.	Opportunity for Public Comment	5
9.	Special Orders of the Day	5
10.	Committee Reports	
	A. Finance	5
	B. Application Review	5
	C. Reciprocity	10
	D. Violations	6
	E. Impairment	7
	F. Reinstatement	8
	G. Tripartite	9
	H. Regulation Revision	10
	I. Executive	11
11.	Staff Reports	
	J. Prescription Monitoring Program	12
	K. General Counsel	13
	L. Executive Director	16
12.	Request for Opinion – Remote Medication Dispensing Device (West Jefferson Medical Center)	16
13.	Announcements	17
14.	Adjourn	17

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, May 29, 2013 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted.

1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 10:30 a.m.

2. Invocation & Pledge

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Mr. Don Resweber then led the group in the recitation of the Pledge of Allegiance.

3. Quorum Call

Mr. Aron then called upon the Secretary, Mr. Bond, to call the roll.

Members Present:

Mr. Joseph L. Adams
Mr. Carl W. Aron
Mr. Brian A. Bond
Mr. Clovis S. Burch
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina
Mr. Marty R. McKay
Mr. Blake P. Pitre
Mr. T. Morris Rabb
Ms. Pamela G. Reed
Mr. Don L. Resweber
Dr. Deborah H. Simonson
Mr. Richard A. Soileau
Mr. Rhonny K. Valentine

Members Absent:

Mr. Ryan M. Dartez
Ms. Chris B. Melancon
Mr. Ronald E. Moore

Staff Present:

Mr. Malcolm J. Broussard, Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. M. Joseph Fontenot, Assistant Executive Director
Mr. Cary D. Aaron, Pharmacist Compliance Officer
Mr. Rayland M. Trisler, Pharmacist Compliance Officer

Guests:

Dr. Lois Anderson – LSU Medical Center, Shreveport
Mr. Larry Anderson
Mr. Kenneth Doucet – Brookshire Bros. Pharmacies

Ms. Rosamaend Oglesbee – CVS Pharmacies
Ms. Kris Hutchinson – LIPA
Mr. John O. LeTard
Mr. Daniel Duggan – The Zachary Post
Mr. Jerry P. Dugas
Ms. Gail Leleux
Mr. Leroy Leleux
Mr. Danny Jackson – LSU Health Care Services Division
Ms. Mary Staples – NACDS
Mr. Mitch Ward – Target Pharmacies
Mr. Korey Patty – LIPA
Ms. Ava B. Williams
Mr. Steven Williams
Mr. Carl Gulino –Walmart Pharmacies
Ms. Crystal Carter – LPA
Ms. Leah Michael – La. Office of Public Health Pharmacy
Mr. Randal Johnson – LIPA

Mr. Bond certified that 14 of the 17 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items

Mr. Aron asked if there were any additional agenda items, but none were offered. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of adjusting the sequence of various reports or guests. There were no objections to that request.

5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting and Administrative Hearing on March 6-7, 2013, both of which were held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. Hearing no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

6. Report on Action Items

Mr. Broussard provided an update on all the legislative proposals then in process, as well as the execution of the contracts and agreements approved at the prior meeting.

7. Confirmation of Acts

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. McKay moved,

Resolved, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since March 7, 2013

are approved, adopted, and ratified by the entire Board.
The motion was adopted after a unanimous vote in the affirmative.

8. Opportunity for Public Comment

Mr. Aron reminded the members and guests that Act 850 of the 2010 Legislature requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and no comments were offered.

9. Special Orders of the Day

Mr. Aron informed the members that new licenses were issued to 122 pharmacists in 1963 and that 35 of those pharmacists had qualified for their Gold Certificate this year, celebrating 50 years of licensure. Of that number, five pharmacists requested the presentation of their certificate at the May meeting of the Board. Mr. Aron then presented Gold Certificates to the following pharmacists:

- PST.008722 – Thomas Rundell Bryan
- PST.008738 – Jerry Paul Dugas
- PST.008755 – Julia LeBlanc Bryan
- PST.008756 – Gail Clarkston Leleux
- PST.008757 – John Odom LeTard

Mr. Aron expressed the Board's appreciation for their collective service to the citizens of Louisiana. The members and guests congratulated each recipient with a standing ovation

10. Committee Reports

A. Finance Committee

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre directed the members to the interim financial report for the current fiscal year. He reviewed the different statements, responded to questions from the members, and then tendered the report for information only since it required no action by the Board.

Finally, Mr. Pitre expressed his appreciation to the other members of the committee for their ongoing efforts.

B. Application Review Committee

In the absence of the committee chair, Mr. Aron called upon Mr. Richard Soileau for the committee report. He reported the committee met on May 9 to consider three referrals from the staff. After interviews and deliberation, the committee approved the issuance of credentials to one of the applicants and deferred consideration of another applicant until a pending criminal matter was concluded. He then referred the following matter to the Board.

Peggy Ann Robins – Applicant for PTC Registration Mr. Soileau moved to deny the application for the registration and refuse to issue the credential. The motion was adopted after a unanimous vote in the affirmative. The Board denied the application and refused to issue the credential.

Mr. Soileau closed his report with appreciation for the other committee members participating in the meeting earlier that month.

Mr. Aron noted the report from the Reciprocity Committee was still under development so he temporarily passed over that agenda item.

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on March 13 to consider their posted agenda which included two pharmacists, six pharmacy technicians, and one pharmacy permit. From the committee deliberations at that conference, Mr. Bond presented the following proposed consent agreements for the Board's consideration.

David Wayne Spears (PST.010314) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for two years and stayed the execution of the suspension, and then placed the license on probation for two years, effective June 1, 2013, subject to certain terms enumerated in the consent agreement; and further, assessed administrative and investigative costs.

Healthcare Services (PHY.002235 & CDS.038972) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand to the permit owner, and further, assessed a fine of \$5,000 plus administrative and investigative costs.

Medical Pharmacy (PHY.000763 & CDS.038669) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand to the permit owner, and further, assessed administrative costs.

Cortina LaShone Richardson (CPT.005255) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for five years and stayed the execution of the suspension, and then placed the certificate on probation for five years, effective June 1, 2013, subject to certain terms enumerated in the consent agreement; and further, assessed administrative costs.

Kori Kiffe Wright (CPT.009060) Mr. Bond moved to approve the proposed voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the certificate for an indefinite period of time, effective March 25, 2013.

Kristi Ann Phillips (CPT.008552) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for an indefinite period of time, effective March 13, 2013; and further, conditioned the acceptance of any future application for reinstatement of the certificate upon the satisfaction of certain requirements identified in the consent agreement.

Mr. Bond then reported the committee was scheduled to meet on June 19-20 to consider that proposed agenda, which included 6 pharmacists, two pharmacy technician candidates, and 12 pharmacy permits.

He then closed his report with appreciation to the other committee members for their ongoing efforts.

E. Impairment Committee

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to consider 9 referrals from staff. Mr. Rabb then presented the following files for Board action.

Kimiko Tiesha Austin (CPT.005676) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended certificate, converted the duration of the suspensive period from an indefinite term to a term of five years and stayed the execution of the suspension, then placed the certificate on probation for five years, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

Roy Kirk Fisher (PST.018600) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of ten years and stayed the execution of the suspension, then placed the license on probation for ten years, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

David Collins Evans (PST.014181) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of ten years and stayed the execution of the suspension, then placed the license on probation for ten years, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

Michael Thomas Savario (PST.016568) Mr. Rabb moved to approve the

proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of 15 years and stayed the execution of the suspension, then placed the license on probation for 15 years, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

Leslie Eileen Rodgers (PST.016948) Mr. Rabb moved to grant the respondent's request for termination of all probationary terms. The motion was adopted after a unanimous vote in the affirmative. The Board terminated all probationary terms and restored the license to active and unrestricted status.

Catherine Powell Kain (PST.020150) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application for pharmacist licensure by reciprocity, authorized the issuance of the pharmacist license immediately, suspended the license for a period of time ending May 17, 2016 and stayed the execution of the suspension, then placed the license on probation for a period of time ending May 17, 2016, subject to certain terms enumerated in the consent agreement.

Michael Glenn Harlton (PTC.020106) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application for a pharmacy technician candidate registration, authorized the issuance of the registration immediately, suspended the registration for five years and stayed the execution of the suspension, then placed the registration on probation for five years, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day.

F. Reinstatement Committee

Mr. Aron called upon Mr. Adams for the committee report. Mr. Adams reported the committee had met the previous day to consider eight referrals from the staff. Following interviews and deliberations, the committee approved the issuance of two credentials with no further requirements. Mr. Adams then presented the following files for Board action.

Bryant Paul Pierce, Jr. (CPT.001594) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement; and

further, placed the Special Work Permit and certificate on probation for one year, effective May 29, 2013, subject to certain terms enumerated in the consent agreement.

Marco Bisa Moran (PST.016442) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board conditioned its further consideration of his request for reinstatement of the previously suspended license upon successful completion of the MPJE and PARE tests prior to May 29, 2014.

Adriel Peter Joseph (PST.017298) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement; and further, placed the Special Work Permit and license on probation for three years, effective on the date of issuance, subject to certain terms enumerated in the consent agreement.

Gradney Donald Couvillion (PST.010009) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Latasha Michelle Carradine (CPT.004121) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Colleen Joiner Hayes (PST.014983) Mr. Adams moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for the conversion of her license from inactive to active status, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Mr. Adams closed his report with his appreciation to his fellow committee members for their work the previous day.

G. Tripartite Committee

Mr. Aron noted the committee had not met since the last Board meeting.

At this point, Mr. Aron declared a luncheon recess. It was noted the Board recessed at 11:55 a.m. and reconvened in open session at 12:40 p.m. He returned to the Reciprocity Committee report agenda item before resuming the posted agenda.

C. *Reciprocity Committee*

Mr. Aron called upon Ms. Hall for the committee report. She reported the committee interviewed 15 applicants in the interim since the previous board meeting, and in conformance with the policies and procedures previously approved by the board, had authorized the issuance of pharmacist licenses for those applicants. She noted their names were recorded on the posted committee meeting agenda for that day. She then reported the committee interviewed an additional 35 applicants earlier that day, and their names were also listed on the posted committee agenda, a copy of which was in the meeting binder. She then moved for the Board to approve all 35 applicants for pharmacist licensure by reciprocity. The motion was adopted after a unanimous vote in the affirmative.

Ms. Hall closed her report with appreciation to her fellow committee members for their work earlier that day.

H. *Regulation Revision Committee*

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reported the committee met on April 9, May 9, and May 28, focusing on the four proposals scheduled for consideration at this meeting. The committee solicited and received stakeholder input for the proposals. Mr. McKay noted that copies of the proposals had been posted in the Board's public library and were also present in the electronic meeting binder. Mr. McKay then moved, **Resolved**, to approve Regulatory Proposal 2013-A ~ Pharmacy Recordkeeping (Draft #6), and further, to authorize the Executive Director to promulgate the proposed amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Prior to the vote, Mr. McKay moved to amend the document by changing the last word on Line 391 from 'hospital' to 'facility.' There was no objection to that amendment. The motion for approval of the amended proposal was adopted after a unanimous vote in the affirmative. Mr. McKay then moved.

Resolved, to approve Regulatory Proposal 2013-G ~ Preferential Licensing for Military Personnel (Draft #2), and further, to authorize the Executive Director to promulgate the proposed amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2013-H ~ Collaborative Drug Therapy Management (Draft #2), and further, to authorize the Executive Director to promulgate the proposed amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2013-J ~ Penal Pharmacy Revision (Draft #2), and further, to authorize the Executive Director to promulgate the proposed amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then reminded the members of their replacement Emergency Rule relative to compounding for prescriber use they issued on January 31. He reported the promulgation process was underway and that the emergency rule was scheduled to expire the following day. He suggested the propriety and necessity of re-issuing and re-publishing the replacement Emergency Rule for the duration of the promulgation process. He then moved,

Resolved, to approve the re-issuance of the Declaration of Emergency – Compounding for Prescriber Use (LAC 46:LIII.2535) effective May 29, 2013; and

Be it further resolved, to continue the approval of Regulatory Proposal 2013-E-C ~ Compounding for Prescriber Use (Draft #1), and further, to authorize the Executive Director to promulgate the proposed amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process, and further, to authorize the Executive Director to re-issue and re-publish the Emergency Rule as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. McKay closed his report with appreciation to his fellow committee members and the administrative officers for their ongoing efforts.

I. *Executive Committee*

Mr. Aron informed the members the executive office had completed its annual review of the Board's Loss Prevention Manual and Policy & Procedure Manual. He reported the committee met the previous day to review the staff recommendations for additions and revisions as well as their recommendations for ongoing approval of the updated manuals. He called upon Mr. Rabb to present the committee's recommendations. Mr. Rabb moved,

Resolved, to approve the proposed new policy entitled *Policy I.M. 1 ~ Bomb Threat Checklist* for the Board's Loss Prevention Manual.

The motion was approved after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to approve the proposed amendments to *Policy II ~ Driver Safety* in the Board's Loss Prevention Manual.

The motion was approved after a unanimous vote in the affirmative. With those two changes, Mr. Rabb reported the committee concurred with the

staff's recommendation for continuing approval of the updated manual, and he then moved,

Resolved, to renew the Board's approval of its Loss Prevention Manual.

The motion was adopted after a unanimous vote in the affirmative. With respect to the Board's Policy & Procedure Manual, Mr. Rabb reminded the members they had issued three opinion statements since their last review of the manual in May 2012. Staff had added those opinion statements to the manual and recommended the continuing approval of the manual. He then moved,

Resolved, to renew the Board's approval of its Policy & Procedure Manual.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb reported the committee had also reviewed staff's recommendations relative to the vendor for the drug screening program as well as the roster of approved addiction medicine specialists used by the Impairment Committee. He then moved,

Resolved, to approve FirstLab as the vendor for the drug screening program for Fiscal Year 2013-2014.

The motion was adopted after a unanimous vote in the affirmative. He then moved,

Resolved, to approve the current updated version of the Impairment Committee's Roster of Approved Addictionists for Fiscal Year 2013-2014.

The motion was approved after a unanimous vote in the affirmative.

In addition to the annual review of its reference manuals, Mr. Aron reported the committee also reviewed the administrative operations and found everything to be satisfactory. In particular, Mr. Aron announced the hiring of a new licensing assistant in the Credentials Division. At Mr. Aron's request, Mr. Fontenot identified the assistant as Ms. Hannah Able and indicated her affiliation with the Board staff would begin on June 17.

On a point of personal privilege, Mr. Aron congratulated Mr. Adams on his election to the office of President-Elect of the National Association of Boards of Pharmacy at the NABP Annual Meeting in St. Louis, MO earlier that month. He noted that Mr. Adams would serve three successive one year terms as President-Elect, then President, and then Chairman. Mr. Aron also congratulated Mr. Broussard on the completion of his term as Chairman of the NABP Executive Committee at that same meeting. Mr. McKay then took a point of personal privilege to inform the members and guests present that Mr. Aron had been selected as Honorary President of NABP at that same meeting.

Finally, Mr. Aron completed his report with appreciation to his fellow officers for their ongoing efforts.

11. Staff Reports

J. Prescription Monitoring Program

Mr. Aron called upon Mr. Fontenot for the report. He directed the

members to the quarterly statistical report in their meeting binder. He reported on the number of prescription transactions reported to the database, and the number of prescribers and dispensers who had acquired access privileges. He also reported on the number of queries made by those prescribers and dispensers, as well as law enforcement and regulatory agencies.

He reminded the members about the 2009 change in the PMP law that authorized the Board to issue waivers to the duty to report data to the program. He then directed the members to a list of five pharmacies requesting such a waiver. Mr. McKay moved,

Resolved, to authorize the issuance of PMP reporting waivers to:

- > PHY.006129, held by Lake Charles Memorial Hospital for Women,
- > PHY.006324, held by Hemophilia of Georgia,
- > PHY.006602, held by Fairway Medical Surgical Hospital,
- > PHY.006658, held by Rx Remote Solutions, and
- > PHY.006664, held by Bella Brands,

once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Fontenot indicated the completion of his report.

K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet presented the following files to the Board for its consideration.

Medisca, Inc. (CDS.025126-DIS) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for three years and stayed the execution of the suspension, then placed the license on probation for three years, beginning retroactively on January 10, 2013, to run concurrently with the probationary period imposed on the firm's South Carolina permit by that state board of pharmacy, subject to certain terms enumerated in the consent agreement.

Mitchell Chad Barrett (PST.016125) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

Institutional Pharmacy Solutions (PHY.006673) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning to the owner of the permit, and further, assessed a fine of \$5,000 plus administrative costs.

Samantha Sellers Michelli (CPT.004416) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, permanently prohibited the acceptance of any future application for the reinstatement of certificate, or for any other credential issued by the Board.

Advantage Pharmacy (PHY.006676) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the permit from June 1, 2013 through May 17, 2014 and stayed the execution of the suspension, then placed the license on probation from June 1, 2013 through May 17, 2014, to run concurrently with the probationary period imposed on the firm's Mississippi permit by that state board of pharmacy, subject to certain terms enumerated in the consent agreement.

Mehrdad Hariri (PST.019770) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license from June 1, 2013 through February 25, 2018 and stayed the execution of the suspension, then placed the license on probation from June 1, 2013 through February 25, 2018 to run concurrently with the probationary period imposed on his Florida license by that state board of pharmacy, subject to certain terms enumerated in the consent agreement.

Travellis Eugene Harrison, Sr. (CPT.010618) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, permanently prohibited the acceptance of any future application for the reinstatement of the certificate, or for any other credential issued by the Board.

Christy Ruth Newbaker (PST.019685) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

Chantelle Denise Williams (CPT.004794) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, permanently prohibited the acceptance of any future application for the reinstatement of the certificate, or for any other credential issued by the Board.

John Edward Bull (PST.010451) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the license for an indefinite period of time, effective May 7, 2013.

Barry Joseph Robichaux (PST.010309) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the license for an indefinite period of time, effective May 10, 2013.

Cherilynn Toni Cottles (CDS.012854-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of her medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 29, 2013.

Jack Albert Voight (CDS.033821-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 29, 2013.

Anthony Stephen Jase (CDS.029511-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the revocation of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 29, 2013.

Jerry Richard Haskin (CDS.007896-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 29, 2013.

Michael Selwyn Hunter (CDS.015927-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the suspension of his medical license for an indefinite period of time. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 29, 2013.

Mr. Finalet reported a recent inquiry into the Board's property, which the realtor agent deemed a serious inquiry. Mr. Finalet will keep the officers posted on any further developments on that project.

Finally, Mr. Finalet indicated the completion of his report.

L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
 - Census Reports – Credentials & Compliance Divisions
 - Production Reports – Credentials Division
 - Exceptions Report
- Examinations
 - MPJE
 - NAPLEX
 - PTCB
- Operations
 - Credentials Division
 - Compliance Division
- State Activities
 - 2013 Legislature
 - Board of Nursing
 - Board of Medical Examiners
- National Activities
 - National Association of Boards of Pharmacy (NABP)
 - MALTAGON
 - NABP-AACP Districts 6-7-8 Annual Meeting
- International Activities
 - International Pharmaceutical Federation

12. Request for Opinion – Remote Medication Dispensing Device (West Jefferson Medical Center)

Mr. Aron recognized Ms. Angela Greener, Chief Administrative Officer, and Mr. Michael Adcock, Chief Nursing Officer, from West Jefferson Medical Center in Marrero, La. The representatives described their plan to open a medical clinic in Grand Isle, La. which would be staffed by nurse practitioners and physicians. They indicated their need to provide to provide medications needed for urgent care, as well as an interest in serving as a source for continuous dispensing to the residents of the area. They described an interest in using a remote medication dispensing device such as one provided by InstyMeds®. The representatives and the members discussed several aspects of the services described, including the dispensing authorities of the different types and locations of licensed health care practitioners. The discussion evolved to the potential use of telepharmacy and the need for the Board to develop rules to permit that

type of practice.

In conclusion, Mr. Aron referred the topic of telepharmacy to the Regulation Revision Committee. Further, he advised the representatives that in the event they chose to move forward with a remote medication dispensing device, that they should do so cautiously, and consider the myriad regulatory issues discussed that day. The representatives expressed their appreciation to the Board for consideration of their request and for the ongoing dialogue on how to best serve the patients in that area of the state.

13. Announcements

Mr. Aron reminded the members and staff of the calendar notes and then directed them to that information in their meeting binders.

14. Adjourn

Mr. Pitre moved to adjourn. Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the meeting at 2:20 p.m.

Respectfully submitted,

Brian A. Bond
Secretary



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Finance Committee has been ordered and called for 8:00 a.m. on Tuesday, August 13, 2013 in the Board office, for the purpose to wit:

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes final.

Revised 07-15-2013

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Consideration of Final Report for Fiscal Year 2012-2013
6. Consideration of Budget Amendment No. 1 for Fiscal Year 2013-2014
7. Adjourn

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Finance Committee

FY 2012-2013 Final Report

August 14, 2013

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
Finance Committee

FY 2012-2013 Final Report

Table of Contents

Statement of Assets, Liabilities, & Equity	03
Statement of Revenue, Expenses, & Budget Performance	05
Summary of Income & Fund Balance Changes	07
Budget Variance Report	08
Schedule A – Prescription Monitoring Program	10
Schedule B – Hurricane Katrina/Rita Pharmacy Relief Fund	12
Summary of Board Actions	13
Iberia Bank Investment Account Statement	14
Cumulative Fund Balance Report	22

Louisiana Board of Pharmacy
 FY 2012-2013
 Statement of Assets, Liabilities, Equity

6/30/2013

ASSETS

> Current Assets		
* Cash		
General Operations		
Whitney Bank	147,965	
Iberia Bank	906,642	
PMP Operations		
Whitney Bank	12,167	
Iberia Bank	484,309	
Hurricane Relief Fund - Whitney Bank	83,054	
Investment Account - Iberia Bank	<u>1,467,662</u>	
<i>Total Cash</i>	3,101,799	
* Prepaid Expenses	<u>18,695</u>	
<i>Total Prepaid Expenses</i>	18,695	
* Accounts Receivable	<u>4,685</u>	
<i>Total Accounts Receivable</i>	4,685	
<i>Total Current Assets</i>	3,125,179	
> Fixed Assets		
Land: Lot 5-A, Towne Center Business Park	709,080	
Land: Lot 1-A-2, Leonard Place Subdivision	295,860	
Office Building - 3388 Brentwood Drive	1,049,655	
Office Equipment	190,669	
Furniture	144,510	
Software: Licensure & Website	408,560	
Accumulated Depreciation	<u>(533,294)</u>	
<i>Total Fixed Assets</i>	2,265,040	
<u>TOTAL ASSETS</u>	<u>5,390,219</u>	

LIABILITIES

> Current Liabilities		
Unemployment taxes payable	57	
State taxes withheld	3,423	
Accrued salaries and benefits	67,036	
Accounts payable	4,319	
Interest payable	5,555	
Compensated absences (ST)	51,306	
Building Loan @ Iberia Bank (ST)	<u>71,150</u>	
<i>Total Current Liabilities</i>	202,846	
> Long Term Liabilities		
Compensated absences (LT)	75,562	
Other Post Employment Benefits (OPEB) Payable	929,700	
Building Loan @ Iberia Bank (LT)	<u>961,058</u>	
<i>Total Long Term Liabilities</i>	1,966,320	
<u>TOTAL LIABILITIES</u>	<u>2,169,166</u>	

Louisiana Board of Pharmacy
FY 2012-2013
Statement of Assets, Liabilities, Equity

6/30/2013

EQUITY

Fund Balance - designated	178,905
Fund Balance @ 6-30-2012	1,525,136
Invested in Fixed Assets	1,232,833
Net Income/Loss	<u>284,179</u>
<i>TOTAL EQUITY</i>	<i>3,221,053</i>

TOTAL LIABILITIES & EQUITY

5,390,219

Louisiana Board of Pharmacy
FY 2012-2013
Statement of Revenue, Expenses, and Budget Performance

Revenue			
	FY 12-13 <u>6/30/2013</u>	FY 12-13 <u>Budget (A#1)</u>	<u>Notes</u>
<i>Licenses & Permits</i>			
Pharmacist Renewals	737,100	715,000	1
New Pharmacist Licensing Fee	140,100	129,000	2
Technician Renewals	295,950	295,000	3
Technician Candidate Registrations	33,275	30,000	4
Lapsed Credential Fees	43,200	32,000	5
Student Registrations	2,560	3,000	6
Permits - Pharmacies	251,500	250,000	7
Permits - CDS	426,980	420,000	8
Permits - Emergency Drug Kits	12,500	14,000	9
Permits - Automated Medication Systems	13,500	10,500	10
Permits - Durable Medical Equipment	25,500	22,500	11
<i>Examinations</i>			
Reciprocity	40,650	30,000	12
Technicians	63,000	67,000	13
<i>Penalties</i>			
Licenses and Certificates	7,630	5,000	14
Permits	11,482	10,000	15
<i>Administrative Fees</i>			
Documents: Copies and Certification Fees	3,712	3,700	16
Duplicate Credentials	4,205	500	17
Silver Certificates	400	500	18
Original Certificates	8,700	9,800	19
NSF Fees	475	1,000	20
Handling & Mailing Fees	83	300	21
<i>Sale of Goods & Services</i>			
Law Books	5,960	2,000	22
Official Lists of Licensees	6,150	4,500	23
USCPSC Inspection Fee	2,250	2,700	24
<i>Enforcement Actions</i>			
Hearing Fees	22,250	24,000	25
Fines	160,081	275,000	26
Investigative Costs	44,133	40,000	27
<i>Prescription Monitoring Program</i>			
Assessments	447,650	440,000	28
Grants	40,035	0	
<i>Miscellaneous</i>			
	918	1,000	29
TOTAL REVENUE	2,851,929	2,838,000	30

Louisiana Board of Pharmacy
 FY 2012-2013
 Statement of Revenue, Expenses, and Budget Performance
Expenses

		FY 12-13 <u>6/30/2013</u>	FY 12-13 <u>Budget (A#1)</u>	<u>Notes</u>
<i>Operations</i>	Rentals - Office & Equipment	5,509	18,000	31
	Equipment Maintenance	2,873	4,000	32
	Telephone	14,952	20,000	33
	Printing	50,742	47,000	34
	Postage	43,007	52,400	35
	Civil Service Assessment	3,748	4,000	36
	Office Insurance (ORM)	8,927	5,000	37
	Dues & Subscriptions	28,417	25,000	38
	Office Supply Expenses	18,417	20,000	39
	Trust Fund Fees	0	1,000	40
	Financial Service Charges	42,460	50,000	41
	Depreciation of Fixed Assets	136,782	130,000	42
	Interest Payments on Building Loan	68,025	77,000	43
	Office Meeting Expenses	863	500	44
	Utilities	9,563	10,000	45
Miscellaneous	14	0	46	
<i>Acquisitions</i>		13,187	28,000	47
<i>Personal Services</i>	Salaries	975,927	975,800	48
	Payroll Taxes (FICA + FUTA)	18,552	20,000	49
	Retirement Contributions	279,473	250,000	50
	Health Insurance (SEGBP)	112,525	108,000	51
	Other Post Employment Benefits (OPEB)	84,798	95,000	52
	Board Member Per Diem	30,975	28,000	53
<i>Professional Services</i>	Accounting	21,086	20,000	54
	Legal	24,593	50,000	55
	Information Systems	89,684	208,000	56
	Property Management	18,496	35,000	57
	Temp. Labor	16,015	20,000	58
	Prescription Monitoring Program	323,814	397,300	59
	<i>Staff Expenses</i>	ED - Travel	4,145	5,000
	GC - Travel	5,495	5,000	61
	CO - Travel	6,600	10,000	62
	CO - Rental Cars & Fuel	6,307	15,000	63
	CO - Education	7,039	10,000	64
	House Staff - Travel	50	1,000	65
	Mileage	29,501	30,000	66
<i>Board Expenses</i>	Meeting Expenses	15,207	15,000	67
	Committee Expenses	8,282	8,000	68
	Conventions	15,950	15,000	69
	Mileage	15,443	15,000	70
	President's Expenses	7,626	10,000	71
	TOTAL EXPENSES		2,565,069	2,838,000

Louisiana Board of Pharmacy
 FY 2012-2013
 Summary of Income Fund Balance Changes

Summary

	<u>FY 12-13 6/30/2013</u>	<u>FY 12-13 Budget (A#1)</u>	<u>Notes</u>
Income Statement			
Total Revenue	2,851,929	2,838,000	73
Total Expenses	2,565,069	2,838,000	74
Net Ordinary Income	286,860	0	
Other Income & Expenses			
Investment	(2,726)	0	75
Disposal of Assets	46	0	76
Net Income	284,180	0	

	<u>FY 11-12 Actual</u>	<u>FY 12-13 6/30/2013</u>	<u>FY 12-13 Budget (A#1)</u>
Fund Balance			
Beginning Fund Balance	2,810,463	2,936,874	2,936,874
Total Income	2,775,418	2,849,249	2,838,000
Total Expenses	2,649,007	2,565,069	2,838,000
Ending Fund Balance	2,936,874	3,221,054	2,936,874
Reservations of Fund Balance	500,000	750,000	750,000
Unreserved Fund Balance	2,436,874	2,471,054	2,186,874

Notes on Reservation of Fund Balance

FY 11-12	Continuing Payroll Obligation	150,000	
	Information Systems Project	200,000	
	Homeland Maintenance	150,000	
			<i>500,000</i>
FY 12-13	Continuing Payroll Obligation	150,000	
	Homeland Maintenance	100,000	
	Debt Service	500,000	
			<i>750,000</i>

Louisiana Board of Pharmacy
FY 2013-2014
Variance Report

<u>Notes</u>	<u>Acct. No.</u>	<u>Account Name</u>	<u>% Variance</u>	<u>Comment</u>
	<u>Revenue</u>			
1	4201	Pharmacist Renewals	3.09	Underestimated by 221 pharmacists
2	4206	New Pharmacist Licensing Fee	8.60	Underestimated by 37 applicants
3	4204	Technician Renewals	0.32	Underestimated by 19 technicians
4	4208	Tech Candidate Registrations	10.92	Underestimated by 131 applicants
5	4205	Lapsed Credential Fees	35.00	Underestimated reinstatements
6	4350	Student Registrations	-14.67	Overestimated by 44 interns
7	4301	Permits - Pharmacies	0.60	Underestimated by 12 permits
8	4302	Permits - CDS	1.66	Underestimated renewals
9	4303	Permits - EDK	-10.71	Overestimated by 60 permits
10	4304	Permits - AMS	28.57	Underestimated by 20 permits
11	4306	Permits - DME	13.33	Underestimated by 20 permits
12	4153	Exams - Reciprocity	35.50	Underestimated by 71 applicants
13	4152	Exams - Technicians	-5.97	Overestimated by 40 applicants
14	4252	Penalties - Licenses	52.60	Underestimated reinstatements
15	4251	Penalties - Permits	14.82	Underestimated reinstatements
16	4460+62	Documents: Copies + Certified	0.32	Close estimate
17	4452	Duplicate credentials	741.00	Underestimated demand
18	4453	Pharmacist Silver Certificates	-20.00	Close estimate
19	4459	Pharmacist Original Certificates	-11.22	Overestimated demand by 15 certificates
20	4454	NSF Fees	-52.50	Overestimated incidence
21	4463	Handling & Mailing Fees	-72.33	Overestimated demand
22	4402	Law Books	198.00	Underestimated demand for supplements
23	4461	Lists of Licensees	36.67	Underestimated demand by 11 requests
24	4458	Inspection Fees	-16.67	Reduced demand from US CPSC
25	4102	Administrative Hearing Fees	-7.29	Overestimated caseload by 7 cases
26	4501	Fines	-42.79	Overestimated amount of sanctions
27	4502	Investigative Costs	10.33	Improved cost recovery procedures
28	4660	PMP Assessments	1.74	Underestimated by 306 accounts
29	4455	Miscellaneous	-8.20	Close estimate
30		Total Revenue	0.49	Actual is \$13,929 over budget

Louisiana Board of Pharmacy
FY 2013-2014
Variance Report

<u>Notes</u>	<u>Acct. No.</u>	<u>Account Name</u>	<u>% Variance</u>	<u>Comment</u>
<i>Expenses</i>				
31	5321	Rentals - Office & Equipment	-69.39	Overestimate planned lease increases
32	5330	Equipment Maintenance	-28.18	Overestimated need for some + timing issue
33	5370	Telephone	-25.24	Overestimated demand
34	5305	Printing	7.96	Underestimated demand
35	5300	Postage	-17.93	Increased use of electronic communications
36	5125	Civil Service Assessment	-6.30	Annual fee, based in part on size of staff
37	5230	Office Insurance (ORM)	78.54	Annual fee, based in part on size of staff
38	5190	Dues & Subscriptions	13.67	Price increase on old + new unplanned
39	5280	Office Supply Expenses	-7.92	Overestimated demand
40	5380	Trust Fund Fees	*	No fees from investment firm
41	5381	Financial Service Charges	-15.08	Overestimated usage of credit cards
42	5180	Depreciation	5.22	Underestimated depreciation schedule
43	5385	Interest Payments on Bldg Loan	-11.66	Fiscal year end timing issue
44	5260	Office Meetings	72.60	Underestimated demand
45	5390	Utilities	-4.37	Close estimate
46	5270	Miscellaneous	*	Close estimate
47	5115	Acquisitions	-52.90	Deliberate deferrals
48	5350	Salaries	0.01	Close estimate
49	5290	Payroll Taxes (FICA + FUTA)	-7.24	Overestimated salaries to be paid
50	5340	Retirement Contributions	11.79	Rate change from the state
51	5220	Health Insurance (SEGBP)	4.19	Slight increase to 11.5% of salary load
52	2400	OPEB	-10.74	Reduction from legislative auditor
53	5152	Board Member Per Diem	10.63	Underestimated meeting activity
54	5110	Accounting Services	5.43	Close estimate
55	5250	Legal Services	-50.81	Overestimated demand for services
56	5295	Information Systems	-56.88	Deferred upgrade implementation
57	5297	Property Management	-47.15	Deferred roof and A/C replacement
58	5296	Temporary Labor	-19.93	Unplanned reduction in force
59	5600	Prescription Monitoring Program	-18.50	PMP-Interconnect funded by NABP
60	5361	Staff Travel - Executive Director	-17.10	Some travel funded by NABP
61	5365	Staff Travel - General Counsel	9.90	Sanctioned travel
62	5363	Staff Travel - Compliance Offcra	-34.00	Improved travel management
63	5371-72	Staff Travel - Rental Cars & Fuel	-57.95	Overestimated demand
64	5368	Staff Educ - Compliance Officers	-29.61	Overestimated need
65	5366	Staff Educ - Office	-95.00	Overestimated need
66	62+64+67	Mileage - entire staff	-1.66	Close estimate
67	5153	Board - Meeting Expenses	1.38	Underestimated meeting travel
68	5155	Board - Committee Expenses	3.53	Underestimated meeting travel
69	5154	Board - Convention Expenses	6.33	Underestimated meeting travel
70	5151	Board - Mileage	2.95	Underestimated meeting travel
71	86+87+88	Board - President's Expenses	-23.74	Overestimated requirements
72		Total Expenses	-9.62	Actual is \$272,931 under budget
<i>Summary</i>				
73		Total Revenue	2.45	Increase from prior fiscal year
74		Total Expenses	-3.02	Decrease from prior fiscal year
75	6003	Investments	*	Overestimated financial market
76	4457	Disposal of Assets	*	Surplus equipment

Louisiana Board of Pharmacy
FY 2012-2013
Schedule A - Prescription Monitoring Program

Revenue

		<u>FY 12-13 6/30/2013</u>	<u>FY 12-13 Budget (A#1)</u>
4620	Grants	40,035	0
4640	Appropriations, State Government	0	0
4660	Assessments	447,650	440,000
4680	Miscellaneous Revenue	0	0
4600	TOTAL REVENUE	487,685	440,000

Louisiana Board of Pharmacy
FY 2012-2013
Schedule A - Prescription Monitoring Program
Expenses

		FY 12-13 <u>6/30/2013</u>	FY 12-13 <u>Budget (A#1)</u>
5610	Operations		
5611	Office rent	10,000	10,000
5612	Equipment rent	0	0
5613	Equipment maintenance	0	0
5614	Telephone	1,827	3,000
5615	Internet access fees	2,500	2,500
5616	Printing	230	1,000
5617	Postage	2,010	4,000
5618	Office supplies	1,267	2,000
5619	Office meeting expenses	0	0
5620	Dues and subscriptions	6,490	7,500
5621	Financial service fees	0	0
5622	Utilities	0	0
5623	Miscellaneous	122	0
5630	Acquisitions		
5632	Furniture	2,063	2,000
5634	Equipment	195	2,000
5640	Personal Services		
5641	Salaries	139,023	137,000
5642	Payroll Taxes	2,812	2,700
5643	Retirement contributions	36,490	35,000
5644	Health insurance premiums	6,373	15,000
5650	Professional Services		
5652	Software Maintenance / Support	33,063	33,100
	Software Enhancements	0	0
	Educational Program Develop.	0	0
5654	Data collection	49,332	49,500
5656	Hosting fees	28,104	28,000
	PMP Interconnect	0	55,000
5660	Staff Expenses		
5661	Manager travel	1,863	5,000
5662	Manager mileage	50	500
5663	Staff travel	0	2,000
5664	Staff mileage	0	500
5670	Advisory Council Expenses	0	0
5680	Miscellaneous Expenses	0	0
5600	TOTAL EXPENSES	323,814	397,300
	<i>Net Profit/Loss</i>	<i>163,871</i>	<i>42,700</i>

Louisiana Board of Pharmacy
 FY 2012-2013
 Schedule B - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity

	<u>6/30/2013</u>
ASSETS	
Current Assets	
Hancock Bank - Checking Account	<u>83,054</u>
<u>TOTAL ASSETS</u>	<u>83,054</u>
 LIABILITIES	
Current Liabilities	0
 EQUITY	
Retained Earnings	82,970
Net Income	<u>84</u>
<u>TOTAL LIABILITIES & EQUITY</u>	<u>83,054</u>

Statement of Receipts & Disbursements

	<u>6/30/2013</u>
RECEIPTS	
FEMA - Funds for payment of claims	8,920,812
FEMA - Administrative allowance	81,103
Pharmacies - reversal of claims	430,138
Interest income	<u>21,979</u>
<u>TOTAL RECEIPTS</u>	<u>9,454,032</u>
 DISBURSEMENTS	
Claims paid to pharmacies	8,920,812
Reversed claim funds returned	430,138
Reversed administrative allowance returned	7,338
Interest earned on reversed admin. allowance returned	<u>12,690</u>
<u>TOTAL DISBURSEMENTS</u>	<u>9,370,978</u>
 FUND BALANCE	 <u>83,054</u>

Note: These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

Louisiana Board of Pharmacy
FY 2012-2013
Summary of Board Actions

Date	Action
11/15/2011	Original Budget - Finance Committee Approval
11/16/2011	Original Budget - Board Approval
8/21/2012	Budget Amendment #1 - Finance Committee Approval
8/22/2012	Budget Amendment #1 - Board Approval
8/14/2013	Acceptance of Final Report

Not Guaranteed by the Bank | Not FDIC Insured | Not a Deposit

* 00147612 01 AV 0.360 01 TR 00625 X109FD13 000000

LOUISIANA BOARD OF PHARMACY
 3388 BRENTWOOD DR
 BATON ROUGE LA 70809-1700



Your Account Executive:
 JOSEPH BARRECA, JR.
 (504) 310-7364

Account Number: H5E-049797
 Statement Period: 06/01/2013 - 06/30/2013


Valuation at a Glance

	This Period
Beginning Account Value	\$1,475,207.03
Dividends/Interest	702.19
Change in Account Value	-9,446.54
Ending Account Value	\$1,466,462.68
Estimated Annual Income	\$7,788.61

Asset Allocation

Cash, Money Funds, and Bank Deposits
 Fixed Income
Account Total (Pie Chart)

This Period	% Allocation
270,837.41	18%
1,195,625.27	82%
\$1,466,462.68	100%



Asset Allocation percentages are rounded to the nearest whole percentage.

Pie Chart allocation only includes products that are of positive value.



Client Service Information

Your Account Executive: X57

JOSEPH BARRECA, JR.
IBERIA FINANCIAL SERVICES
200 W. CONGRESS STREET 1ST FLOOR
LAFAYETTE LA 70501

Contact Information

Telephone Number: (504) 310-7364

Default Tax Lot Disposition Method for Mutual Funds: AVERAGE COST (USING FIRST IN FIRST OUT)

Default Tax Lot Disposition Method for Stocks in a Dividend Reinvestment Plan: FIRST IN FIRST OUT

Default Tax Lot Disposition Method for All Other Securities: FIRST IN FIRST OUT

As you requested, copies of this statement have been sent to:

KOLDER, CHAMPAGNE, SLAVEN & CO

Electronic Delivery

You have not selected any account communications for electronic delivery. To register and turn off paper communications, log in to your account or contact your Account Executive for more information.

Activity Summary (All amounts shown are in base currency: USD)

	This Period	Year-to-Date	Debits	This Period	Year-to-Date
Securities			Securities		
Securities Bought	0.00	0.00	Securities Bought	0.00	-315,004.00
Total Securities	\$0.00	\$0.00	Total Securities	\$0.00	-\$315,004.00
Dividends and Interest	\$702.19	\$5,345.30	Dividends and Interest	\$0.00	\$0.00
Distributions	\$50,000.00	\$170,000.00	Distributions	\$0.00	\$0.00
Cash			Cash		
Deposits	0.00	140,000.00	Deposits	0.00	0.00
Total Cash	\$0.00	\$140,000.00	Total Cash	\$0.00	\$0.00
Total Credits	\$50,702.19	\$315,345.30	Total Debits	\$0.00	-\$315,004.00

Transactions in Date Sequence

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CCY
06/03/13	BOND INTEREST RECEIVED 31331GZL6	50000 FEDERAL FARM CR BKS CONS SYSTEMWIDE BDS CONS BOND 2.800% 06/03/13 B/E DTD 07/01/09 RD 05/31 PD 06/03/13				700.00	USD
06/03/13	SECURITY REDEEMED 31331GZL6	FEDERAL FARM CR BKS CONS SYSTEMWIDE BDS CONS BOND 2.800% 06/03/13 B/E DTD 07/01/09 ACCOUNT REDEMPTION	-50,000.000			50,000.00	USD

of 22

Statement Period: 06/01/2013 - 06/30/2013

Transactions in Date Sequence (continued)

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CCY
06/28/13	MONEY MARKET FUND INCOME RECEIVED	GENERAL MNY MKT CL B				2.19	USD
Total Value of Transactions						\$50,702.19	

The price and quantity displayed may have been rounded.

Portfolio Holdings

Quantity	Description	Opening Balance	Closing Balance	Accrued Income	Income This Year	30-day Yield
Cash, Money Funds, and Bank Deposits 18.00% of Portfolio						
270,837.410	GENERAL MNY MKT FUND CL B	220,135.22	270,837.41	0.00	16.11	0.01%
Total Money Market		\$220,135.22	\$270,837.41	\$0.00	\$16.11	
Total Cash, Money Funds, and Bank Deposits						
		\$220,135.22	\$270,837.41	\$0.00	\$16.11	

Quantity	Description	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income 82.00% of Portfolio (In Maturity Date Sequence)						
Certificates of Deposit						
120,000.000	HUNTINGTON NATL BK COLUMBUS OHIO CTF DEP ACT/365 0.500% 05/27/14 B/E DTD 05/25/12 1ST CPN DTE 11/25/12 CPN PMT SEMI ANNUAL ON MAY 25 AND NOV 25 Security Identifier: 446438PP2	100.2640	120,316.80	59.18	600.00	0.49%
88,000.000	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 Security Identifier: 90521AHS0	100.0700	88,061.60	0.00		



Portfolio Holdings (continued)

Quantity	Description	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
120,000.000	ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.000% 05/26/15 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 02005QF57	100.6190	120,742.80	124.93	1,200.00	0.99%
88,000.000	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 INTEREST PAYABLE AT MATURITY Security Identifier: 90521AHP6	103.4900	91,071.20	0.00		
120,000.000	DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 1.250% 05/23/16 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 254671BG4	100.5660	120,679.20	156.16	1,500.00	1.24%
89,000.000	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 1ST CPN DTE 12/28/12 CPN PMT ANNUALLY ON DEC 28 Security Identifier: 06426XCL2	96.0700	85,502.30	0.00		
120,000.000	GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 1.800% 05/23/17 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 38143ASV8	100.8630	121,035.60	224.88	2,160.00	1.78%
83,000.000	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD PERFORM OF A BSKT 0.000% 05/30/17 B/E DTD 05/31/12 1ST CPN DTE 05/31/13 CPN PMT ANNUALLY ON MAY 31 Security Identifier: 06740ATS8	91.0900	75,604.70	0.00		
160,000.000	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 0.000% 04/27/18 B/E DTD 04/30/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 27 Security Identifier: 06740AY52	91.2900	146,064.00	0.00		

Not Guaranteed by the Bank. Not FDIC Insured. Not a Deposit.

Statement Period: 06/01/2013 - 06/30/2013

Portfolio Holdings (continued)

Quantity	Description	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
155,000.000	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 04/30/18 B/E DTD 04/29/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 29 Security Identifier: 06426XCL8	94.8000	146,940.00	0.00		
Total Certificates of Deposit: 1,143,000.000			\$1,116,018.20	\$565.15	\$5,460.00	
25,000.000 ⁶	UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 Moody Rating AAA Factor: 1.06635000 Effective Date: 06/28/13 Current Face Value: 26,658.750 Security Identifier: 912828NMB	108.6250	28,958.07	152.81		
Total U.S. Treasury Securities: 25,000.000			\$28,958.07	\$152.81		
Total Current Face Value: 26,658.750						
50,000.000	FEDERAL NATL MTG ASSN BENCHMARK NTS 4.625% 10/15/13 B/E DTD 09/26/03 1ST CPN DTE 04/15/04 CPN PMT SEMI ANNUAL ON APR 15 AND OCT 15 Moody Rating AAA S & P Rating AA+ Security Identifier: 31359MTC8	101.2980	50,649.00	481.77	2,312.50	4.56%
Total U.S. Government Bonds: 50,000.000			\$50,649.00	\$481.77	\$2,312.50	
Total Fixed Income: 1,218,000.000			\$1,195,625.27	\$1,199.73	\$7,772.50	
Total Portfolio Holdings						
			\$1,466,462.68	\$1,199.73	\$7,788.61	

⁶ The Current Face value represents the outstanding principal balance of the underlying security. The Current Face value is determined by multiplying the current factor times the original face amount of the

Portfolio Holdings (continued)

security. Factors may change over time and are obtained from sources we believe to be reliable.

Disclosures and Other Information

Pricing

This section includes the net market value of the securities in your account on a settlement date basis, including short positions, at the close of the statement period. The market prices have been obtained from quotation services, which we believe to be reliable. Securities for which a price is not available are marked "N/A" and are omitted from the Total.

The estimated annual income (EAI) and estimated current yield (ECY) figures are estimates and for informational purposes only. These figures are not considered to be a forecast or guarantee of future results. These figures are computed using information from providers believed to be reliable; however, no assurance can be made as to the accuracy. Since interest and dividend rates are subject to change at any time, and may be affected by current and future economic, political, and business conditions, they should not be relied on for making investment, trading, or tax decisions. These figures assume that the position quantities, interest and dividend rates, and prices remain constant. A capital gain or return of principal may be included in the figures for certain securities, thereby overstating them. Refer to www.pershing.com/business_continuity.html for specific details as to formulas used to calculate the figures. Accrued interest represents interest earned but not yet received.

The Estimated Price as of Date only appears when the price date does not equal the statement date and the price indicated is estimated since it is not reflective of a last trade price on a recognized exchange.

Reinvestment

The dollar amount of Mutual Fund distributions, Money Market Fund dividend income, Bank Deposit interest income, or dividends for other securities shown on your Statement may have been reinvested. You will not receive confirmation of these reinvestments. Upon written request to your financial institution, information pertaining to these transactions, including the time of execution and the name of the person from whom your security was purchased, in dividend reinvestment transactions, Pershing acts as your agent and receives payment for order flow.

Option Disclosure

Information with respect to commissions and other charges incurred in connection with the execution of option transactions has been included in confirmations previously furnished to you. A summary of this information is available to you promptly upon your written request directed to your introducing firm. In order to assist your introducing firm in maintaining current background and financial information concerning your option accounts, please promptly advise them in writing of any material change in your investment objectives or financial situation. Expiring options which are valuable are exercised automatically pursuant to the exercise by exception procedure of the Options Clearing Corporation. Additional information regarding this procedure is available upon written request to your introducing firm.

Please be advised that the secondary market for CDs is generally illiquid; the actual value of CDs may be different from their purchase price; and a significant loss of principal could result if your CDs are sold prior to maturity. In the event that the CDs listed above do not indicate a market valuation, an accurate market value could not be determined. In the event that a price is listed above for your CDs, Pershing has obtained a price from sources deemed to be reliable or has priced your CDs using a matrix formula. Prices are estimates and the actual value you may obtain for your CD may be different if you elect to sell your CD in the secondary market.

Foreign Currency Transactions

Pershing may execute foreign currency transactions as principal for your account. Pershing may automatically convert foreign currency to or from U.S. dollars for dividends and similar corporate action transactions unless you instruct your financial organization otherwise. Pershing's currency conversion rate will not exceed the highest interbank conversion rate identified from customary banking sources on the conversion date or the prior business day, increased by up to 1%, unless a particular rate is required by applicable law. Your financial organization may also increase the currency conversion rate. This conversion rate may differ from rates in effect on the date you executed a transaction, incurred a charge, or received a credit. Transactions converted by agents (such as depositories) will be billed at the rates such agents use.

Proxy Vote

Securities not fully paid for in your margin account may be lent by Pershing to itself or others in accordance with the terms outlined in the Margin Agreement. The right to vote your shares held on margin may be reduced by the amount of shares on loan. The Proxy Voting Instruction Form sent to you may reflect a smaller number of shares entitled to vote than the number of shares in your margin account.

Ratings

This statement may contain credit rating information obtained from Standard & Poor's. Reproducing and distributing any information received from Standard & Poor's is not permitted without prior written authorization from Standard & Poor's. Standard & Poor's does not guarantee the accuracy, completeness, timeliness or availability of any information. Standard & Poor's is not responsible for any errors or omissions, regardless of the cause, or for the results of using such content. Standard & Poor's makes no express or implied warranties including warranties of merchantability or fitness for a particular purpose. Standard & Poor's shall not be legally responsible for any fees, costs, expenses or losses in connection with the use of their content. Credit ratings are opinions and not statements of facts; are not recommendations to purchase, hold or sell securities; and do not address suitability for investment purpose. Credit ratings should not be relied upon as investment advice.

22

Not Guaranteed by the Bank. Not FDIC Insured. Not a Deposit.

Statement Period: 06/01/2013 - 06/30/2013

Money Market Fund Detail

Date	Activity Type	Description	Amount	Balance
Sweep Money Market Fund				
GENERAL MNY MKT FUND CL B				
Account Number: 0000671452 Current Yield: 0.01% Activity Ending: 06/28/13				
06/01/13	Opening Balance		220,135.22	220,135.22
06/04/13	Deposit	MONEY FUND PURCHASE	50,700.00	270,835.22
06/28/13	Deposit	INCOME REINVEST	2.19	270,837.41
06/28/13	Closing Balance			\$270,837.41
Total All Money Market Funds				\$270,837.41

Messages

Although a money market mutual fund seeks to preserve the value of your investment at \$1 per share, it is possible to lose money by investing in a money market mutual fund. Please see the money market mutual fund's prospectus or contact your investment professional for additional information.

Important Arbitration Disclosures and Important Arbitration Agreement

Important Arbitration Disclosures

- All parties to this agreement are giving up the right to sue each other in court, including the right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed.
- Arbitration awards are generally final and binding; a party's ability to have a court reverse or modify an arbitration award is very limited.
- The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings.
- The arbitrators do not have to explain the reason(s) for their award, unless, in an eligible case, a joint request for an explained decision has been submitted by all parties to the panel at least 20 days prior to the first scheduled hearing date.
- The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.
- The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court.
- The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this agreement.

Important Arbitration Agreement

Any controversy between you and Pershing LLC shall be submitted to arbitration before the Financial Industry Regulatory Authority. No person shall bring a putative or certified class action to arbitration, nor seek to enforce any predispute arbitration agreement against any person who has initiated in court a putative class action, who is a member of a putative class who has not opted out of the class with respect to any claims encompassed by the putative class action until: (i) the class certification is denied; (ii) the class is decertified; or (iii) the client is excluded from the class by the court. Such forbearance to enforce an agreement to arbitrate shall not constitute a waiver of any rights under this agreement except to the extent stated herein. The laws of the State of New York govern.

Pershing's contact information is as follows: Pershing LLC; Legal Department; One Pershing Plaza; Jersey City, New Jersey 07399; (201) 413-3330.



TERMS AND CONDITIONS

GENERAL INFORMATION

1. ANY FREE CREDIT BALANCE CARRIED FOR YOUR ACCOUNT REPRESENTS FUNDS PAYABLE UPON DEMAND WHICH, ALTHOUGH PROPERLY ACCOUNTED FOR ON PERSHING'S BOOKS OF RECORD, ARE NOT SEGREGATED AND MAY BE USED IN THE CONDUCT OF YOUR BUSINESS.
2. ALL ORDERS AND TRANSACTIONS SHALL BE SOLELY FOR YOUR ACCOUNT AND RISK SHALL BE SUBJECT TO THE CONSTITUTION, RULES, REGULATIONS, CUSTOMS, USAGES, RULINGS AND INTERPRETATIONS OF THE EXCHANGE OR MARKET AND THE CLEARING FACILITY, IF ANY, WHERE THE TRANSACTIONS ARE EXECUTED AND/OR SETTLED, OR IF APPLICABLE, OF THE FINANCIAL INDUSTRY REGULATORY AUTHORITY AND TO ALL APPLICABLE LAWS AND REGULATIONS.
3. WHENEVER YOU ARE INDEBTED TO PERSHING LLC ("PERSHING") FOR ANY AMOUNT, ALL SECURITIES HELD BY IT FOR YOU IN ANY ACCOUNT IN WHICH YOU HAVE ANY INTEREST SHALL SECURE ALL YOUR LIABILITIES TO PERSHING, AND PERSHING MAY IN ITS DISCRETION AT ANY TIME, WITHOUT TENDER, DEMAND OR NOTICE TO YOU, CLOSE OR REDUCE ANY OR ALL OF YOUR ACCOUNTS BY PUBLIC OR PRIVATE SALE OR PURCHASE OR BOTH OF ALL OR ANY SECURITIES CARRIED IN SUCH ACCOUNTS; ANY BALANCE REMAINING DUE PERSHING TO BE PROMPTLY PAID BY YOU.
4. WHENEVER YOU ARE INDEBTED TO PERSHING FOR ANY AMOUNT, ALL SECURITIES CARRIED FOR YOUR ACCOUNT ARE OR MAY BE, WITHOUT FURTHER NOTICE TO YOU, LOANED OR PLEDGED BY PERSHING, EITHER SEPARATELY OR UNDER CIRCUMSTANCES WHICH WILL PERMIT THE COMMINGLING THEREOF, WITH OTHER SECURITIES FOR ANY AMOUNT LESS THAN, EQUAL TO OR GREATER THAN YOUR LIABILITIES TO PERSHING, BUT NOT UNDER CIRCUMSTANCES FOR AN AMOUNT PROHIBITED BY LAW.
5. TITLE TO SECURITIES SOLD TO YOU, WHERE PERSHING HAS ACTED AS PRINCIPAL, SHALL REMAIN WITH PERSHING UNTIL THE ENTIRE PURCHASE PRICE IS RECEIVED OR UNTIL THE SETTLEMENT DATE, WHICHEVER IS LATER.
6. YOU MAY HAVE RECEIVED CONFIRMATIONS FOR TRANSACTIONS WHICH DO NOT APPEAR ON YOUR STATEMENT. IF SO, THE TRANSACTIONS WILL APPEAR ON YOUR NEXT PERIODIC STATEMENT. SUCH TRANSACTIONS MUST BE CONSIDERED BY YOU WHEN COMPUTING THE VALUE OF YOUR ACCOUNT. THIS IS ESPECIALLY TRUE IF YOU HAVE WRITTEN OPTIONS WHICH HAVE BEEN EXERCISED.
7. IF YOU MAINTAIN A MARGIN ACCOUNT, THIS IS A COMBINED STATEMENT OF YOUR GENERAL ACCOUNT AND A SPECIAL MEMORANDUM ACCOUNT MAINTAINED FOR YOU UNDER REGULATION T OF THE BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM. THE PERMANENT RECORD OF THE SEPARATE ACCOUNT AS REQUIRED BY REGULATION T IS AVAILABLE FOR YOUR INSPECTION UPON REQUEST.
8. INTEREST CHARGED ON DEBIT BALANCES IN YOUR ACCOUNT APPEARS ON THE STATEMENT. THE RATE OF INTEREST AND PERIOD COVERED ARE INDICATED. THE RATE MAY CHANGE FROM TIME TO TIME DUE TO FLUCTUATIONS IN MONEY RATES OR OTHER REASONS. INTEREST IS COMPUTED AS DESCRIBED IN MATERIAL PREVIOUSLY FURNISHED TO YOU. PLEASE CONTACT YOUR FINANCIAL INSTITUTION IF YOU DESIRE ADDITIONAL COPIES.
9. DIVIDENDS, INTEREST AND OTHER DISTRIBUTIONS SHOWN ON THIS STATEMENT WERE CLASSIFIED AS TAXABLE OR NON-TAXABLE BASED ON CERTAIN INFORMATION KNOWN AS OF THE DISTRIBUTION DATE. THIS CLASSIFICATION IS SUBJECT TO CHANGE AND IS SOLELY INTENDED FOR USE AS GENERAL INFORMATION. AFTER YEAR END, PERSHING IS REQUIRED TO PROVIDE TAX INFORMATION TO THE INTERNAL REVENUE SERVICE AND OTHER GOVERNMENTAL AUTHORITIES. AT THAT TIME PERSHING WILL PROVIDE THAT INFORMATION ON THE ANNUAL TAX INFORMATION STATEMENT TO YOU; USE THAT STATEMENT TO PREPARE YOUR TAX FILINGS. THE TAX STATEMENT ALSO INCLUDES OTHER USEFUL INFORMATION TO ASSIST IN ACCUMULATING THE DATA TO PREPARE YOUR TAX RETURNS.
10. PERSHING DOES NOT PROVIDE TAX, INVESTMENT OR LEGAL ADVISORY SERVICES AND NO ONE ASSOCIATED WITH PERSHING IS AUTHORIZED TO RENDER SUCH ADVICE. DO NOT RELY UPON ANY SUCH ADVICE. IF GIVEN, INVESTORS ARE ENCOURAGED TO CONSULT THEIR TAX ADVISORS TO DETERMINE THE APPROPRIATE TAX TREATMENT OF THEIR BUSINESS.
11. PERSHING MAY TRADE FOR ITS OWN ACCOUNT AS A MARKET MAKER, SPECIALIST, ODD LOT SELLER, BLOCK POSITIONER, ARBITRAGEUR OR INVESTOR. CONSEQUENTLY, AT THE TIME OF ANY TRANSACTION YOU MAY MAKE, PERSHING MAY HAVE A POSITION IN SUCH SECURITIES, WHICH POSITION MAY BE PARTIALLY OR COMPLETELY HEDGED.
12. IF AVERAGE PRICE TRANSACTION IS INDICATED ON THE FRONT OF THIS STATEMENT YOUR FINANCIAL INSTITUTION OR PERSHING MAY HAVE ACTED AS PRINCIPAL, AGENT OR BOTH. DETAILS AVAILABLE UPON REQUEST.

13. A FINANCIAL STATEMENT OF PERSHING IS AVAILABLE FOR YOUR PERSONAL INSPECTION AT PERSHING'S OFFICES. A COPY OF IT WILL BE MAILED UPON YOUR WRITTEN REQUEST OR YOU CAN VIEW IT ONLINE AT PERSHING.COM.
14. THIS STATEMENT SHOULD BE RETAINED FOR YOUR RECORDS.

THE ROLE OF PERSHING

PERSHING CARRIES YOUR ACCOUNT AS CLEARING BROKER PURSUANT TO A CLEARING AGREEMENT WITH YOUR FINANCIAL INSTITUTION. PERSHING MAY ACCEPT FROM YOUR FINANCIAL INSTITUTION WITHOUT INQUIRY OR INVESTIGATION (I) ORDERS FOR THE PURCHASE AND SALE OF SECURITIES AND OTHER PROPERTY AND (II) ANY OTHER INSTRUCTIONS CONCERNING YOUR ACCOUNT. PERSHING IS NOT RESPONSIBLE OR LIABLE FOR ANY ACTS OR OMISSIONS OF YOUR FINANCIAL INSTITUTION OR ITS EMPLOYEES AND IT DOES NOT SUPERVISE THEM. PERSHING PROVIDES NO INVESTMENT ADVICE NOR DOES IT ASSESS THE SUITABILITY OF ANY TRANSACTION OR ORDER. PERSHING ACTS AS THE AGENT OF YOUR FINANCIAL INSTITUTION AND YOU AGREE THAT YOU WILL NOT HOLD PERSHING OR ANY PERSON CONTROLLING OR UNDER COMMON CONTROL WITH IT LIABLE FOR ANY INVESTMENT LOSSES INCURRED BY YOU. PERSHING PERFORMS SEVERAL KEY FUNCTIONS AT THE DIRECTION OF YOUR FINANCIAL INSTITUTION. IT ACTS AS CUSTODIAN FOR FUNDS AND SECURITIES YOU MAY DEPOSIT WITH IT DIRECTLY OR THROUGH YOUR FINANCIAL INSTITUTION OR THAT IT RECEIVES AS THE RESULT OF SECURITIES TRANSACTIONS. IT PROCESSES:

INQUIRIES CONCERNING THE POSITIONS AND BALANCES IN YOUR ACCOUNT MAY ONLY BE DIRECTED TO THE PERSHING CUSTOMER SERVICE DEPARTMENT AT (201) 413-3333. ALL OTHER INQUIRIES REGARDING YOUR ACCOUNT OR ACTIVITY SHOULD BE DIRECTED TO YOUR FINANCIAL INSTITUTION.

FOR A DESCRIPTION OF OTHER FUNCTIONS PERFORMED BY PERSHING PLEASE CONSULT THE DISCLOSURE STATEMENT PROVIDED TO YOU UPON THE OPENING OF YOUR ACCOUNT.

YOUR FINANCIAL INSTITUTION IS RESPONSIBLE FOR ADHERENCE TO THE SECURITIES LAWS, REGULATIONS AND RULES WHICH APPLY TO IT REGARDING ITS OWN OPERATIONS AND THE SUPERVISION OF YOUR ACCOUNT, ITS SALES REPRESENTATIVES AND OTHER PERSONNEL. YOUR FINANCIAL INSTITUTION IS ALSO RESPONSIBLE FOR APPROVING THE OPENING OF ACCOUNTS AND OBTAINING ACCOUNT DOCUMENTS; THE ACCEPTANCE AND, IN CERTAIN INSTANCES, EXECUTION OF SECURITIES ORDERS; THE ASSESSMENT OF THE SUITABILITY OF THOSE TRANSACTIONS, WHERE APPLICABLE; THE RENDERING OF INVESTMENT ADVICE, IF ANY, TO YOU AND IN GENERAL, FOR THE ONGOING RELATIONSHIP THAT IT HAS WITH YOU.

PERSHING MAY CAPTURE AND STORE DATA ABOUT YOU SUCH AS YOUR FINANCIAL INFORMATION AND INVESTMENT OBJECTIVES. HOWEVER, PERSHING IS NOT REVIEWING THIS INFORMATION AND EVALUATING WHETHER YOUR INVESTMENTS COMPORT WITH YOUR FINANCIAL STATUS AND OBJECTIVES AND YOU HEREBY RELEASE PERSHING FROM ANY LIABILITY TO DO SO. SIMILARLY, PERSHING MAY CAPTURE AND STORE INFORMATION ABOUT WHETHER A BROKER OR AN INTRODUCING FIRM IS REGISTERED IN A GIVEN STATE. YOU HEREBY RELEASE PERSHING FROM ANY LIABILITY TO REVIEW THIS DATA OR TO EVALUATE WHETHER A PARTICULAR SECURITY IS REGISTERED OR EXEMPT FROM REGISTRATION IN YOUR STATE. THIS NOTICE IS NOT MEANT AS A DEFINITIVE ENUMERATION OF EVERY POSSIBLE CIRCUMSTANCE, BUT AS A GENERAL DISCLOSURE. IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE OR IF YOU WOULD LIKE ADDITIONAL COPIES OF THE DISCLOSURE STATEMENT, PLEASE CONTACT YOUR FINANCIAL INSTITUTION.

PERSHING IS A MEMBER OF THE SECURITIES INVESTOR PROTECTION CORPORATION (SIPC). PLEASE NOTE THAT SIPC DOES NOT PROTECT AGAINST LOSS DUE TO MARKET FLUCTUATION. IN ADDITION TO SIPC PROTECTION, PERSHING PROVIDES COVERAGE IN EXCESS OF SIPC LIMITS. FOR MORE DETAILED INFORMATION PLEASE VISIT: WWW.PERSHING.COM/STRENGTH_STABILITY.HTML

THIS STATEMENT WILL BE DEEMED CONCLUSIVE AND AN ACCOUNT STATED UNLESS YOU ADVISE PERSHING IN WRITING OF ANY OBJECTION TO IT WITHIN TEN DAYS AFTER RECEIPT. A YOU ARE ADVISED TO REPORT PROMPTLY ANY INACCURACY OR DISCREPANCY IN YOUR ACCOUNT (INCLUDING UNAUTHORIZED TRADING) TO YOUR FINANCIAL ORGANIZATION AND PERSHING, THE CUSTODIAN OF YOUR ACCOUNT. PLEASE BE ADVISED THAT ANY ORAL COMMUNICATION SHOULD BE RE-CONFIRMED IN WRITING TO FURTHER PROTECT YOUR RIGHTS, INCLUDING YOUR RIGHTS UNDER THE SECURITIES INVESTOR PROTECTION ACT.

YOUR FINANCIAL ORGANIZATION'S CONTACT INFORMATION CAN BE FOUND ON THE FIRST PAGE OF THIS STATEMENT. PERSHING'S CONTACT INFORMATION IS AS FOLLOWS: PERSHING LLC, LEGAL DEPARTMENT; ONE PERSHING PLAZA, JERSEY CITY, NEW JERSEY 07399; (201) 413-3330. ERRORS AND OMISSIONS EXCEPTED.

PAYMENT FOR ORDER FLOW AND ORDER ROUTING POLICIES DISCLOSURES [REGULATION NMS—RULE 607(A)(1)-(4)]

PERSHING SENDS CERTAIN EQUITY ORDERS TO EXCHANGES, ELECTRONIC COMMUNICATION NETWORKS, OR BROKER-DEALERS DURING NORMAL BUSINESS HOURS AND DURING EXTENDED TRADING SESSIONS. CERTAIN OF THESE VENUES PROVIDE PAYMENTS TO PERSHING OR CHARGE ACCESS FEES TO PERSHING DEPENDING UPON THE CHARACTERISTICS OF THE ORDER AND ANY SUBSEQUENT EXECUTION. IN ADDITION PERSHING MAY EXECUTE CERTAIN EQUITY ORDERS AS PRINCIPAL. THE DETAILS OF THESE PAYMENTS AND FEES ARE AVAILABLE UPON WRITTEN REQUEST. PERSHING RECEIVES PAYMENTS FOR DIRECTING LISTED OPTIONS ORDER FLOW TO CERTAIN OPTION EXCHANGES. COMPENSATION IS GENERALLY IN THE FORM OF A PER OPTION CONTRACT CASH PAYMENT.

BEST EXECUTION: NOTWITHSTANDING THE PREVIOUS PARAGRAPH REGARDING PAYMENT FOR ORDER FLOW, PERSHING SELECTS CERTAIN MARKET CENTERS TO PROVIDE EXECUTION OF OVER-THE-COUNTER AND EXCHANGE-LISTED SECURITIES TRANSACTIONS WHICH AGREE TO ACCEPT ORDERS. TRANSMITTED ELECTRONICALLY UP TO A SPECIFIED SIZE, AND TO EXECUTE THEM AT OR BETTER THAN THE NATIONAL BEST BID OR OFFER (NBBO). ON CERTAIN LARGER ORDERS, OR IF THE DESIGNATED MARKET CENTERS DO NOT MAKE A MARKET IN THE SUBJECT SECURITY, PERSHING DIRECTLY CONTACTS MARKET CENTERS TO OBTAIN AN EXECUTION. THE DESIGNATED MARKET CENTERS TO WHICH ORDERS ARE AUTOMATICALLY ROUTED ARE SELECTED BASED ON THE CONSISTENT HIGH QUALITY OF THEIR EXECUTIONS IN ONE OR MORE MARKET SEGMENTS AND THEIR ABILITY TO PROVIDE OPPORTUNITIES FOR EXECUTIONS AT PRICES SUPERIOR TO THE NBBO. PERSHING ALSO REGULARLY REVIEWS REPORTS FOR QUALITY OF EXECUTION PURPOSES. WRAP ACCOUNT CUSTOMERS WHO ELECTED NOT TO RECEIVE IMMEDIATE CONFIRMATION OF TRANSACTIONS

THE FOLLOWING TERMS AND CONDITIONS ARE APPLICABLE ONLY IF YOUR ACCOUNT IS AN INVESTMENT ADVISORY ACCOUNT AND THE TRANSACTION CONFIRMATIONS ARE NOT SENT TO YOU (SENT ONLY TO YOUR FIDUCIARY) PURSUANT TO YOUR INSTRUCTION:

1. THE FOLLOWING INFORMATION WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR FINANCIAL INSTITUTION ("INTRODUCING FIRM") WITH RESPECT TO ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU: THE MARKET UPON WHICH ANY TRANSACTION WAS EXECUTED; THE TIME OF DAY THAT ANY TRANSACTION WAS EXECUTED; THE NAME OF THE PERSON FROM WHOM ANY SECURITY WAS PURCHASED OR TO WHOM SUCH SECURITY WAS SOLD; THE SOURCE AND AMOUNT OF OTHER COMMISSIONS RECEIVED IN CONNECTION WITH ANY TRANSACTION; AND A COPY OF THE TRANSACTION CONFIRMATION.
2. YOUR INTRODUCING FIRM EFFECTS EACH TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU AS YOUR AGENT.
3. IN CONNECTION WITH EACH EQUITY SECURITY AND CERTAIN OTHER SECURITIES SOLD, YOUR INTRODUCING FIRM CHARGES TO YOU, AND REMITS TO A REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE, A "TRANS. FEE." PERSHING CALCULATES THIS FEE BASED ON AMOUNTS PAID BY YOUR INTRODUCING FIRM TO THE APPLICABLE REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE. THIS, IN TURN, IS BASED ON THE VALUE OF THE APPLICABLE SECURITIES SOLD. TO DETERMINE THE EXACT AMOUNT OF THIS FEE WITH RESPECT TO ANY TRANSACTION, PLEASE CONTACT YOUR INTRODUCING FIRM.
4. YOUR INTRODUCING FIRM DOES NOT RECEIVE ANY PAYMENT FOR ORDER FLOW FOR ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU.
5. CALL FEATURES MAY EXIST FOR SECURITIES. CALL FEATURES FOR FIXED INCOME SECURITIES MAY AFFECT YIELD. COMPLETE INFORMATION WILL BE PROVIDED UPON REQUEST.
6. IF ANY TRANSACTION INVOLVES AN ASSET-BACKED SECURITY, INCLUDING A MUNICIPAL COLLATERALIZED MORTGAGE OBLIGATION, WHICH REPRESENTS AN INTEREST IN OR IS SECURED BY A POOL OF RECEIVABLES OR OTHER FINANCIAL ASSETS THAT ARE SUBJECT CONTINUOUSLY TO PREPAYMENT, THEN THE ACTUAL YIELD OF SUCH SECURITY MAY VARY ACCORDING TO THE RATE AT WHICH THE UNDERLYING RECEIVABLES OR OTHER FINANCIAL ASSETS ARE PREPAID. INFORMATION CONCERNING THE FACTORS THAT AFFECT YIELD INCLUDING AT A MINIMUM ESTIMATED YIELD, WEIGHTED AVERAGE LIFE, AND THE PREPAYMENT ASSUMPTIONS OF UNDERLYING YIELD) WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR INTRODUCING FIRM.
7. THE RATINGS THAT APPEAR IN THE DESCRIPTION OF SOME FIXED INCOME SECURITIES HAVE BEEN OBTAINED FROM RATINGS SERVICES WHICH PERSHING BELIEVES TO BE RELIABLE; HOWEVER, PERSHING CANNOT GUARANTEE THEIR ACCURACY. SECURITIES FOR WHICH A RATING IS NOT AVAILABLE ARE MARKED "UNRATED."

IF ANY OF THE ABOVE TERMS AND CONDITIONS ARE UNACCEPTABLE TO YOU, PLEASE NOTIFY PERSHING IMMEDIATELY IN WRITING BY CERTIFIED MAIL TO ONE PERSHING PLAZA, JERSEY CITY, NJ 07399, ATTN: LEGAL DEPT

Louisiana Board of Pharmacy

Cumulative Fund Balance Reports

	FY 98-99 <u>Actual</u>	FY 99-00 <u>Actual</u>	FY 00-01 <u>Actual</u>	FY 01-02 <u>Actual</u>	FY 02-03 <u>Actual</u>	FY 03-04 <u>Actual</u>	FY 04-05 <u>Actual</u>	FY 05-06 <u>Actual</u>	FY 06-07 <u>Actual</u>	FY 07-08 <u>Actual</u>
Beginning Fund Balance	910,394	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236
Total Income	984,414	1,030,423	1,168,798	1,200,575	1,223,872	1,274,804	1,524,411	1,627,306	2,228,918	2,657,168
Total Expenses	767,569	890,586	1,084,683	1,029,959	1,170,252	1,384,533	1,415,474	1,536,986	1,829,351	2,184,076
Ending Fund Balance	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236	2,550,328
Reservations of Fund Balance	48,884	102,368	476,000	524,000	1,210,000	1,245,000	1,300,000	1,300,000	1,400,000	2,050,000
Unreserved Fund Balance	1,078,355	1,164,708	763,515	997,807	378,141	233,412	287,349	377,669	677,236	500,328

	FY 08-09 <u>Actual</u>	FY 09-10 <u>Actual</u>	FY 10-11 <u>Actual</u>	FY 11-12 <u>Actual</u>	FY 12-13 <u>Actual</u>	FY 13-14 <u>Actual</u>
Beginning Fund Balance	2,550,328	2,607,575	2,715,185	2,810,463	2,936,874	3,225,061
Total Income	2,570,282	2,706,829	2,808,468	2,775,418	2,849,249	
Total Expenses	2,513,035	2,599,219	2,713,190	2,649,007	2,565,069	
Ending Fund Balance	2,607,575	2,715,185	2,810,463	2,936,874	3,221,054	
Reservations of Fund Balance	1,900,000	1,650,000	1,650,000	500,000	750,000	2,162,000
Unreserved Fund Balance	707,575	1,065,185	1,160,463	2,436,874	2,471,054	



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Finance Committee

Proposed Budget Amendment No. 1 Fiscal Year 2013-2014

August 13, 2013

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
FY 2013-2014 Budget

Draft #1

		Revenue		
<u>Acct. No.</u>		<u>FY 13-14 Original</u>	<u>FY 13-14 Amend. #1</u>	<u>Notes</u>
	Licenses & Permits			
4201	Pharmacist Renewals	716,000	737,000	1
4206	New Pharmacist Licensing Fee	130,000	140,100	2
4204	Technician Renewals	295,000	296,000	3
4208	Tech Candidate Registrations	35,000	35,000	
4205	Lapsed Credential Fees	30,000	42,000	4
4350	Student Registrations	3,000	3,000	
4301	Permits - Pharmacies	255,000	250,000	5
4302	Permits - CDS	420,000	430,000	6
4303	Permits - Emergency Drug Kits	14,000	12,500	7
4304	Permits - Automated Medication Systems	13,500	13,500	8
4306	Permits - Durable Medical Equipment	37,500	25,500	9
	Examinations			
4153	Reciprocity	30,000	40,000	10
4152	Technicians	67,000	63,000	11
	Penalties			
4252	Licenses and Certificates	5,000	7,500	12
4251	Permits	10,000	11,000	13
	Administrative Fees			
4460+4462	Documents: Copies and Certification Fees	3,500	3,500	
4452	Duplicate Credentials	4,000	4,000	
4453	Pharmacist Silver Certificates	500	500	
4459	Pharmacist Original Certificates	10,000	10,000	
4454	NSF Fees	500	500	
4463	Handling & Mailing Fees	300	150	14
	Sale of Goods & Services			
4402	Law Books	2,000	6,000	15
4461	Official Lists of Licensees	4,500	6,000	16
4458	USCPSC Inspection Fee	2,700	2,250	17
	Enforcement Actions			
4102	Hearing Fees	24,000	24,000	
4502	Investigative Costs	40,000	45,000	18
4501	Fines	285,000	160,000	19
	Prescription Monitoring Program			
4660	Assessments	440,000	448,000	20
4455	Miscellaneous	1,000	1,000	
	TOTAL REVENUE	2,879,000	2,817,000	21

Louisiana Board of Pharmacy
FY 2013-2014 Budget

Draft #1

Expenses

<u>Acct. No.</u>			FY 13-14 <u>Original</u>	FY 13-14 <u>Amend. #1</u>	<u>Notes</u>
5321	<i>Operations</i>	Rentals - Equipment	18,000	18,000	
5330		Equipment Maintenance	4,000	4,000	
5370		Telephone	20,000	15,000	22
5305		Printing	47,000	47,500	23
5300		Postage	52,000	40,000	24
5125		Civil Service Assessment	4,000	4,000	
5230		Office Insurance (ORM)	9,000	9,000	
5190		Dues & Subscriptions	15,000	20,000	25
5280		Office Supply Expenses	20,000	20,000	
5380		Trust Fund Fees	1,000	0	26
5381		Financial Service Charges	50,000	50,000	
5180		Depreciation of Fixed Assets	130,000	135,000	27
5385		Interest Payments on Building Loan	64,000	68,000	28
5260		Office Meeting Expenses	1,000	1,000	
5390		Utilities	10,000	10,000	
5270-5310		Miscellaneous	0	0	
5105	<i>Acquisitions</i>		25,000	2,500	29
5350	<i>Personal Services</i>	Salaries	1,204,000	1,096,000	30
5290		Payroll Taxes (FICA + FUTA)	24,100	22,500	31
5340		Retirement Contributions	308,000	341,000	32
5220		Health Insurance (SEGBP)	132,000	126,000	33
2400		Other Post Employment Benefits (OPEB)	95,000	85,000	34
5152		Board Member Per Diem	28,000	31,000	35
5110	<i>Professional Services</i>	Accounting	20,000	22,000	36
5250		Legal	50,000	25,000	37
5295		Information Systems	100,000	98,000	38
5297		Property Management	35,000	35,000	
5296		Temp. Labor	20,000	20,000	
5600		Prescription Monitoring Program	383,400	360,500	39
5361	<i>Staff Expenses</i>	Travel - Executive Director	10,000	0	40
5365		Travel - General Counsel	5,000	0	41
5363		Travel - Compliance Officers	10,000	7,000	42
5371+72		Travel - Compliance Officers - Rental & Fuel	15,000	10,000	43
5368		Education - Compliance Officers	12,000	6,000	44
5366		Travel & Education - Office Staff	1,000	0	45
5362-5364-5367		Mileage - entire staff	30,500	25,000	46
5153	<i>Board Expenses</i>	Meeting Expenses	15,000	15,000	
5155		Committee Expenses	8,000	8,000	
5154		Conventions	15,000	15,000	
5151		Mileage	15,000	15,000	
5286-5287-5288		President's Expenses	10,000	10,000	
TOTAL EXPENSES			3,016,000	2,817,000	47

Summary

<u>Acct. No.</u>		<u>FY 13-14 Original</u>	<u>FY 13-14 Amend. #1</u>	<u>Notes</u>
Income Statement				
	Total Revenue	2,879,000	2,817,000	
	Total Expenses	3,016,000	2,817,000	
	Net Ordinary Income	(137,000)	0	
	Other Income & Expenses			
6003	Investments	0	0	
	Disposal of Assets	0	0	
	Net Income	(137,000)	0	

	<u>FY 12-13 Actual</u>	<u>FY 13-14 Budget</u>	<u>FY 13-14 Amend #1</u>	
Fund Balance				
	Beginning Fund Balance	2,940,881	2,774,730	3,225,061
	Total Income	2,849,249	2,879,000	2,817,000
	Total Expenses	2,565,069	3,016,000	2,817,000
	Ending Fund Balance	3,225,061	2,637,730	3,225,061
	Reservations of Fund Balance	750,000	1,250,000	2,162,000
	Unreserved Fund Balance	2,475,061	1,387,730	1,063,061

Notes on Reservation of Fund Balance

FY 12-13

Continuing Payroll Obligation	150,000
Homeland Maintenance	100,000
Debt Service	<u>500,000</u>
TOTAL	750,000

FY 13-14

Other Post Employment Benefits Payable	850,000	929,700
Debt Service Payable	150,000	1,032,300
Continuing Payroll Obligations	150,000	150,000
Homeland Maintenance	<u>100,000</u>	<u>50,000</u>
TOTAL	1,250,000	2,162,000

Notes

Revenue

- 1 Using historical data, estimate 7,370 pharmacists renewing @ \$100 each
- 2 Using historical data, estimate 467 new pharmacists @ \$300 each
- 3 Using historical data, estimate 5,920 technicians renewing @ \$50 each
- 4 Using historical data
- 5 Using historical data, estimate 2,000 pharmacy permits renewing @ \$125 each
- 6 Using historical data
- 7 Using historical data, estimate 500 permits renewing @ \$25 each
- 8 Using historical data, estimate 90 registrations renewing @ \$150 each
- 9 Using historical data, estimate 170 permits renewing @ \$150 each
- 10 Using historical data, estimate 267 applicants @ \$150 each
- 11 Using historical data, estimate 630 applicants @ \$100 each
- 12 Using historical data
- 13 Using historical data
- 14 Using historical data
- 15 Using historical data
- 16 Using historical data
- 17 Using historical data
- 18 Using historical data
- 19 Using historical data
- 20 Using historical data, estimate 17,920 accounts renewing @ \$25 each
- 21 Reflects 1.2% reduction from FY 13 actual revenue

Expenses

- 22 Using historical data
- 23 Using historical data
- 24 Using historical data with planned focus to increase use of email
- 25 Using historical data, less \$9,300 costs of Melissa Data subscription (3 year premium paid)
- 26 Using historical data
- 27 Using historical data
- 28 Using historical data
- 29 Planned deferral of all acquisitions with potential for two emergency replacements.
- 30 De-fund both vacancies + no raises for existing staff
- 31 Calculated value: 2% of salaries + temp labor
- 32 Calculated value: 31.1% of salaries
- 33 Calculated value: 11.5% of salaries, using historical data
- 34 Using historical data
- 35 Using historical data
- 36 Using historical data
- 37 Using historical data
- 38 Using historical data
- 39 See Schedule A for notes on Prescription Monitoring Program
- 40 All travel reimbursement cancelled
- 41 All travel reimbursement cancelled
- 42 Using historical data
- 43 Using historical data
- 44 All educational conference travel cancelled, except for two seminars already booked.
- 45 All travel reimbursement cancelled
- 46 Using historical data
- 47 Reflects 9.8% increase over FY 13 actual expenses

Louisiana Board of Pharmacy
FY 2013 - 2014 Budget
Schedule A - Prescription Monitoring Program
Revenue

Draft #1

		<u>FY 13-14 Budget</u>	<u>FY 13-14 Amend. #1</u>	<u>Notes</u>
4620	Grants	0	0	
4640	Appropriations, State Government	0	0	
4660	Assessments	425,000	448,000	1
4680	Miscellaneous Revenue	0	0	
4600	TOTAL REVENUE	425,000	448,000	

Louisiana Board of Pharmacy
 FY 2013 - 2014 Budget
 Schedule A - Prescription Monitoring Program
Expenses

Draft #1

		FY 13-14 <u>Budget</u>	FY 13-14 <u>Amend. #1</u>	<u>Notes</u>
5610	Operations			
5611	Office rent	10,000	10,000	
5612	Equipment rent	0	0	
5613	Equipment maintenance	0	0	
5614	Telephone	3,000	3,000	
5615	Internet access fees	2,500	2,500	
5616	Printing	1,000	1,000	
5617	Postage	4,000	4,000	
5618	Office supplies	2,000	2,000	
5619	Office meeting expenses	0	0	
5620	Dues and subscriptions	7,500	7,000	2
5621	Financial service fees	0	0	
5622	Utilities	0	2,000	3
5623	Miscellaneous	0	0	
5630	Acquisitions			
5632	Furniture	2,500	0	4
5634	Equipment	2,500	0	5
5640	Personal Services			
5641	Salaries	155,000	147,100	6
5642	Payroll Taxes	3,100	3,000	7
5643	Retirement contributions	39,700	45,800	8
5644	Health insurance premiums	17,000	17,000	9
5650	Professional Services			
5652	Software Maintenance/Support	33,100	33,100	
	Software Enhancements	0	0	
	Educational Program Develop.	0	0	
5654	Data collection	49,500	49,500	
5656	Hosting fees	28,000	28,000	
5655	Interstate hub support fees	15,000	0	
5660	Staff Expenses			
5661	Manager education/travel	5,000	5,000	
5662	Manager mileage	500	500	
5663	Staff education/travel	2,000	0	
5664	Staff mileage	500	0	
5670	Advisory Council Expenses	0	0	
5680	Miscellaneous Expenses	0	0	
5600	TOTAL EXPENSES	383,400	360,500	10
	Net Profit/Loss	91,600	87,500	

Louisiana Board of Pharmacy
FY 2013 - 2014 Budget
Schedule A - Prescription Monitoring Program
Notes

Draft #1

Revenue

- 1 Using historical data

Expenses

- 2 Using historical data
- 3 Propose to allocate partial cost of utilities to PMP
- 4 Planned deferral of all acquisitions
- 5 Planned deferral of all acquisitions
- 6 Salary for program manager and administrative coordinator
- 7 Calculated value: 2% of salaries
- 8 Calculated value: 31.1% of salaries
- 9 Calculated value: 11.5% of salaries, using historical data
- 10 Reflects 11.3% increase over FY 13 actual expenses

Board Action Summary

Date	Action
12/10/2012	Original Budget - Finance Committee Approval
12/11/2012	Original Budget - Board Approval
8/13/2013	Budget Amendment #1 - Finance Committee Approval
8/14/2013	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
	Acceptance of Final Report

LOUISIANA BOARD OF PHARMACY

BATON ROUGE, LOUISIANA

IN THE MATTER OF:

CONSENT ORDER

FRED'S PHARMACY #2679

LOUISIANA PHARMACY PERMIT APPLICANT

Case No. 13-0147

CONSENT AGREEMENT

WHEREAS, an informal conference was conducted by the Application Review Committee of the Louisiana Board of Pharmacy (hereinafter referred to as the "Board") on July 25, 2013 at the Board office, 3388 Brentwood Drive, Baton Rouge, Louisiana 70809, in the matter of, **FRED'S PHARMACY #2679** (hereinafter referred to as "Respondent"), Louisiana Pharmacy Permit Applicant.

WHEREAS, Respondent's application for a pharmacy permit failed to state disciplinary history against its proposed pharmacist-in-charge, Marc S. Capello, Pharmacist License No. 11217.

WHEREAS, Respondent has a pending pharmacy permit application with the Board.

WHEREAS, pursuant to information received and/or gathered by the Board which produced evidence indicating that Respondent violated the following laws and regulations:

La. R.S. 37: 1241(A)(1): Practiced or assisted in the practice of pharmacy, or knowingly permitted or has permitted anyone in his employ or under his supervision to practice or assist in the practice of pharmacy, in violation of the provisions of this Chapter and any rules and regulations promulgated thereto in accordance with the Administrative Procedure Act.

La. R.S. 37:1241(A)(2): Attempted to or obtained a license, registration, certificate, permit or any other designation deemed necessary to engage in the practice of pharmacy by fraud or misrepresentation.

To facilitate the submission of this Consent Agreement, Respondent agrees that there is sufficient evidence upon which to predicate a finding of those violations.

Respondent further understands that this Consent Agreement shall constitute a Public Record, pursuant to La. R.S. 44:1 et seq., and is considered disciplinary action by the Board.

In order to avoid further administrative and judicial proceedings, Respondent hereby consents to accept and abide by the following order of the Board:

1. **A Letter of Warning is issued to FRED'S PHARMACY #2679; and**
2. **Before any application for a pharmacy permit may be considered, FRED'S PHARMACY #2679 is ordered to reimburse the Board \$250.00 for administrative costs, with total payment due the Board of \$250.00, to be paid simultaneously with the execution of this Consent Agreement by Respondent.**

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.

By signing this Consent Agreement, Respondent agrees that any failure to comply with the terms of this Agreement is a basis for discipline by the Board.

Both Respondent and the Board stipulate that this Consent Order shall not become effective and shall not become binding on the Board unless and until approved by the Board at formal meeting. However, Respondent agrees that this Consent Order shall be effective and binding upon Respondent without recourse upon its authorized representative signing said Order.

Respondent agrees to provide the Board with the following for reporting purposes to the National Practitioner Data Bank – Healthcare Integrity and Protection Data Bank (NPDB-HIPDB):

Respondent's National Provider Identifier (NPI) Number: pending


Medicare Provider Number (if in the possession of one): pending

I, Michael Hudak, authorized to act on behalf of and acting on behalf of **FRED'S PHARMACY #2679**, understand that this Consent Agreement is effective as a Board Order upon affirmative vote by the Board at formal hearing. It is also understood that, should the Board not approve this Consent Agreement, the agreement therein does not preclude the Louisiana Board of Pharmacy from requiring a formal hearing of this case.


It is further understood that, should this Consent Agreement not be accepted by the Board, the presentation to and consideration by the Board of this Agreement, including presented documentary evidence and information, shall not unfairly or illegally prejudice or preclude the Board or any of its members from further participation in hearings or resolution of these proceedings.

SIGNED, AGREED TO AND ENTERED ON THIS 25th DAY OF July, 2013.


FRED'S PHARMACY #2679
Louisiana Pharmacy Permit APPLICANT



BY:
Authorized Representative



STEPHEN C. RESOR
Salley, Hite, Mercer & Resor LLC
365 Canal Pl., Ste 1710
New Orleans, LA 70130



CARLOS M. FINALET, III
General Counsel, Louisiana Board of Pharmacy

ACCEPTANCE OF THE CONSENT AGREEMENT BY THE LOUISIANA BOARD OF PHARMACY:

By a majority vote of the Board members voting in favor of the foregoing Consent Agreement at the Board meeting on August, 2013, the Board hereby adopts said Agreement as a Final Order of the Board.

FOR THE BOARD:

Carl W. Aron
President and Hearing Officer for the Board



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reciprocity Committee has been ordered and called for 7:00 a.m. on Wednesday, August 14, 2013 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-13-2013

- A. Call to Order
- B. Quorum Call
- C. Call for Additional Agenda Items
- D. Opportunity for Public Comment
- E. Activity since last Board Meeting

<u>Applicant</u>	<u>Interviewer</u>	<u>Result</u>
1. Jerry Franklin Reed, II (NC)	Mr. Dartez	PST.020156 issued 06-20-2013
2. Lara Diane Simmons (KS)	Mr. Dartez	PST.020157 issued 06-20-2013
3. John Michael Driscoll, Jr. (PA)	Mr. Dartez	PST.020158 issued 06-20-2013
4. Shaley Gupta (IL)	Mr. Dartez	PST.020159 issued 06-20-2013
5. Randy William Pennington (AR)	Ms. Reed	PST.020160 issued 06-20-2013
6. Nicole Alexandra Balarezo (FL)	Mr. Dartez	PST.020161 issued 06-20-2013
7. Timothy Robert Moser (OH)	Mr. Dartez	PST.020162 issued 06-20-2013
8. Priya Bose Cheeran (TX)	Ms. Reed	PST.020163 issued 06-20-2013
9. Ritchie Lee Longoria, III (OR)	Mr. Dartez	PST.020164 issued 06-20-2013
10. Douglas Jason Massey (AZ)	Mr. Dartez	PST.020165 issued 06-20-2013
11. Scott Anthony Cerami (FL)	Ms. Reed	PST.020166 issued 06-20-2013
12. Thien Chi Kieu (OK)	Mr. Dartez	PST.020167 issued 06-20-2013
13. Joanne Pipikios (FL)	Mr. Dartez	PST.020168 issued 06-20-2013
14. Renee Lynne Licwinko (PA)	Mr. Dartez	PST.020169 issued 06-20-2013
15. Michael Patrick McDonald (TX)	Ms. Reed	PST.020170 issued 06-20-2013
16. Radha Sumintra Hussain (FL)	Mr. Dartez	PST.020171 issued 06-20-2013
17. Chad James Forinash (MO)	Mr. Dartez	PST.020172 issued 06-20-2013
18. Christina Jo Ferrier (AZ)	Ms. Reed	PST.020173 issued 06-20-2013
19. Paul Marvin Peak (TN)	Ms. Reed	PST.020174 issued 06-20-2013
20. Angela Angotti Morris (WV)	Ms. Reed	PST.020192 issued 07-18-2013
21. Bradley Donovan Wooldridge (TN)	Ms. Reed	PST.020193 issued 07-18-2013
22. Dean Albert Pedalino (FL)	Ms. Reed	PST.020194 issued 07-18-2013
23. Martin John Szkodzinski (FL)	Ms. Reed	PST.020195 issued 07-18-2013
24. Shivani Suryakant Patel (NJ)	Ms. Reed	PST.020196 issued 07-18-2013
25. Stuart Elliott Tolman (NY)	Ms. Reed	PST.020197 issued 07-18-2013

F. Appearances for Interview

- 1. Vern Alvin Allen (FL)
- 2. Brent Francis Boudreaux (CO)
- 3. Tony Chiu (TX)
- 4. Joseph Anthony Collins, Jr. (TN)
- 5. Amy Jean Delano (AZ)
- 6. Adam James DeRue (NY)
- 7. Ella Diaz Echavia (TN)

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

8. Thomas Edward Edinger (PA)
9. Adelaide Samantha Harper-Delgado (FL)
10. Jeffery James Hinchey (KS)
11. Katherine Ann Jennings (IL)
12. Ashell Lyn Ladner (MS)
13. Julius Li (NJ)
14. Deborah Nix Lively (TN)
15. Damion Wayne Murphy (FL)
16. Souchinda Nanthavongdouangsy (TX)
17. Susan Rapp (AZ)
18. Anne Frances Salisbury (CT)
19. Christopher James Simpson (AL)
20. Thomas Jude Soignet (TX)
21. Victor Glen Spearman (TX)
22. Chelsey Hunter Tate (TN)
23. Jermaine Gerard Tiller (AL)
24. Jennifer Anne Torrey (MA)
25. Shibu Varughese, MD (FL)

G. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Tuesday, August 13, 2013 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-08-2013

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Presentation by Dr. Douglas Cook
6. Review of Docket
 - A. *For Acceptance of Voluntary Surrenders of Credentials*
 - i. Case No. 13-0112 ~ PST.011807 – Lanny Joseph Richard
 - ii. Case No. 13-0266 ~ PST.013008 – William Francis McCarthy, Jr.
 - iii. Case No. 13-0148 ~ PST.018065 – Matthew Marston Lane
 - B. *Petitions For Reinstatement of Suspended Credentials*
 - i. Case No. 13-0239 ~ PST.018503 – Paul Ryan Lemaire
 - ii. Case No. 13-0251 ~ PST.016814 – Brian Gregory Bazajou
 - C. *Petitions for Modification of Previous Orders*
 - i. Case No. 13-0253 ~ PST.014835 – Karen Odom Howington
 - ii. Case No. 13-0252 ~ PST.015624 – Michael Wayne Lindsey
 - iii. Case No. 13-0278 ~ PST.014181 – David Collins Evans
 - D. *Applications for Pharmacist Licensure by Reciprocity*
 - i. Case No. 13-0220 ~ PST-A – John Oliver Capezzuto
 - ii. Case No. 13-0233 ~ PST-A – John Adam Lochridge
 - iii. Case No. 13-0270 ~ PST-A – Elizabeth Farrell Heard
 - E. *Appearances for Informal Conference*
 - i. Case No. 13-0097 ~ PST.013642 – Darlene Deaton Holt
7. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Email: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reinstatement Committee has been ordered and called for 9:00 a.m. on Tuesday, August 13, 2013 in the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 07-30-2013

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Docket
 - A. *Petitions for Reinstatement (suspended + lapsed > 5 years + chair's discretion)*
 - i. PST.017587 – Brian Alan Burford Case No. 13-0156
 - ii. PST.017996 – Robert Lee Harger, III Case No. 13-0219
 - iii. PST.010721 – Motilall Soodeen Case No. 13-0246
 - iv. CPT.007472 – Nikita Antionetta Bush Case No. 13-0247
 - v. CPT.006478 – Ingrid Aisha Hughes Case No. 13-0256
 - B. *Petitions for Modification of Previous Orders*
 - i. PST.010009 – Gradney Donald Couvillon Case No. 13-0243
 - C. *Petitions for Return of Inactive Licenses to Active Status*
 - D. *CDS Petitions for Reinstatement (lapsed > 5 years, appearance not required)*
 - i. CDS.015465.DDS – James A. Crouch
 - ii. CDS.027690.DDS – Charles Coleman
 - iii. CDS.021939.DDS – Nick Gerard Governale
 - iv. CDS.028261.MD – Alphonse Michael Reed
 - v. CDS.028826.DVM – Michelle Arrillaga
 - vi. CDS.009675.DVM – Joseph Michael Breaux
 - vii. CDS.012146.MD – Eric Edward Holt
 - viii. CDS.026551.DDS – David Michael Ellis
 - ix. CDS.008034.MD – James P. Carter
 - x. CDS.032768.DVM – Patience K. Newman
 - E. *Reinstatement of CDS Licenses Previously Suspended Secondary to Action by Another Agency*

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

F. Discretionary Approvals by Committee Chair (lapsed > 1 year but < 5 years)

- i. CDS.033391.MD – Ginger Auer Black
- ii. CDS.037745.MD – Ralph Lee Abraham, III
- iii. CDS.038421.PA – Bartholomew J. Cortez
- iv. CDS.035539.MD – Zia Rehman Khan
- v. CDS.035964.DVM – Andrea Mae Andersen
- vi. CDS.035320.MD – Mohammad Zubir Malik
- vii. CDS.034810.MD – Marjorie N. Person
- viii. CDS.030301.MD – Richard William Awtrey
- ix. CDS.030843.RN – Therese Novak
- x. PST.017643 – Lawrence Wah Tom
- xi. CDS.037542.MD – Christina L. Moll
- xii. CDS.036860.MD – Meredith Portalatin
- xiii. PHY.002850-OS – Apria Pharmacy Network
- xiv. CDS.039867.MD – Valy Fontil
- xv. CDS.034578.DVM – Liza Ledet
- xvi. CDS.037982.DVM – Morgan Fruge Bryant
- xvii. CDS.034623.DDS – Melanie Tucker Chelette
- xviii. CDS.040412.DO – Ashley E. Ferraro
- xix. CDS.026040.HOS – Central Louisiana State Hospital
- xx. CDS.034830.RN – Brenda Cormier Sonnier
- xxi. CDS.040306.DVM – Michael Eugene Dugan
- xxii. CDS.034684.MD – Douglas Matthew Casey
- xxiii. CPT.001277 – Marguerite Daniels Morgan
- xxiv. CPT.006683 – Kristie Renee Steadman
- xxv. CPT.005661 – Sharon Mayzel Bennett
- xxvi. CDS.033249.APN – Yvette Ortego
- xxvii. CDS.007251.MD – Edward Neal Brin
- xxviii. CDS.021937.DDS – Wendell Ellis Grimes
- xxix. CDS.037129.PA – Emma Marie Long
- xxx. CDS.013680.MD – Marcia Benita Davila
- xxxi. CDS.039872.PA – Benjamin Blyte Erwin
- xxxii. CDS.037861.MD – Sonia Kamboj
- xxxiii. CDS.017633.DDS – Patricia E. Baranco
- xxxiv. CDS.012770.MD – Rao Vera Puvvada
- xxxv. CPT.006147 – Rickey O'Neal Watkins
- xxxvi. CPT.007213 – Jennifer Michelle Morse
- xxxvii. CPT.005115 – Priscilla Ann Green
- xxxviii. CDS.012501.MD – Robert Lee Humble
- xxxix. CDS.031026.MD – Paul Cheletre Bernard
- xl. CDS.028164.MD – Rodney E. Hillis
- xli. PHY.003666 – BioPlus Specialty Pharmacy Services
- xl.ii. PHY.005670 – CVS Caremark

G. Staff Approvals by Board Policy (lapsed < 1 year)

- i. CDS.016130.DDS – Bobby D. Jones
- ii. CDS.040520.DVM – Angela Lacoste Ledet
- iii. CDS.040871.MD – Lynda Ebere Mbah
- iv. CDS.034182.MD – Michael John Karge, Jr.
- v. CDS.026817.MD – Gary Wayne Menefee
- vi. CDS.032276.DVM – Rechelle Lynn Diaz

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- vii. CDS.027802.MD – Jaime Gabito Dorotan
- viii. CDS.041200.MD – Justin Kurt Liegmann
- ix. CDS.025271.MD – David Gill Carmouche
- x. CDS.037358.MD – Charles Anthony Stanich
- xi. CDS.019102.MD – Rajat Bhushan
- xii. CDS.040241.MD – John Forrest Engle
- xiii. CDS.041568.RN – Colleen F. Bodet
- xiv. CDS.040039.DO – Ashley Lena Weiss
- xv. CDS.024368.MD – Zahid Imran
- xvi. CDS.041340.DDS – Anitra M. Roberts
- xvii. CDS.037536.MD – Charles C. Mary, Jr.
- xviii. CDS.041518.OD – Manuel M. De la Rua
- xix. CDS.034246.RN – Chris Parmelee Nelson
- xx. CDS.021662.MD – Robert G. Lottinger
- xxi. CDS.030344.MD – Jennifer Avegno
- xxii. CDS.032311.RN – Shirley Freeman Wade
- xxiii. CDS.033310.OD – David Richard Heitmeier
- xxiv. CDS.009669.MD – Jacquelyn Ann Robinson
- xxv. CDS.019570.DDS – Johnnie Hayes Breaux
- xxvi. CDS.034655.DVM – Monique Marie Koll
- xxvii. CPT.008271 – Therese Marie Allen-Varnado
- xxviii. CDS.005093.MD – Rise Delmar Ochsner
- xxix. CDS.030768.MD – Elizabeth S. Taylor
- xxx. CDS.019195.MD – Josefina Cifra Baltazar
- xxxi. CDS.039990.PA – Bethany C. Crosby
- xxxii. CDS.026137.MD – Hossam Abdel-Rahman
- xxxiii. CDS.032143.MIS – River Region Hospice House
- xxxiv. CDS.041522.HOS – Meridian Psychiatric Hospital, Inc.
- xxxv. CDS.013437.MD – William E. Kintzing
- xxxvi. PST.018010 – Nimesh Chandrakant Patel
- xxxvii. CDS.011105.MD – Zeynel A. Karcioğlu
- xxxviii. CDS.032795.RN – Elizabeth Angelette Gisclair
- xxxix. CDS.041452.MD – Danielle Marie Levy
 - xl. CDS.021745.MD – Lisa Ann Perez
 - xli. CDS.017013.MD – Parveen G. Anand
 - xl.ii. PHY.006201-OS – Memorial Compounding Pharmacy
 - xl.iii. CDS.033797.MD – Mohammed A. Amari
 - xl.iv. CDS.002145.MD – Mary Frances Gardner
 - xl.v. CDS.035950.DVM – Jude T. Bordelon
 - xl.vi. CDS.041495.DDS – Waheed V. Mohammed
 - xl.vii. CDS.038123.DVM – Kelly Melinda Folse
 - xl.viii. CDS.041605.DDS – Sean C. Owens
 - xl.ix. CDS.041590.DDS – Allen Neal Sawyer
 - I. CDS.034944.MD – Marc R. Matrana
 - li. CDS.040878.MD – Brent Edward Jones
 - lii. CDS.034203.MD – Mark Harrod Smith
 - liii. CDS.020970.DDS – Charles S. Williams
 - liv. CDS.014979.DDS – Ronald Anthony Barrett
 - lv. CDS.033427.RN – Jennifer Bennett
 - lvi. CDS.041600.MD – Maneesh K. Gupta
 - lvii. CDS.028521.MD – Richa Dhawan

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- lviii. CDS.032195.MD – Marta Fechete
- lix. CPT.010333 – Tabitha Marie Allred
- lx. PST.018524 – Kaveh Askari
- lxi. CPT.009972 – Sarah Elizabeth Logue
- lxii. CDS.041630.RN – Valarie S. Waldmeir
- lxiii. CPT.008913 – Hannah Troia Lewis
- lxiv. CDS.018489.MD – Susan Anthony Crawford
- lxv. CDS.040788.MD – Margaret E. Hollister
- lxvi. CPT.005115 – Priscilla Ann Green
- lxvii. CDS.001816.MD – Robert Vincent Cazayoux
- lxviii. CDS.033405.MD – Elsayed Magdy Elrakabawy
- lxix. CDS.037822.MD – Jared Thomas Geist
- lxx. CDS.040913.MD – Jason Paul Turner
- lxxi. CDS.013444.MD – Teri S. O’Neal
- lxxii. CDS.032429.PA – Marcus D. Wimberley
- lxxiii. CDS.034353.DET – Alexandria Police Department
- lxxiv. CDS.030845.MD – David Spence Texada
- lxxv. CDS.022576.MD – Cary Jason Sharp
- lxxvi. CDS.041536.MD – Dennis Patrick Lindfors
- lxxvii. CDS.037806.DVM – Elizabeth M. Brown
- lxxviii. CDS.041662.MD – James Leighton Mayo
- lxxix. CDS.033349.MD – Windy Marie Dean-Colomb
- lxxx. CDS.026958.DVM – Mark Lewis Gray
- lxxxi. CDS.017883.DDS – Michael Edward Hiller
- lxxxii. CDS.041705.MD – Nathaniel Ross Duhon
- lxxxiii. CDS.020414.DDS – A’lise Steward
- lxxxiv. PST.019290 – Deanna Carol Smith
- lxxxv. CDS.041721.RN – Lisa Harwell Bishop
- lxxxvi. CDS.041812.DVM – Caroline Adele Landry
- lxxxvii. CDS.041764.HOS – St. Jude Baton Rouge Affiliate Clinic
- lxxxviii. CDS.015390.MD – Martha Johnston Brewer
- lxxxix. CDS.002313.MD – James Robert Calvin
 - xc. CDS.024090.MD – Abida Banu Butler
 - xcii. CDS.008244.DDS – Galen Frank Meyers, Jr.
 - xciii. CDS.032486.DDS – Brock Jason Barras
 - xciv. CDS.033459.DDS – Christy Billings Barras
 - xcv. CDS.035446.DDS – Paola Maria Donaire
 - xcvi. CDS.017789.MD – Eric Teiji Ifune
 - xcvii. CDS.035478.OD – Cathy M. Guidry
 - xcviii. CDS.033237.DDS – Jovian S. Monette
 - xcix. CDS.007007.MD – Lynn Simon
 - c. CDS.002395.MD – John Lawrence Moore
 - ci. CDS.037929.DDS – Allison Claire Melancon
 - cii. CDS.037824.RN – Rena Fontenot Braswell
 - ciii. CDS.040404.MD – Sean Elizabeth Hays
 - civ. CDS.035275.DDS – James Bradley Fruge
 - cv. CDS.036595.MD – Elizabeth S. Wasson
 - cvi. CDS.033447.OD – Gregory A. Woodall
 - cvi. CDS.027055.DDS – Louis Charles Passauer, Jr.
 - cvi. CDS.041633.MD – Richard Gitter
 - cvi. CDS.031522.DDS – Sean Gaffney

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- cix. CDS.033815.RN – Tammy T. Stewart-Dixon
- cx. CDS.016348.DDS – Robert Benjamin Coffman
- cxi. CDS.040545.DDS – Erin L. Katz

6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 25. Prescriptions, Drugs, and Devices

...

Subchapter C. Compounding of Drugs

...

§2535. General Standards

A – C ...

D. Compounding for Prescriber’s Use. Pharmacists may prepare practitioner administered compounds for a prescriber’s use with the following requirements:

1 – 3 ...

4. A pharmacy may prepare such products not to exceed ten percent of the total number of drug dosage units dispensed and distributed by the pharmacy on an annual basis.

E. ...

F. Compounding Commercial Products Not Available

A pharmacy may prepare a copy of a commercial product when that product is not available as evidenced by either of the following:

- 1 Products appearing on a website maintained by the federal Food and Drug Administration (FDA) and/or the American Society of Health-System Pharmacists (ASHP).
- 2 Products temporarily unavailable from distributors, as documented by invoice or other communication from the distributor.

G. Labeling of Compounded Products.

1 – 2 ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 23:1316 (October 1997), amended LR 29:2105 (October 2003), effective January 1, 2004, amended LR 39:

CODING: ~~Stricken~~ text is proposed for deletion; underscored text is proposed for addition.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Public Hearing ~ May 30, 2013

Summary of Testimony & Public Comments

1. Vitreoretinal Institute (Baton Rouge) letter received 5-21-2013

Writer informed by his compounding pharmacist that proposed rule would limit his ability to acquire medication for intraocular injection to ten percent of the previously ordered dosage. His patient population cannot afford the prepackaged medication which costs \$2100, and rely on the compounded medication which costs \$50. Objected to the proposed rule; offered no alternative.

2. The Eye Clinic (Lake Charles) letter received 5-28-2013

Writer understands the proposed rule would place a 10% dosage unit restriction on pharmacies in the state. They indicated there is only one compounding pharmacy in the area. Within their five office system, there are more than 400 patient encounters per day and more than 70 surgeries weekly. When considering only the surgical encounters, the pharmacy would have to move 700 units a week. The writer is concerned the pharmacy will have to deny patients that fall beyond the quota. Objected to the proposed rule; offered no alternative.

3. Imperial Calcasieu Surgical Center (Lake Charles) letter received 5-30-2013

Writer indicated over 4500 cataract surgeries performed at facility last year. They indicated there is only one compounding pharmacy in the area to supply the preservative-free dilating drops. Writer indicated a 10% dosage restriction would compromise patient care. The writer is concerned the pharmacy will have to deny patients that fall beyond the quota. Objected to the proposed rule; offered no alternative.

4. Dianne Richards e-mail received 5-30-2013

Writer responded to front page article in Baton Rouge Advocate about extra costs forced on compounding pharmacies. Writer stated these costs will be passed on to seniors who have allergies such as wheat and milk and need compounded medicine. Objected to the proposed rule; offered no alternative.

5. Merrill Patin e-mail received 5-30-2013

Writer indicated information about services provided by PCCA, and further, indicated there were 98 members of that organization within Louisiana, and further, estimated only 10% have the capacity to do sterile compounding in a significant way.

6. Prescription Compounds (Baton Rouge) letter received 5-30-2013

Writer included a calculation table demonstrating impact of proposed rule on her practice. She described most of the sterile compounding activity in her pharmacy to be designated as high-risk according to USP Chapter 797. Objected to the proposed rule; offered no alternative.

7. Ear Nose & Throat Medical Center (Baton Rouge) letter dated 05-28-2013 and received 06-04-2013

Writer uses sterile and non-sterile compounded medications, and ordering medications on a patient-specific basis is not possible. Also concerned about the 10% restriction; a pint

volume (480 ml) would be used on multiple patients and would significantly impact the compounding volume that a pharmacy could provide. It is their goal to deal locally with pharmacists in the state, and suggests the Board should try to keep business in the state. Objected to the proposed rule; offered no alternative.

8. John Liggio, Executive Director at and appearing for La. State Board of Wholesale Drug Distributors

Suggested a clarification of the provisions of §2535.F.1.b to specifically require that the commercial non-availability of a drug product be secondary to a manufacturer back-order and not include a distributor back-order.

9. Merrill Patin, Pharmacist at and appearing for Pharmaceutical Specialties

Requested the Board to reconsider the ten percent limitation. He indicated the proposed rule does not address the appropriate standard of quality and safety governing the product preparation activity, but merely "cuts our losses."

Offered a statement from PCCA and read same into the record.

10. Naomi Mitchell appearing for Total Vein Care

Uses Prescription Compounds for their needs. Due to implementation of proposed rule, they have had to start searching for providers in other state. Would prefer to use providers within the state. Requested the Board to reconsider the ten percent limitation.

11. Wade Riddick, appearing for himself, along with his father, Winston Riddick, with Riddick & Associates.

Described his medical condition and special medication needs; uses Prescription Compounds for compounded medication. Questioned applicability of proposed rule to pharmacies based in hospitals.

Winston Riddick suggested clarification of proposed rule to specify its applicability to drug preparation in response to purchase order and that drug preparation in response to prescription is regulated elsewhere in the rules.

12. Clint Daniels, Pharmacist at and appearing for Boudreaux New Drug Store

Described ability of compounding pharmacy to dispense prescriptions arising from their ability to prepare drugs in response to purchase orders. Economically, they would not be able to dispense prescriptions of drugs without ability to spread cost over products sold to practitioners.

Suggested proposed rule address issue of compounding pharmacies supplying hospitals and health care entities in addition to practitioner's offices.

13. Merrill Patin, Pharmacist at and appearing for Pharmaceutical Specialties

Reported adverse economic impact of emergency rule on his pharmacy in that he was forced to release a staff pharmacist since January 2013 due to reduced ability to respond to customer demand.

Made inquiry of FDA on process to acquire manufacturer registration. Stated it would cost him \$300,000 and two years time.

14. Wade Riddick

Asked what standards were in place for compounding and manufacturing. Described USP and cGMP standards.

15. John Liggio

Suggested Board reinstate use of its parenteral/enteral pharmacy permit in effort to identify and regulate compounding activity.

16. Elaine Patin

Suggested Board consider standards for compounding pharmacies instead of limiting their business activities on a percentage basis.

17. Max Huff

Requested information on the potential risk of manufacturing activity according to compounding standards.

18. Pat Riddick and Winston Riddick

Requested information on whether compounding pharmacies had been disciplined for violations of compounding standards. Asked what problems had occurred within the state that caused the Board to propose the rule amendments.

19. Merrill Patin

Questioned status of New England Compounding Center pharmacy permit.

20. Patricea Angelle, Pharmacist at and appearing for Prescription Compounds

Referenced her letter (Item 6 above). Described impact of proposed rule on her practice. Asked Board's position on PCAB accreditation. Asked whether survey of pharmacies included information about high-risk compounding.

21. Wade Riddick

Asked whether compounding survey results are available.

22. Michael Dorman, Pharmacist at Baton Rouge General Medical Center Pharmacy

His facility purchases compounded preparations from local pharmacies to keep on hand for administration to patients within the facility. Concerned the proposed rule may affect the compounding pharmacy's ability to supply medications needed by their patients.

Requested the Board consider adding authority for compounding pharmacies to supply hospitals or other health care entities in addition to practitioner offices.

23. Patricea Angelle

Requested the Board consider an amendment to require compounding pharmacies keep records of products prepared in response to purchase orders (she objected to that term, but agreed it was in response to something other than a patient-specific prescription), and further, require the pharmacy to develop a patient tracking log for the customer's office, and further, require the customer to record the names of patients receiving the drug preparation (or document wastage) for at least 50% of the amount supplied by the pharmacy, then return the completed tracking log to the issuing pharmacy, and further, for the pharmacies to retain those records for at least two years.



May 16, 2013

Malcolm Broussard
Executive Director
Louisiana State Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700


RE: Proposed Compounding Rule

Dear Mr. Broussard,

I have been informed by my compounding pharmacists that the proposed rule to the legislature would limit our ability to acquire essential medication for intraocular injection. Apparently the idea is to limit our accessibility to ten percent of the previous ordered dosage. Accordingly, this will present a devastating effect on our patient population limiting their access to drugs that prevent blindness. Our patient population can not afford the prepackaged expensive medication from the drug companies and will go untreated if this rule goes into affect. The actual cost of the prepackaged drug is \$2100 whereas the compounded pharmacy drug is \$50. It is shameful that our legislature would consider the hardship imposed upon these patients and the resultant cost of blindness to society.

Please make every effort to correct this problem and allow us access to any amount of the compound and injectible drugs that are needed.

Sincerely yours,


Stephen M. Breaud, M.D., FACS
SMB/lc
05/16/13

cc: Mary Olive Pierson
8702 Jefferson Hwy
Suite B
Baton Rouge, LA 70809



L.D. Stewart, M.D.
W.A. Mixon, M.D.
A.D. Lacoste, M.D.
W.L. Iglinsky, M.D.
J.A. Yokubaitis, M.D.
D.A. Bravin, M.D.
P.M. Crawford, Jr., M.D.
A.J. O'Byrne, M.D.
L.V. Murray, IV, M.D.
M.M. Gehrig, O.D.
J.S. Hankin, O.D.
S.C. East, O.D.
D.N. Lafleur, O.D.

1717 Oak Park Blvd.
Suite 1
Lake Charles Medical Plaza
Lake Charles, LA 70601
(337) 478-3810
1-800-826-5223
FAX (337) 478-6360
Surgery Fax (337) 477-9191

2100 Maplewood Dr.
Sulphur, LA 70663
(337) 625-8948
Fax (337) 625-8949

801 S. Pine Street
DeRidder, LA 70634
(337) 462-3937
Fax (337) 463-9575

1219 Eiton Road
Jennings, LA 70546
(337) 824-0040
Fax (337) 824-0027

277 Hwy 171 N. Ste 4
Lake Charles, LA 70611
(337) 310-0775
Fax (337) 310-0785

May 28, 2013

Malcolm Broussard
Executive Director
Louisiana State Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700

Re: Board Hearing Scheduled for Thursday, May 30, 2013

Mr. Broussard:

Because we are physicians concerned with providing the best care for our patients, we feel the need to bring our perspective to your attention as you consider outcomes that will affect our possible treatment options. We are the physicians of The Eye Clinic in Southwest Louisiana, an organization composed of five offices and thirteen doctors, and for many years we have used the compounding services of local pharmacies on a regular basis. We rely on compounding services to aid our surgery patients and we understand that you are considering placing a 10% dosage unit restriction on state pharmacies. Given that there is now in our area only a single pharmacy that will continue to compound, we are greatly concerned that our patients will be denied what is appropriate.

Our biggest worry is that our patients will suffer as a direct result of these cuts. In our offices alone, we have more than 400 patient encounters a day and more than 70 surgeries weekly. We are just one practice, and there are many practices in the Lake Charles area. If we consider only our surgical encounters, the compounding pharmacy would have to move 700 units a week to accommodate just our surgical patients. Certainly you can see the problem—the local pharmacy will have to deny patients that happen to fall in the 'beyond the quota' area, even when related to surgery or other emergent problems.

We realize that a serious problem predicated your reevaluation of compounding rules in general and we, as healthcare professionals, appreciate that this Board is carefully evaluating this process in order to protect the public. We feel strongly that proceeding with these overly conservative rulings will bring an uncertainty of whether our patients will receive the care they deserve.



L.D. Stewart, M.D.
W.A. Mixon, M.D.
A.D. Lacoste, M.D.
W.L. Iglinsky, M.D.
J.A. Yokubaitis, M.D.
D.A. Bravin, M.D.
P.M. Crawford, Jr., M.D.
A.J. O'Byrne, M.D.
L.V. Murray, IV, M.D.
M.M. Gehrig, O.D.
J.S. Hankin, O.D.
S.C. East, O.D.
D.N. Lafleur, O.D.

1717 Oak Park Blvd.
Suite 1
Lake Charles Medical Plaza
Lake Charles, LA 70601
(337) 478-3810
1-800-826-5223
FAX (337) 478-6360
Surgery Fax (337) 477-9191

2100 Maplewood Dr.
Sulphur, LA 70663
(337) 625-8948
Fax (337) 625-8949

801 S. Pine Street
DeRidder, LA 70634
(337) 462-3937
Fax (337) 463-9575

1219 Elton Road
Jennings, LA 70546
(337) 824-0040
Fax (337) 824-0027

277 Hwy 171 N. Ste 4
Lake Charles, LA 70611
(337) 310-0775
Fax (337) 310-0785

Like you, our greatest concern is for the public's well being. Also like you, we feel that safety in our Louisiana pharmacies is of the utmost importance. However, we do not feel the current plan is in the best interests of either our patients or our practice.

Thank you for your consideration of our position. Please feel free to contact our office if you should have any questions.

Sincerely,

Patrick Mark Crawford, Jr., M.D.

Jon A. Yokubaitis, M.D.

L. Virgil Murray, IV, M.D.

Alvaro J. O'Byrne, M.D.

Alan D. Lacoste, M.D.



Imperial Calcasieu Surgical Center

1757 Imperial Blvd.
Lake Charles, LA 70605
(337) 310-2832 phone
(337) 310-1426 fax
www.icsurg.com

May 30th 2013

Malcolm Broussard
Executive Director
Louisiana State Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 708091700

Re: Board Hearing

Mr Broussard:

We rely on compounding services of local pharmacies on a regular basis for the cataract surgery performed at our facility. Last year the local physicians performed over 4500 cataract surgeries using compounded preservative free dilating drops. If you are considering a 10% dosage restriction it would compromise patient care within our community. We have only one local pharmacy within our community that will continue to compound. I am sure the intent is not to deny patients that fall in "beyond the quota" area, as it relates to our surgeries.

As healthcare professionals we appreciate that the Board is carefully evaluating this process to protect the public. However, we feel strongly that proceeding with these overly conservative rulings will bring an uncertainty of whether our patients will receive the care they deserve.

Thank you for your consideration of our position.

Kindest Regards,

A handwritten signature in cursive script that reads "Bonnie Goodwin".

Bonnie Goodwin
Administrator

Malcolm J. Broussard

From: info
Sent: Thursday, May 30, 2013 10:01 AM
To: Malcolm J. Broussard
Subject: FW: Compounding plan



From: Grimes [grimesaj@bellsouth.net]
Sent: Thursday, May 30, 2013 9:04 AM
To: info
Subject: Compounding plan

Board:

I am responding to a front page article in today's *Advocate* about extra costs forced on compounding pharmacies. These costs will be passed on to seniors who have allergies such as wheat and milk and need compounded medicine. The cost of compounded medicine is already higher than brands and generics and this will just make it worse. Part D does not cover compounded medicine so these will be out-of-pocket increases.

Please reconsider this plan with seniors in mind.

Dianne Richards



Merrill Patin <merrillpatin@gmail.com>

For your hearing

Stephan Beek <SBeek@pccarx.com>
To: merrillpatin@gmail.com
Cc: Jim Smith <JSmith@pccarx.com>

Thu, May 30, 2013 at 12:43 PM

Jim asked that we send you a short statement, below.

I am available via cell ([713-397-1435](tel:713-397-1435)) for any questions.

PCCA serves over 3500 independent community pharmacies in the USA by providing them access to modern, contemporary compounding support. For the past 30 years, PCCA has focused on providing them with world-class education, consulting, formulation, pharmaceutical grade chemicals and dispensing supplies. PCCA prides itself on having the strictest 14-step quality standards for chemicals in the industry along with more pharmacists and pharmaceutical chemists on hand for members to consult with.

The state of LA has 98 PCCA members, whom we consider to be the key compounders in the state. About half of those members are very involved in compounding. It is estimated that only 10% have the capacity to do sterile compounding in a significant way.

Stephan Beek | Director of Marketing / Communications

PCCA | 9901 South Wilcrest Dr. | Houston, TX 77099-5132

Ph: [800.331.2498](tel:800.331.2498) | Cell: [713-397-1435](tel:713-397-1435)

Fax: [281.933.6016](tel:281.933.6016)

www.pccarx.com

Follow Us on Facebook: www.facebook.com/pccarx

Follow Us on Twitter: www.twitter.com/pccarx

Network with Your PCCA Colleagues: www.pccarxchange.com



PRESCRIPTION COMPOUNDS

PHONE: 225-766-9577
FAX: 225-766-7997

5302 O'DONOVAN DRIVE
BATON ROUGE, LA 70808

TOLL FREE NUMBER: 1-888-876-8778
EMAIL: PHARMACIST@PRESCRIPTION-COMPOUNDS.COM



Louisiana's First PCAB™ Accredited Compounding Pharmacy

May 30, 2013

Dear Board Members,

I appreciate the long hours of work and the meetings that all of you put in. I was there once and sincerely understand.

Several of you have asked me to give better information in print regarding the proposed rule regarding Prescriber Use Medications. I have prepared a sample table that reflects what the 10% restriction would mean to a facility – bear in mind that this figure includes sterile and non-sterile preparations.

Information included with this letter:

- A - Proposed regulatory language
- B - Calculation Table regarding dosage unit restrictions

Prescriber/Office Use:

The math does not work. (Sample dosage unit calculations are provided in the attached document.) As reflected in the Calculation Table, this 10% dosage unit restriction will potentially limit access to compounded medications (non-sterile and sterile) used by prescribers. Once the 10% dosage unit figure is reached, any further compounded medication orders must be refused to be compliant with this proposed rule.

Sterile Compounding - Office Use and Patient Specific Medications:

Our facility, Prescription Compounds is the **ONLY PCAB Accredited Compounding Pharmacy in the State of Louisiana** that has continued to compound Sterile Medications.

What does PCAB (Pharmacy Compounding Accreditation Board) Accreditation mean:

It means that our standards not only meet, but exceed the industry standards set forth by the United States Pharmacopeia (USP) and the Louisiana State Board of Pharmacy. We are *Louisiana's First* Pharmacy to be accredited by PCAB - the Pharmacy Compounding Accreditation Board for sterile and non-sterile pharmacy compounding. It is a voluntary accreditation, that represents many hours of work to achieve and maintain. We first earned this status in 2007 and have worked hard to maintain it. It is one more layer of quality and consistency that we chose to provide to patients and practitioners. There are less than 1% of pharmacies in the nation to have earned this SEAL.

Today, these proposed restrictions are directly affecting access to Sterile - Office Use Medications.

Next, is the consequential impact to the compounding of sterile medications for patient-specific needs.


Patient access is of greatest concern. We have already started to adjust our business model, as other compounding pharmacies have already been forced to do. Patient access within the state of Louisiana is being directly impacted and will only continue to decline. The patient population that we service is NOT the majority, but they need help too. Many of them are very sickly and unable to prepare correspondence or attend hearings, etc.

Most of the sterile compounding that we are called on to do is designated as High Risk according to USP 797. Of the 200 pharmacies that have been identified to prepare sterile compounds (according to counts from 2012 renewal cycle for state of Louisiana), there are no other PCAB accredited pharmacies in that number. I do not have the information as to whether these facilities are truly able to provide high-risk sterile preparations.

We are committed to work with the Board to get to workable solutions. This is what our practice is about. I truly believe this is achievable. Your charge as a Board is to provide public safety for the consumer. This patient population is no less important because of their unique health conditions and/or medication needs.

Sincerely,

Patricea 'Patsy' Angelle. PD, FACA, FIACP
Pharmacist-in-Charge



A. Proposed Language is as follows:

' A pharmacy may prepare such products not to exceed 10% of the total number of drug dosage units dispensed and distributed by the pharmacy on an annual basis. '

B. Calculations regarding Monthly Dosage Unit Restriction:

(based on 60 Rx's per day or 36000 dosage units total per month)

Office Medication	Med Orders per month	Volume Disp ea/gm/ml	Total Vol from Orders	Patient Dose gm/ml	Dosage Units ea	Dosage Units per month 3600
Derm Topical	2	454	908	1	908	2692
Injectables - 1 x 30ml	2	30	60	1	60	2632
Injectables - 2 x 30ml	2	60	120	5	24	2608
Injectables - 3 x 30ml	2	90	180	5	36	2572
Nasal Spray	2	480	960	1	960	1612
Nasal Topical	3	480	1440	1	1440	172
Opth Surgery Prep	4	1	80	1	80	92
Single dose syringes	3	1	150	1	150	-58
Topical - 20 x 3ml	2	60	120	3	40	-98

Dear Practitioner,

**As you can see from this calculation table,
the 10% dosage unit figure does significantly limit the
office use medications that we are able to provide to you.**

This example reflects only 6 offices serviced.

Last 2 entries = 4 offices = 6 med orders

3 Medication Orders would have to be denied because of the 10% restriction.



May 28, 2013

Board Members
c/o Malcolm Broussard, Executive Director
Louisiana State Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700

Re: Proposed Compounding Rules

Dear Board Members,

I am sincerely concerned about the proposed rule regarding Prescriber/Office Use compounded medications. We use several sterile and non-sterile compounded medications that are very important in the diagnosis and treatment of our patient population. Our patients present with a multitude of conditions. It is impossible to know what medications will be needed to diagnosis, treat, and care for these patients before the office visit. Therefore, ordering medications on a patient-specific basis to be used in the diagnosis is just not possible.

I am also concerned about the 10% restriction. As a pint volume (480mL) of nasal solution would be used on multiple patients and does significantly impact the compounding volume that the pharmacy would be allowed to provide.

I understand that the Board is in place to provide public safety; however, it should also take into consideration that this type of restriction will directly impact patient care which is the ultimate goal of our professions – as physicians and pharmacists.

Without access to these preparations, it would be increasingly difficult to offer the proper care and treatment to these patients. It is our goal to deal locally with pharmacists in our state. Since you are the agency that is charged with oversight of the pharmacies here in Louisiana, I am confident that your oversight would be more efficient and that as practitioners we could rely on that expertise. Additionally, in these economic times, I would hope that you would try to keep business here in our state.

Please make every effort to consider the impact to patient care and treatment.

Sincerely,

Charles Mitchell, MD





Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Executive Committee has been ordered and called for 5:00 p.m. on Tuesday, August 13, 2013 at the Board office, for the purpose to wit:

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-09-2013

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Consideration of Amendments to Board's Policy & Procedure Manual
 - a. Policy # II.B.7 – Dress Code
 - b. Policy # II.C.2 – Employment
 - c. Policy # II.C.3 – Employment Benefits
 - d. Policy # II.C.5 – Office Hours
 - e. Policy # II.C.6 – Attendance
 - f. Policy # II.C.7 – Performance Planning & Review
 - g. Policy # II.C.9 – Holidays
 - h. Policy # II.C.10 – Layoffs & Layoff Avoidance Measures
 - i. Policy # III.B – Document Depository Program
6. Consideration of Amendment to Existing Contract with NexLearn
7. Review of Administrative Operations
8. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Title: Dress Code

Policy No. II.B.7

Approved: 05-11-2005

Revised:

.....

Employees of the Louisiana Board of Pharmacy are expected to be well groomed and dress in a professional manner. Remember to conduct yourself at all times in a way that best represents you and the office.

~~During Board or Board committee meetings, employees of the Louisiana Board of Pharmacy making public appearances, and/or appointments both inside and outside of the office shall wear proper attire as follows:~~

The Board has defined proper attire as follows for its staff:

Women: Slacks, skirts, or dresses are appropriate. Shorts, leggings, mini-skirts, halter-tops and tennis shoes or sneakers are not appropriate. Hosiery should be worn with any dress or skirt worn above knee-length.

Men: Suits, sport coats, ties, polo, button front dress shirts and pants may be worn to maintain a professional appearance. Tennis shoes or sneakers are not appropriate. Facial hair such as beards and sideburns must be neat, clean, and well trimmed.

Students: Casual attire is appropriate. Jeans are appropriate; however, faded, worn down jeans are not acceptable. Inappropriately printed T-shirts, flip flops, muscle-shirts, tank tops, shorts, leggings, sweatpants, mini-skirts, and halter-tops are not appropriate. If there is a Board or Board committee meeting, dark denim, khakis, or other casual pants of the same quality should be worn. Facial hair such as beards and sideburns must be neat, clean, and well-trimmed.

Fridays: Casual attire may be worn. Jeans, khakis, or other casual pants of the same quality may be worn; however, faded, worn down pants are not acceptable. Inappropriately printed T-shirts, flip flops, muscle shirts, tank tops, shorts, leggings, sweatpants, mini-skirts, and halter-tops are not appropriate.

If an employee has business outside the office, please adhere to the above dress code.

Exceptions to the above policy may be approved in advance by your supervisor, upon a showing of good cause.

A supervisor is authorized to send an employee home if the attire does not meet these professional standards. Always remember the Louisiana Board of Pharmacy is a professional organization and these provisions should be interpreted with that in mind.

Title: Dress Code

Policy No. II.B.7

Approved: 05-11-2005

Revised:



Revision History

08-14-2013 Added sneakers as an example of inappropriate attire.

DRAFT

Title: Employment

Policy No. II.C.2

Approved: 05-11-2005

Revised:

.....

No individual will be deprived of, or granted, an employment opportunity, promotion, or transfer opportunity due to their race, color, religion, sex, sexual orientation, national origin, political affiliation, or disability.

New Employees

New employees will familiarize themselves with the Policy & Procedure Manual. Questions regarding an office policy or procedure should be directed to the Office Manager or Appointing Authority.

Consent to a background check is a condition of employment within the Louisiana Board of Pharmacy.

Each new employee shall be processed through the Office Manager and complete personnel data records, payroll withholding forms, group insurance selection and retirement system forms and any other forms deemed necessary.

All full-time employees must obtain an identification card issued by the Office Manager. The ID card, which contains a photograph of the employee, remains the property of the Louisiana Board of Pharmacy.

Termination (Voluntary or Involuntary)

Employees desiring to voluntarily terminate their employment are urged to notify the Louisiana Board of Pharmacy at least two weeks in advance of their intended termination. Such notice should preferably be given in writing to the immediate supervisor and the Office Manager. The notice should be addressed to the Appointing Authority and then forwarded to the Office Manager for processing. Proper notice allows the Office Manager time to prepare your final payroll documents and to calculate any accumulated leave to which you may be entitled. Employees who are terminated for any reason, voluntary or involuntary, shall be paid wages due on or before the next regularly scheduled payday, or within fifteen (15) days of termination, whichever occurs first.

Employees who are planning to retire should notify the Office Manager a minimum of three months in advance. This will allow ample time to file the application for retirement and other supporting documentation. Employees eligible for Social Security should contact their local Social Security Administration office at least three months in advance of their expected retirement date to allow for processing of the related Social Security documents.

Title: Employment

Policy No. II.C.2

Approved: 05-11-2005

Revised:

.....

All temporary appointments (restricted, intermittent, job appointments, probational, and provisional appointments) are on an “at will” basis and may be terminated at any time with no reason given.

Permanent employees may also be non-disciplinarily terminated in accordance with Civil Service Rule 12.6 when

- They exhaust sick leave and are still not able to report to work;
- When they fail to maintain a required license; or
- When they have ~~ten~~ seven or more unscheduled absences ~~in a six month period~~ during any consecutive 26 week period. For more information, see the Unscheduled Absence provisions of Civil Service Rule 12.6.

Permanent classified employees may be terminated for cause or by an approved lay off in accordance with Civil Service Rules. Although it is hoped the relationships with employees are long-term and mutually rewarding, the Louisiana Board of Pharmacy reserves the right to terminate employee relationships in accordance with applicable Civil Service Rules. For example, if an employee who is required to drive as part of the essential duties of the position has his/her license revoked or suspended, the employee may be subject to non-disciplinary removal because the employee is no longer able to carry out the duties of the position.

Exit interviews are held with the Appointing Authority. This is usually done on the last official day of work. The purpose of this interview is to review eligibility for continuation of benefits and conversion to ensure that all necessary forms are completed, to collect all Louisiana Board of Pharmacy property including, but not limited to, all office equipment, office keys, building access cards, identification card, board-owned cell phone, badge, and the Policy & Procedure Manual, and to provide the employee with an opportunity to discuss their job-related experiences. The terminated employee shall complete the exit interview before receiving a final paycheck.

Title: Employment

Policy No. II.C.2

Approved: 05-11-2005

Revised:



Revision History

08-14-2013 Updated the unscheduled absence rule to conform to the revision in the Civil Service rules.

DRAFT

Title: Employment Benefits

Policy No. II.C.3

Approved: 05-11-2005

Revised:

.....

Full-time employees are entitled to receive certain benefits and earn annual and sick leave on a continual basis in accordance with policies set forth by the State of Louisiana.

Health Insurance

New employees must enroll in a group benefit plan within the first 30 days of employment. If this deadline is missed the employee may still enroll as a late applicant, but they must provide proof of insurability, which is subject to approval by the insurance plan selected. Also, a pre-existing condition clause may be imposed on the applicant for a period of one year from the date of coverage. The portability law may be applicable in some cases for late applicants who had other health insurance coverage within 60 days prior to the effective date of coverage with the Louisiana Board of Pharmacy health plan. If an employee declines to enroll in health insurance a waiver of coverage must be filled out within the first 30 days of employment.

IMPORTANT: A new enrollment form must be completed for each new dependent within 30 days after acquiring the new dependent (birth, adoption, marriage, etc.). Failure to comply with this rule will subject your dependent to the pre-existing condition clause even if adding the new dependent does not result in a change in classification of coverage of the premium.

NOTIFICATION OF CHANGE ERROR: It is the employee's responsibility to notify the program of any change or error in classification of coverage or any other error affecting his contribution amount. Any failure later determined will be corrected on the first of the following month. All refunds shall be limited to six months from the date notice is received by the Office of Group Benefits.

Employees may change their health care provider every year during open enrollment only, which is held every year beginning ~~April~~ October 1st. Dates are subject to change. All changes executed in the month of ~~April~~ October will become effective ~~July~~ January 1 of the current year, through ~~June 30~~ December 31 of the following year.

Because health care providers change on a yearly basis, please see the Office Manager for the most current up-to-date health care providers in your area.

Retirement

Classified employees or unclassified employees who were members of LASERS prior to July 1, 1991 are eligible for membership in LASERS. Full-time employees are automatically enrolled in the Louisiana State Employees' Retirement System (LASERS). Certain employees are not eligible for membership in LASERS: part-time (20 hours or

Title: Employment Benefits

Policy No. II.C.3

Approved: 05-11-2005

Revised:

.....

less per week) and temporary employees (restricted job appointments). Persons who are age 60 or older at the time of employment have the option to join LASERS, if they meet all other eligibility requirements. If employment is terminated prior to retirement, the employee can request a refund of retirement contributions. The employee must be out of state service at least 30 days to obtain a refund. Since retirement contributions are tax deferred, taxes and related penalties will apply to cash refunds.

For more information about Louisiana State Employees Retirement System (LASERS), please visit their home page at <http://www.lasers.state.la.us>.

La Capitol Federal Credit Union

La Capitol Federal Credit Union offers a wide array of financial products to all state employees. Because this is a not-for profit, they are able to offer products at low costs. For membership or service information, check out their website at <http://www.lacapfcu.org>, email securemail@lacapfcu.org, or visit any office.

START Savings Program

The Office Manager can setup payroll deductions for the Louisiana Tuition Trust Authority's START Saving Program. The program is a college savings plan for children and qualifies as a Qualified Tuition Program under Section 529 of the Federal Internal Revenue Code.

For enrollment and information, interested employees should contact the START Saving Program at 1-800-256-5625 or access the START portal by logging on to the LOSFA website at: <http://www.osfa.state.la.us>.

Worker's Compensation

Employees are covered by workers compensation, which provides for payment of medical expenses and partial salary payments in the event of an approved work-related injury or illness. The amount of the benefits payable and the duration of payment depend on the nature of the injury or illness and the employee's salary. In general, usual and customary medical expenses incurred in connection with an injury or illness are paid and partial salary payments are provided beginning after the seven-day waiting period.

For more information concerning employee benefits, please contact the Office Manager.

Title: Employment Benefits

Policy No. II.C.3

Approved: 05-11-2005

Revised:

Revision History

08-14-2013 Updated dates of the plan year as stipulated by the State Employees Group Benefit Plan (SEGBP).

DRAFT

Title: Office Hours

Policy No. II.C.5

Approved: 05-11-2005

Revised:

.....

The office of the Louisiana Board of Pharmacy is open from 8:00 am to 4:30 pm Monday through Thursday and from 8:00 am to 4:00 pm on Friday.

1. Lunch

- A. Each employee who works an eight hour day shall be granted a thirty minute lunch break each day.
- B. An employee is not allowed to work during their lunch break unless absolutely necessary. If absolutely necessary, the employee must have prior approval from the Appointing Authority before doing so. If prior approval was not given, the employee is on his/her own time during this period and he/she will not be paid overtime.
- C. In order to provide sufficient time for the entire office staff to have a lunch break, the supervisors shall ensure that no lunch break shall begin prior to 10:30 am or extend past 2:30 pm. However, supervisors may authorize variations in this range when such variations are in the best interest of office operations.

2. Breaks

- A. Each employee who works a four hour day shall be granted one fifteen minute paid work break or rest period.
- B. Each employee who works an eight hour day shall be granted two fifteen minute paid work breaks or rest periods.
- C. Each employee who works an eight hour day may combine the thirty minute lunch break along with the two fifteen minute breaks for a total of a one hour lunch break. However, no employee should ever leave a customer waiting by going to lunch and/or on a break.

3. Outside Normal Office Hours

If circumstances require an employee to vary their work schedule from the normal office hours, a written request shall be sent to the Appointing Authority for approval.

Title: Office Hours

Policy No. II.C.5

Approved: 05-11-2005

Revised:



Revision History

08-14-2013

Established a range of time for lunch breaks in Item 2 as well as the right of a single work break for the employee working four hours per day.

DRAFT

Title: Attendance

Policy No. II.C.6

Approved: 05-11-2005

Revised:

.....

To ensure that accurate records are kept of the hours employees actually work (including overtime hours worked where applicable) and of the accrued leave time taken, and to ensure that employees are paid in a timely manner, employees based in the office shall use the time clock system, and employees based at home are required to complete a Daily Attendance and Leave Record Form. At the end of the pay period, the time should be reported as it was worked with any leave taken reported to their immediate supervisor within ten (10) business days following the end of each pay period.

Daily Attendance and Leave Record Forms shall then be submitted by the immediate supervisor to the Office Manager for processing within three (3) business days. No employee is permitted to date, complete and/or sign a Daily Attendance and Leave Record Form for another employee.

Falsification of payroll records is a breach of Louisiana Board of Pharmacy policy, a violation of state law, and is grounds shall constitute an adequate basis for disciplinary action, including termination for payroll fraud.

Absenteeism

The Louisiana Board of Pharmacy expects all employees to assume diligent responsibility for their attendance and promptness. Should an employee be unable to report to work because of an illness, the immediate supervisor or Appointing Authority shall be notified within thirty minutes of expected time of duty, unless it is an extreme circumstance. Failure to properly notify the immediate supervisor or Appointing Authority may result in an unexcused absence.

If an employee is absent for more than three consecutive days, a statement from a health care professional is required before being permitted to return to work. The Louisiana Board of Pharmacy reserves the right to require an employee to be examined by a health care professional designated by the Louisiana Board of Pharmacy at its discretion, especially where abuse is suspected, e.g., or example, when an employee's leave record indicates a pattern of absences and/or frequent absences before or after holidays or weekends.

For the office to operate efficiently, each employee shall be at their place of assignment at the scheduled time. When an employee is away from the office on business, their immediate supervisor should be aware of the employee's whereabouts at all times. Absenteeism that is unexcused or excessive in the judgment of the Louisiana Board of Pharmacy is grounds shall constitute an adequate basis for disciplinary action, up to and including dismissal.

Louisiana Board of Pharmacy

Policies & Procedures

Title: Attendance

Policy No. II.C.6

Approved: 05-11-2005

Revised:

.....
Tardiness

Employees are expected to be punctual. It is understood that common problems do occur; however, an employee who is excessively tardy for an extended period of time may result in leave without pay during the actual period(s) of time he/she was late and could further lead to disciplinary action or discharge. Tardiness that is unexcused or excessive in the judgment of the Appointing Authority ~~is grounds~~ shall constitute an adequate basis for disciplinary action, up to and including dismissal. Excessive tardiness on the part of any employee may be considered when recommending salary increases or promotions.

DRAFT

Title: Attendance

Policy No. II.C.6

Approved: 05-11-2005

Revised:

Revision History

08-14-2013

Added requirement for office-based employees to use time clock system, and home-based employees to continue to use paper time sheets.

DRAFT

Title: Performance Planning & Review

Policy No. II.C.7

Approved: 05-11-2005

Revised:

.....

~~All Civil Service classified employees will receive an annual performance appraisal, which is an evaluation of the individual's work performance. Only at the discretion of the Appointing Authority shall Civil Service unclassified employees have an annual performance appraisal.~~

~~New employees hired on probational appointments serve up to a twenty four month probation period. If their job performance is satisfactory during this time, the supervisor can recommend that they be made permanent as early as six months into the probationary period. However, employees hired under Civil Service Rule 6.5(g) — Flexible Hire Rate Policy are required to serve a minimum of a twelve month probationary period.~~

~~A probational employee may be terminated at any time during the probationary period. Performance and task standards have been established for each position. The supervisor will have a planning session with the employee within 30 days of his/her date of hire so that there will be a clear understanding as to what is considered standard performance of the tasks assigned. At the end of the sixth month of work, the supervisor will be required to formally evaluate the new employee to determine whether to continue probation or to recommend permanent Civil Service status and/or a merit increase. If the probationary employee is recommended for permanent status and funds are available, the Appointing Authority may grant the employee a 4% merit increase.~~

~~Per Civil Service Rule 10.6(c), the employee's rating session shall take place within 60 calendar days before or on the employee's anniversary date. Failure to follow proper performance planning and review procedures should be reflected on the supervisor's performance review.~~

~~Per Civil Service Rule 10.10(b), any employee whose official overall rating or re-rating is "Needs Improvement" or "Poor" shall not receive a merit increase, promotion or permanent status. An employee whose official overall rating or re-rating is "Needs Improvement" or "Poor" shall not be detailed to a higher level position except as approved in advance by the Director of Civil Service.~~

~~When considering employees for permanent status, merit raises, promotions or reallocations, supervisors are to review and document their consideration of performance planning and review ratings. To ensure that employees perform their respective jobs to the best of their abilities, it is important that they be recognized for good performance and that they receive appropriate suggestions for improvement when necessary. Consistent with this goal, their performance will be evaluated by their supervisor on an ongoing basis. All written performance reviews will be based on overall performance in relation to job responsibilities and will also take into account~~

.....

~~conduct, demeanor, and record of attendance and tardiness along with other related factors. In addition to the regular performance evaluations described above, special written performance evaluations may be conducted by a supervisor at any time to advise the employee of the existence of performance problems. After a supervisor reviews an employee's performance rating with the employee, the employee will have the opportunity to attach comments regarding the evaluation of the appraisal form.~~

~~Procedure for Completing Performance Planning & Review~~

~~• Probationary Performances~~

~~Approximately sixty (60) days in advance of the completion of the employee's probationary period, the Office Manager will forward a Performance Appraisal form, with "probationary" checked off, to the Appointing Authority. If the Appointing Authority is not the employee's rating supervisor, the Appointing Authority will then forward it to the appropriate rating supervisor.~~

~~If the employee has successfully completed the probationary period, the rating supervisor should fill out the form and discuss each area of the form with the employee. The rating supervisor and employee must sign the form. After completion, the rating supervisor should forward the form to the Appointing Authority for signature. The Appointing Authority is responsible for returning the original form to the Office Manager and providing a duplicate copy to the employee. If the employee receives a rating of "outstanding", "very good", or "satisfactory", he/she may be eligible for a merit increase per Civil Service Rule 6.14(a). Any employee who receives a rating of "poor" or "needs improvement" shall not be eligible for any increase under the provisions of Civil Service Rule 6.14(i).~~

~~If the employee has unsuccessfully completed the probationary period and problems exist with the employee's work performance, the rating supervisor should fill out the form and discuss each area of the form with the employee. The employee must be informed which area of performance needs to be improved. The employee will then be re-evaluated on his/her anniversary date. During this period, the probation is extended for a period to be determined by the Appointing Authority. Both the rating supervisor and the employee must sign the form. The rating supervisor should forward the form to the Appointing Authority for signature. The Appointing Authority is responsible for returning the original to the Office Manager and providing a duplicate to the employee.~~

.....

- ~~Annual Performance Appraisal~~

~~Approximately sixty (60) days in advance of the established anniversary date, the Office Manager will forward a Performance Appraisal Form with "Annual Appraisal" checked off, to the Appointing Authority. If the Appointing Authority is not the employee's rating supervisor, the Appointing Authority will then forward it to the appropriate rating supervisor. After completion, the rating supervisor should fill out the form and discuss each area of the form with the employee. Both the rating supervisor and the employee must sign the form. The rating supervisor should forward the form to the Appointing Authority for signature. The Appointing Authority is responsible for returning the original to the Office Manager and providing a duplicate to the employee. If the employee receives a rating of "outstanding", "very good", or "satisfactory", he/she may be eligible for a merit increase per Civil Service Rule 6.14(a). However, an employee who has a current official overall performance planning and review rating of "poor" or "needs improvement" shall not be eligible for any increase under the provisions of Civil Service Rule 6.14(i).~~

Merit/Salary Increases

- ~~Merit Increases (Classified Employees Only)~~

~~When a new employee has been continuously employed, without a break in service of one or more working days for a period of six months, he becomes eligible for and may be granted a merit increase provided that the Appointing Authority has determined his/her performance merits such an award per Civil Service Rule 6.14(a).~~

~~At the end of each subsequent twelve (12) month period of such continuous employment, he/she may be granted an additional merit increase if the Appointing Authority has determined that his/her performance merits such an award. This date of eligibility shall then be known as his/her anniversary date and shall not change through such continuous employment within the classified service per Civil Service Rule 6.14(b).~~

~~The amount of merit increases is four (4) percent of the employee's individual pay rate per Civil Service Rule 6.14(c). Merit increases are only given to employees at the sole discretion of the Appointing Authority. No supervisor has the right to give merit increases.~~

- ~~Salary Increases (Unclassified Employees Only)~~

~~A salary increase may be given at any point in time and does not have a minimum or maximum percentage. The salary increase is solely at the discretion of the Appointing Authority and/or the Louisiana Board of Pharmacy.~~

Title: Performance Planning & Review

Policy No. II.C.7

Approved: 05-11-2005

Revised:

.....

With respect to those Board employees serving in the classified state civil service system, they shall receive an annual performance appraisal in compliance with the relevant rules of the Dept. of State Civil Service. Any performance adjustments granted shall comply with the relevant rules of the Dept. of State Civil Service.

With respect to those Board employees serving in unclassified positions, the Appointing Authority shall determine whether and when to conduct an annual performance appraisal. Any performance adjustments granted shall be at the sole discretion of the Appointing Authority or the Board.

DRAFT

Title: Performance Planning & Review

Policy No. II.C.7

Approved: 05-11-2005

Revised:

Revision History

08-14-2013

Due to significant changes in the Civil Service rules, this entire section was stricken and replaced with two paragraphs, one relative to classified employees and the other related to unclassified employees.

DRAFT

Title: Holidays

Policy No. II.C.9

Approved: 05-11-2005

Revised:

.....

Holidays shall be observed as provided in La. R.S. 1:55, and by any proclamation issued by the Governor. The Appointing Authority will also grant paid holidays declared as such in the Governor's proclamation when a holiday falls on a Saturday or Sunday.

To be eligible to receive holiday pay, an employee must be in pay status a minimum of 4 hours the day before or the day following the holiday. In other words, hours worked must touch the holiday. Approved paid leave is considered a day worked for holiday pay eligibility.

Employees shall be eligible for compensation on holidays observed except:

- When the employee's regular work schedule averages less than twenty (20) hours per week;
- When the employee is a temporary, intermittent, restricted, or seasonal employee; or
- When the employee is on leave without pay immediately preceding and following the holiday period.

The Louisiana Board of Pharmacy grants full-time employees the following paid holidays:

- New Year's Day
- Martin Luther King, Jr. Day
- Mardi Gras Day
- Good Friday
- ~~Memorial Day~~
- Independence Day
- Labor Day
- Veterans Day
- Thanksgiving Day
- Christmas Day
- Inauguration Day (once every four years; city of Baton Rouge)
- General Election Day (in even numbered years)

With Governor's Proclamation only:

- President's Day
- Memorial Day
- Acadian Day (day after Thanksgiving)
- Any and all other proclaimed holidays

Title: Holidays

Policy No. II.C.9

Approved: 05-11-2005

Revised:

Revision History

08-14-2013

Re-classified Memorial Day as a holiday requiring a proclamation from the Office of the Governor.

DRAFT

Title: Layoffs & Layoff Avoidance Measures

Policy No. II.C.10

Approved:

Revised:

-
1. In the event the appointing authority certifies the board does not have sufficient funds to continue current operations without the implementation of a layoff or layoff avoidance measures, the appointing authority shall submit a written plan for a layoff or one or more layoff avoidance measures to the Director of the Dept. of State Civil Service for approval at least two weeks prior to the implementation of the plan.
 2. The Director may (a) approve the plan, (b) disapprove the plan, or (c) refer the plan directly to the Civil Service Commission for consideration at its next regularly-scheduled meeting.
 3. The appointing authority shall, as soon as it is determined that a layoff or layoff avoidance measure is necessary, make a reasonable attempt to notify all employees who could be affected.
 4. Once a layoff avoidance plan is approved by the Director or Commission, it shall be made generally available to the employees who are affected.
 5. The appointing authority is authorized by the board to seek approval of any, including one or more, of the following layoff avoidance measures, but only in compliance with Chapter 17 of the Commission's rules:
 - a. Reduction or Elimination of Performance Adjustments
 - b. Reduction in Work Hours
 - c. Furlough Without Pay
 - d. Retirement Incentive
 6. In the event layoffs are required, such actions shall be accomplished in compliance with Chapter 17 of the Commission's rules.

Title: Louisiana State Documents Depository Program

Policy No. III.B

Approved: 05-09-2007

Revised:

-
1. The statutory authority for this program is RS 25:121-124.
 2. The regulatory authority for this program is LAC 25:VII.4301 – 4317.
 3. The staff shall compile and maintain a roster and inventory of agency publications.
 - 3.4. The staff shall cooperate with the Louisiana State Library's Document Depository Program by transmitting the required number of copies of all public documents on a periodic basis to the state library, at:

~~Ms. Feroi Foes~~ Dr. Karen J Cook
Recorder of Documents
State Library of Louisiana
701 N. 4th Street
Baton Rouge, LA 70802-5232
Telephone 225.342.4929
Facsimile 225.219.4725 4804
Email ffoes@pelican.state.lib.la.us KCook@slol.lib.la.us

- a. For all documents printed commercially, 20 copies shall be reserved for and transmitted to the Document Depository Program.
 - b. For all documents posted electronically, a PDF copy of the file shall be transmitted to the Document Depository Program.
4. ~~Twenty (20) copies of the following publications, and their subsequent updates, shall be transmitted to the library on a quarterly basis:~~

~~Laws & Regulations
Newsletters
Bulletins
Annual Reports
Special Reports
Minutes of Board Meetings
Website Documents~~

5. ~~The staff shall maintain a record of the quarterly transmittals to the library.~~

Title: Louisiana State Documents Depository Program

Policy No. III.B

Approved: 05-09-2007

Revised:

Revision History

08-14-2013

Added Item 3, updated the contact information in Item 4, and added sub-items (a) and (b).

DRAFT

**APPENDIX D
Amendment to "CareerMap License Agreement"**

In reference to the CareerMap License Agreement (the "Agreement") made by and between NexLearn, LLC ("NexLearn") and Louisiana Board of Pharmacy ("Licensee"), dated June 24, 2013, such Agreement is hereby amended to include the following conditions. Except as set forth in this Amendment, the Agreement is unaffected and shall continue in full force and effect in accordance with its terms. If there is a conflict between this Amendment and the Agreement or any earlier amendment, the terms of this Amendment will prevail.

The Section titled "APPENDIX A - Billing, Pricing, and Payment Terms" of the Agreement is amended as follows:

NexLearn shall make available to Authorized Users the Offered Courseware on a Per Course Completion Fee. NexLearn shall perform a monthly Completion Report to calculate the number of Authorized Users that completed courses in CareerMap. NexLearn shall submit to Licensee a monthly invoice based on that calculation for the previous calendar month. Licensee may pay for a number of course completions in advance at the Per Course Completion Fee.

Any existing assignments (or "seats") shall be made available to Licensee through the duration of the Term and shall expire on the Expiration Date specified in Section 3(a). Any seats that are unused will expire on the Expiration Date specified in Section 3(a).

CareerMap Fees	1-Year Contract Term
Per Course Completion Fee	\$5.00

NexLearn terms are Net 30.

The undersigned agree that the terms of this Amendment are made effective as of _____.

NexLearn, LLC
100 S. Main Street, Suite 300
Wichita, KS 67202

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809

By: _____

By: _____

Name: _____

Name: _____

Title: _____

Title: _____

Date: _____

Date: _____



Prescription Monitoring Program


Board Meeting
August 14, 2013

Joe Fontenot, R.Ph. Assistant Executive Director
Danielle C. Meadors, Administrative Assistant

Number of Eligible Transactions Reported to the PMP

Total Reported as of
June 30, 2013


61,431,545




Practitioner Access

(as of June 30, 2013)

Prescribers – Total
Authorized 3,652




Dispensers – Total
Authorized 2,380



Total Number of Practitioners with Access – 6,032

Practitioner Queries – 2013

Overall Query total = 575,830



Practitioner Queries


(01/01/2009 through 06/30/2013)

Overall Query total = 2,878,864



Board and Regulatory Agencies

Profile Views by Boards & Regulatory Agencies Total = **6,135**
(01/01/2009 through 06/30/2013)



Law Enforcement Access and Requests

Number of Law Enforcement
Requests Processed = **4,266**
(01/01/2009 through 06/30/13)

2009	2010	2011	2012	2013
680	889	1,230	845	622

Prescription Painkiller Overdoses

A growing epidemic, especially among women



48,000

Nearly 48,000 women died of prescription painkiller* overdoses between 1999 and 2010.



400%

Deaths from prescription painkiller overdoses among women have increased more than 400% since 1999, compared to 265% among men.



30

For every woman who dies of a prescription painkiller overdose, 30 go to the emergency department for painkiller misuse or abuse.

About 18 women die every day of a prescription painkiller overdose in the US, more than 6,600 deaths in 2010. Prescription painkiller overdoses are an under-recognized and growing problem for women.

Although men are still more likely to die of prescription painkiller overdoses (more than 10,000 deaths in 2010), the gap between men and women is closing. Deaths from prescription painkiller overdose among women have risen more sharply than among men; since 1999 the percentage increase in deaths was more than 400% among women compared to 265% in men. This rise relates closely to increased prescribing of these drugs during the past decade. Health care providers can help improve the way painkillers are prescribed while making sure women have access to safe, effective pain treatment.

When prescribing painkillers, health care providers can

- ◇ Recognize that women are at risk of prescription painkiller overdose.
- ◇ Follow guidelines for responsible prescribing, including screening and monitoring for substance abuse and mental health problems.
- ◇ Use prescription drug monitoring programs to identify patients who may be improperly obtaining or using prescription painkillers and other drugs.

*“Prescription painkillers” refers to opioid or narcotic pain relievers, including drugs such as Vicodin (hydrocodone), OxyContin (oxycodone), Opana (oxymorphone), and methadone.

→ See page 4

Want to learn more? Visit

[www **http://www.cdc.gov/vitalsigns**](http://www.cdc.gov/vitalsigns)

Problem

The prescription painkiller epidemic is killing more women than ever before.

Prescription painkiller overdoses are a serious and growing problem among women.

- ◇ More than 5 times as many women died from prescription painkiller overdoses in 2010 as in 1999.
- ◇ Women between the ages of 25 and 54 are more likely than other age groups to go to the emergency department from prescription painkiller misuse or abuse. Women ages 45 to 54 have the highest risk of dying from a prescription painkiller overdose.*
- ◇ Non-Hispanic white and American Indian or Alaska Native women have the highest risk of dying from a prescription painkiller overdose.
- ◇ Prescription painkillers are involved in 1 in 10 suicides among women.

*Death data include unintentional, suicide, and other deaths. Emergency department visits only include suicide attempts if an illicit drug was involved in the attempt.

The prescription painkiller problem affects women in different ways than men.


- ◇ Women are more likely to have chronic pain, be prescribed prescription painkillers, be given higher doses, and use them for longer time periods than men.
- ◇ Women may become dependent on prescription painkillers more quickly than men.
- ◇ Women may be more likely than men to engage in “doctor shopping” (obtaining prescriptions from multiple prescribers).
- ◇ Abuse of prescription painkillers by pregnant women can put an infant at risk. Cases of neonatal abstinence syndrome (NAS)—which is a group of problems that can occur in newborns exposed to prescription painkillers or other drugs while in the womb—grew by almost 300% in the US between 2000 and 2009.

Potential risks of combining medications

Medicines for treatment of pain and mental illness have benefits and risks. For women, 7 in 10 prescription drug deaths include painkillers. But other prescription drugs play a role in overdoses as well. Women are more likely than men to die of overdoses on medicines for mental health conditions, like antidepressants. Antidepressants and benzodiazepines (anti-anxiety or sleep drugs) send more women than men to emergency departments. Mental health drugs can be especially dangerous when mixed with prescription painkillers and/or alcohol. If you take mental health drugs and prescription painkillers, discuss the combination with your health care provider.




Prescription painkiller overdose deaths are a growing problem among women.



Every 3 minutes, a woman goes to the emergency department for prescription painkiller misuse or abuse.

Women between the ages of 25 and 54 are most likely to go to the emergency department because of prescription painkiller misuse or abuse.



SOURCE: Drug Abuse Warning Network, 2010. (Suicide attempts are included for the cases (.03% of total) where opioids were combined with illicit drugs in the attempt.)

What Can Be Done



The US government is

- ◇ Tracking prescription drug overdose trends to better understand the epidemic.
- ◇ Educating health care providers and the public about prescription drug misuse, abuse, suicide, and overdose, and the risks for women.
- ◇ Developing and evaluating programs and policies that prevent and treat prescription drug abuse and overdose, while making sure patients have access to safe, effective pain treatment.
- ◇ Working to improve access to mental health and substance abuse treatment through implementation of the Affordable Care Act.



Health care providers can

- ◇ Recognize that women can be at risk of prescription drug overdose.
- ◇ Discuss pain treatment options, including ones that do not involve prescription drugs.
- ◇ Discuss the risks and benefits of taking prescription painkillers, especially during pregnancy. This includes when painkillers are taken for chronic conditions.
- ◇ Follow guidelines for responsible painkiller prescribing, including:
 - Screening and monitoring for substance abuse and mental health problems.
 - Prescribing only the quantity needed based on appropriate pain diagnosis.
 - Using patient-provider agreements combined with urine drug tests for people using prescription painkillers long term.
 - Teaching patients how to safely use, store, and dispose of drugs.
 - Avoiding combinations of prescription painkillers and benzodiazepines (such as Xanax and Valium) unless there is a specific medical indication.
- ◇ Talk with pregnant women who are dependent on prescription painkillers about treatment options, such as opioid agonist therapy.
- ◇ Use prescription drug monitoring programs (PDMPs)—electronic databases that track all controlled substance prescriptions in the state—to identify patients who may be improperly using prescription painkillers and other drugs.

States can



- ◇ Take steps to improve PDMPs, such as real time data reporting and access, integration with electronic health records, proactive unsolicited reporting, incentives for provider use, and interoperability with other states.
- ◇ Identify improper prescribing of painkillers and other prescription drugs by using PDMPs and other data.
- ◇ Increase access to substance abuse treatment, including getting immediate treatment help for pregnant women.
- ◇ Consider steps that can reduce barriers (such as lack of childcare) to substance abuse treatment for women.



Women can

- ◇ Discuss all medications they are taking (including over-the-counter) with their health care provider.
- ◇ Use prescription drugs only as directed by a health care provider, and store them in a secure place.
- ◇ Dispose of medications properly, as soon as the course of treatment is done. Do not keep prescription medications around “just in case.” (See www.cdc.gov/HomeandRecreationalSafety/Poisoning/preventionontips.htm)
- ◇ Help prevent misuse and abuse by not selling or sharing prescription drugs. Never use another person’s prescription drugs.
- ◇ Discuss pregnancy plans with their health care provider before taking prescription painkillers.
- ◇ Get help for substance abuse problems (1-800-662-HELP); call Poison Help (1-800-222-1222) for questions about medicines.

www

<http://www.cdc.gov/vitalsigns>

www

<http://www.cdc.gov/mmwr>

For more information, please contact

Telephone: 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov

Web: www.cdc.gov

Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Publication date: 7/2/2013

CS238899B

LA R.S. 40§1006(C). Reporting of prescription monitoring information.

The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

(Amended by Act 129 of 2009 Legislature.)

Louisiana Pharmacy Permits requesting an exemption from the reporting requirements:

Permit	Credential
Brand Direct Health Pharmacy 68397 Tammany Trace Dr. Mandeville, LA 70471-7776	PHY.006723-IR CDS.043453-PHY DEA Registration - No
Ochsner Medical Center-Baptist Pharmacy 2700 Napoleon Ave. New Orleans, LA 70115	PHY.006730-HOS CDS.043532-PHY DEA Registration - Yes
Valley Vet Pharmacy 1118 Pony Express Hwy. Marysville, KS 66508-8647	PHY.006417-OS DEA Registration - No

Danielle Clausen

From: Carrie Belsom <Carrie.Belsom@branddirecthealth.com>
Sent: Monday, July 22, 2013 2:17 PM
To: Danielle Clausen
Subject: request for waiver in PMP

Good Afternoon,

Brand Direct Health, permit #006723, currently does not stock or dispense any Controlled Drug Substances or drugs of concern such as Tramadol, Carisoprodol or Butalbital.

Brand Direct Health dispenses the following medical food products only which are:

- Cerefolin and Cerefolin NAC
- Deplin
- Metanx
- Neevo DHA

and beginning 8/1/13 will dispense Axona.

I respectfully request that you consider removing the requirement that Brand Direct Health report Zero Activity every seven day in adherence to the Prescription Monitoring Program.

Thank you for your time in this matter,
Carrie Belsom

Carrie Belsom, PharmD
Pharmacy Manager
Brand Direct Health, L.L.C.

carrie.belsom@branddirecthealth.com

866-331-6440 ext. 8493

This E-mail is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply E-mail, and destroy all copies of the original message.

HIPAA NOTICE: It is against Brand Direct Health's policy to receive or send un-encrypted or non-secured e-mail correspondence containing Protected Health Information (PHI) as defined by HIPAA law. Please use fax or phone for correspondence containing PHI



August 6, 2013

Louisiana Board of Pharmacy
3388 Brentwood Dr
Baton Rouge, LA 80809-1700

To Whom It May Concern:

Ochsner Medical Center-Baptist Pharmacy does not dispense controlled substances or drugs of concern within Louisiana to outpatients, and does not intend to include this in our scope of practice in the future. This pharmacy serves hospital-based patients, providing medications being held for administration within our facility only. I believe our practice may be inconsistent with the intent of the reporting requirements of the Prescription Monitoring Program (PMP), and therefore I am requesting Ochsner Medical Center-Baptist Pharmacy be granted a waiver from the reporting requirements.

- Pharmacy Name: Ochsner Medical Center-Baptist Pharmacy
- Pharmacy Permit Number: 6730-HOS
- Pharmacy DEA Number: FO1207578
- Pharmacy Representative: Suzanne N Warren, RPh, MS
Director of Pharmacy
- Scope of Practice: Hospital patient dispensing only

Sincerely,

A handwritten signature in black ink that reads "Suzanne N. Warren".

Suzanne N. Warren, RPh, MS
Director of Pharmacy
Ochsner Medical Center-Baptist Pharmacy
2700 Napoleon Ave
New Orleans, LA 70115



Danielle Clausen

From: Joe Fontenot
Sent: Wednesday, August 07, 2013 2:37 PM
To: Danielle Clausen
Subject: FW: Pharmacy prescription waiver

From: Larry Leseberg [<mailto:larryl@valleyvet.com>]
Sent: Wednesday, August 07, 2013 1:31 PM
To: Joe Fontenot
Subject: RE: Pharmacy prescription waiver

Joe Fontenot,
Valley Vet Pharmacy has blocked all clients in Louisiana from placing an order for Tramadol. There are a number of states that have Tramadol listed as a drug of concern or designated as a controlled substance. We do not stock Butalbital. A client from Louisiana will not be allowed to place an order for Tramadol. All states are coded to be blocked if the status of Tramadol is changed in that state.

Larry Leseberg
larryl@valleyvet.com

From: Joe Fontenot [<mailto:jfontenot@pharmacy.la.gov>]
Sent: Wednesday, August 07, 2013 9:27 AM
To: larryl@valleyvet.com
Cc: Danielle Clausen
Subject: RE: Pharmacy prescription waiver

Pharmacist Leseberg,

In addition to controlled substances the Louisiana PMP also collects prescription transactions on Tramadol containing products and Butalbital containing products.

Does your pharmacy permit possess and/or ship these products into Louisiana?

Sincerely,

Joe Fontenot, R.Ph.
Assistant Executive Director

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700
Office 225.922.0094
Fax 225.923.5670
E-mail: jfontenot@pharmacy.la.gov
Website: www.pharmacy.la.gov

From: Danielle Clausen
Sent: Monday, August 05, 2013 2:34 PM

To: Joe Fontenot
Subject: FW: Pharmacy prescription waiver

From: Larry Leseberg [<mailto:larryl@valleyvet.com>]
Sent: Monday, August 05, 2013 2:27 PM
To: Danielle Clausen
Subject: Pharmacy prescription waiver

Danielle Clausen Meadors, administrative assistant

I would like to request a waiver for reporting controlled substances for our clients in Louisiana. Valley Vet Pharmacy does not have a DEA number nor do we ship a controlled substances to any clients in Louisiana. Our prescriptions are for veterinary medications. We have been reporting zero every Monday morning.

Valley Vet Pharmacy
1118 Pony Express Highway
Marysville, KS 66508
larryl@valleyvet.com
Ph 800-898-8026 Ext 220
Pharmacy Permit: PHY.006417-OS

Thank You
Larry Leseberg, RPH



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



August 14, 2013

Agenda Item 10-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

July 12-13	LPA Annual Meeting – Natchez, MS
Aug. 3-4	DEA Pharmacy Diversion Awareness Conference – Baton Rouge, LA

2. **Reports** (all in the Boardroom Library)

A. Census Reports

1. Compliance Division – Practitioner Recovery Program & Discipline
2. Credentials Division – CDS & Pharmacy Programs

B. Credentials Division Production Reports

1. Licensure Activity Report [new credentials in previous quarter]
2. Application Activity Report [pending applications count]

C. Exceptions Report

1. PIC in Multiple Locations
2. Resurrected Credentials / Special Work Permits

D. Annual Reports

1. Compliance Division Statistical Summary
2. Annual Report for the Board

The Pharmacy Law requires the production of this report, its approval by the Board, and the submission of same to the Office of the Governor. I prepared this report for the prior fiscal year and tender it to the Board for its consideration. In the event you deem it appropriate, the following motion is suggested.

Resolved, to approve the Annual Report dated July 1, 2013, and further, to authorize the Executive Director to send a copy of the Report to the Office of the Governor, and further, to post a copy on the Board's website.

3. **Examinations**

- A. MPJE – the results for the first trimester of 2013 are available.
- B. NAPLEX – the results for the first trimester of 2013 are available.

- C. PTCB – the results for the first half of 2013 are available.

4. **Operations**

A. Credentials Division

We conducted the renewal cycles for pharmacy technician certificates, emergency drug kit (EDK) permits, and automated medication system (AMS) registrations from May 1 through July 1.

- Of the 6,273 technicians who were noticed for renewal, 90% of them renewed timely, and of that number, 91% did so online. We had a larger than usual number of technicians who did not renew timely (463); it will remain to be seen whether we have a larger attrition rate or a larger late renewal rate.
- Of the 474 EDK permit holders who were noticed for renewal, 90 of them renewed timely.
- Of the 422 AMS registration holders who were noticed for renewal, 94% of them renewed timely.

We opened the renewal cycles for DME permit holders on July 1, mailing renewal reminder notices to 378 permits. They have until August 31 to renew their credentials without penalty.

We have revised the credential application forms for the pharmacy technician candidate registration and the pharmacy technician certificate to reflect the recent rule change relative to pharmacy technician training programs that became effective on July 20. The proof of enrollment in a board-approved pharmacy technician training program is no longer a required attachment for the application form for a pharmacy technician candidate registration, and the certificate of completion of a board-approved pharmacy technician training program is no longer a required attachment for the application form for a pharmacy technician certificate.

B. Compliance Division

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflects just under 1,400 pharmacies within the state, as well as approximately 900 various types of facilities for CDS visits, including hospitals, distributors, ambulatory surgical centers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 218 cases pending from the prior fiscal year. We entered 392 new cases and closed 355, leaving 255 cases pending at the beginning of this fiscal year. Of the cases closed during the prior fiscal year, 49% were disposed of through staff activities and the balance through committee and Board action.

C. Administrative Division

i. Prescription Monitoring Program (PMP) Vendor Contract

You may recall we began the Prescription Monitoring Program in 2008 after selecting a vendor for that program via the public bid process. As you know, Health Information Designs, Inc. (HIS) was the successful bidder, and we entered into a contract with that vendor for a one year term with an option for four additional one year terms, for a maximum of five years as allowed by the state's procurement laws. That contract is scheduled to expire on August 31, 2013.

Mr. Fontenot and I have been working with the Div. of Administration's Procurement Support Team to draft an Invitation to Bid for a successor vendor contract for the Prescription Monitoring Program. The ITB was posted August 2. The sealed bids are scheduled for opening on September 10. We will evaluate the bid responses and then select the lowest responsive and responsible bidder.

ii. *Annual Audit*

As you know, we are subject to an annual audit of our financial and operational activities by the Office of the Legislative Auditor (OLA), or in the alternative, a private firm operating under a contract with the OLA. As part of that audit, I am required to certify to you our compliance with a broad range of laws that govern state agencies financial and operational activities. In turn, the Board – through its President and Secretary – is required to certify the agency’s compliance with those requirements. To facilitate that requirement, the OLA furnishes a document entitled the Louisiana Compliance Questionnaire.

I have completed the Louisiana Compliance Questionnaire for 2013 and tender it to the Board for its consideration. I posted an electronic copy in the Boardroom Library. In the event you believe it appropriate, the following motion is suggested:

Resolved, to approve the Louisiana Compliance Questionnaire for 2013, and further, to authorize the President and Secretary to execute the document for the Board.

iii. *Document Depository Program*

As you may have noticed within the compliance questionnaire, one of the programs with which we are required to participate is the Document Depository Program of the Louisiana State Library. One of their new requirements is the obligation for every agency to compile a roster of all publications available from the agency as well as an inventory of such publications. We recently compiled that document for the June 2013 reporting cycle, and a copy of that roster and inventory was posted in the Boardroom Library for your information. It requires no action on your part.

5. State Activities

A. 2013 Louisiana Legislature

The legislature convened their regular session on April 8 and adjourned on June 6. All four of the Board’s bills were adopted without opposition. There were other measures that will impact the Board’s operations. A copy of the Final Legislative Brief was posted in the Boardroom Library. As a result of the passage of certain bills, the following actions have been taken, or in some cases, are recommended for your consideration:

- *HB 10 (Act 7)* – updated the list of controlled substances in Title 40 of the Pharmacy Law Book and posted the updated information on August 1.
- *HB 15 (Act 8)* – updated the list of controlled substances in Title 40 of the Pharmacy Law Book and posted the updated information on August 1.
- *HB 365 (Act 110)* – updated the PMP law in Title 40 of the Pharmacy Law Book and posted the updated information on August 1. Further, this change will require rulemaking to implement the ability for prescribers and dispensers to appoint delegates for the purpose of retrieving information from the PMP database. A referral to the Regulation Revision Committee is suggested.
- *HB 390 (Act 112)* – updated the definition of “approved college of pharmacy” in Title 37 of the Pharmacy Law Book and posted the updated information on August 1.

With this new requirement for the Board to approve colleges and schools of pharmacy, we have prepared a comprehensive list of colleges and schools of pharmacy known to the Accreditation Council for Pharmacy Education (ACPE), along with their current accreditation status. In the event you believe it appropriate, the following motion is suggested:

Resolved, to approve the June 2013 Roster of Colleges and Schools of Pharmacy for Fiscal Year 2013-2014.

- *HB 391 (Act 282)* – updated the section relative to nonresident pharmacies in Title 37 of the Pharmacy Law Book and posted the updated information on August 1. We mailed a special bulletin to the nonresident pharmacies shortly after August 1 advising them of the new requirements. Further, this change will impact the office operations for these licensees, and a referral to the Executive Committee is suggested.

- *HB 674 (Act 168)* – inserted the definition of the new term “pharmacy generated drug” in Title 37 of the Pharmacy Law Book and posted the updated information on August 1. Further, this change will require rulemaking to implement the ability of pharmacies to make drugs through a process other than compounding. A referral to the Regulation Revision Committee is suggested.
- *SB 187 (Act 27)* – removed the references to veterinarians from the PMP law in Title 40 of the Pharmacy Law Book and posted the updated information on August 1. Further, this change will require rulemaking to remove the references to veterinarians from the PMP rules. A referral to the Regulation Revision Committee is suggested.
- *HCR 129* – directs each state agency that has a custodian of public records to make the identity and contact information of the custodian available to the public and posted on the agency’s website. We complied with this directive prior to July 1.
- *HSR 1* – this study resolution concerns the feasibility and effectiveness of legalizing marijuana possession and use. The Board of Pharmacy is one of ten named organizations identified to work with the House Committee on Administration of Criminal Justice. The group is required to present their findings prior to the beginning of the 2014 legislative session. We will participate as requested by the legislature.
- *HSR 6* – this study resolution concerns the feasibility and practicality of limiting the sale of products containing dextromethorphan. The Board of Pharmacy is one of ten named organizations identified to work with the House Committee on Health and Welfare. The group is required to present their findings prior to the beginning of the 2014 legislative session. We will participate as requested by the legislature.

B. Board of Nursing

As we reported during your last meeting, the Board of Nursing published a Notice of Intent to amend its rules relative to the prescriptive authority of nurse practitioners, more specifically, the required data elements on prescriptions written by APRNs. We will continue to monitor those activities to determine any impact on the Board’s rules on the same topic.

C. Board of Medical Examiners

The Board of Medical Examiners is in the process of amending its rules relative to collaborative drug therapy management (CDTM) with pharmacists. That board and the Board of Pharmacy are required to jointly promulgate the proposed changes to the CDTM rules. Since we published our notice of intent before the medical board, we will wait until both boards are prepared to publish their final rules.

6. ***National Activities***

A. National Association of Boards of Pharmacy (NABP)

For your planning purposes, the 2014 meeting will be held in Phoenix, AZ and the 2015 meeting will be held in New Orleans, LA. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.

B. MALTAGON

The 2013 conference will be hosted by the North Carolina Board of Pharmacy in Asheville on September 29 – October 2. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49. You should have already received conference registration materials.

C. NABP-AACP District 6 Annual Meeting

The 2013 conference will be a joint meeting of Districts 6, 7, and 8. The Colorado Board of Pharmacy will host the meeting this year on September 8-11 at the Hotel Boulderado in Boulder, CO. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49. You should have already received conference registration materials.

7. *International Activities*

A. International Pharmaceutical Federation (FIP)

The 2013 World Congress is scheduled for August 31 – September 5 in Dublin, IE. The Social & Administrative Pharmacy Section will sponsor a regulatory session on September 2: *Pharmacy Practice in the Face of Globalism, Ethics and Regulation*. We will have three presentations – benefits and challenges of reciprocity and mutual recognition agreements, regulation of virtual pharmacy practice, and current issues in the regulation of Internet pharmacies. I have been asked to co-chair the session.

FIP has invited NABP to join FIP as an observer organization. Although that status does not grant voting privileges in the FIP Council (which functions like a house of delegates), it does grant access and participation privileges in their deliberations. NABP has requested my service as its delegate to the FIP Council.

Respectfully submitted,
Malcolm J. Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Compliance Division Census Report

August 14, 2013

Practitioner Recovery Program

- Probation Completion Report

[none since last Board meeting]

- Active Probation 50 pharmacist
 3 intern
 5 technician
 1 technician candidate
- Active Suspension 38 pharmacist
 2 intern
 11 technician
 5 technician candidate

Disciplinary Restrictions

- Probation Completion Report

07-01-2013 PST.009961 – David Louis Matherne
 PST.018076 – Tena Louise Parker

- Active Probation 33 pharmacist
 0 intern
 5 technician
 3 technician candidate
 12 pharmacy permit (+2 on restriction, w/o probation)
 7 CDS license @ pharmacy
 1 CDS license @ distributor
- Active Suspension 39 pharmacist
 1 intern
 55 technician
 13 technician candidate
 10 pharmacy permit
 1 CDS license @ pharmacy
 17 CDS licenses for practitioners

Louisiana Board of Pharmacy
 Credentials Division
 CDS Program

		<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>
<i>Classification</i>								
ACS	Animal Control Shelter	0	0	0	1	1	1	1
APN	APRN	346	479	607	758	889	1,015	1,103
ASC	Ambulatory Surgical Ctr	94	101	106	113	90	88	85
CRX	Correctional Ctr - Exempt	0	0	0	0	7	6	5
DDS	Dentist	2,090	2,177	2,267	2,363	2,027	2,048	1,902
DET	Drug Detection / Canine	20	20	20	22	14	12	10
DIS	Distributor	285	322	363	400	279	288	273
DPM	Podiatrist	147	153	161	165	139	136	118
DVM	Veterinarian	870	936	1,000	1,065	922	901	852
DYS	Dialysis Ctr	63	63	63	63	6	4	3
EMC	Emergency Medical Ctr	17	17	17	18	14	16	17
EMS	Emergency Medical Service	57	58	63	66	54	50	45
ETC	Animal Euthanasia Tech - Cert	31	39	44	49	16	7	6
ETL	Animal Euthanasia Tech - Lead	0	0	0	0	12	20	21
HOS	Hospital	369	387	405	438	280	267	263
HOX	Hospital - Exempt	0	0	0	0	12	14	5
LAB	Laboratory	13	14	14	15	8	6	7
LAX	Laboratory - Exempt	0	0	0	0	4	5	5
MD	Physician	13,195	13,876	14,599	15,269	12,362	11,727	10,698
MED	Medical Clinic	73	78	88	102	77	81	68
MEX	Medical Clinic - Exempt	0	0	0	0	3	5	14
MFR	Manufacturer	36	43	52	58	48	50	45
MIS	Miscellaneous	74	73	58	59	11	10	9
MIX	Miscellaneous - Exempt	0	0	0	0	9	4	3
MP	Medical Psychologist	37	44	50	58	65	67	69
OD	Optometrist	230	253	269	278	275	287	279
PA	Physician Assistant	170	194	232	272	294	326	344
PHX	Pharmacy - Exempt	0	0	0	0	50	47	41
PHY	Pharmacy	0	0	0	0	1,307	1,318	1,329
REP	Sales Representative	57	65	66	88	29	20	7
RES	Researcher	100	110	119	156	109	110	98
RHC	Rural Health Clinic	19	20	21	23	17	12	11
SAC	Substance Abuse Clinic	14	14	14	17	7	9	9
SAX	Subst. Abuse Clinic - Exempt	<u>0</u>						
Total		18,407	19,536	20,698	21,916	19,437	18,957	17,745

Total Credentials Under Management

Pharmacy	16,056	16,407	16,601	17,818	18,260	18,625	21,405
CDS	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>
Total	34,463	35,943	37,299	39,734	37,697	37,582	39,150

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>3/17/1995</u>	<u>6/30/1996</u>	<u>3/19/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>	<u>6/30/2003</u>	<u>6/30/2004</u>
Pharmacists										
In-state	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486
Out-of-state	377	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484
TOTAL	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970
Pharmacy Interns										
In-state										
Out-of-state										
TOTAL							957	976	929	995
Pharmacy Technicians										
In-state										
Out-of-state										
TOTAL							3,216	3,453	3,505	4,114
Pharmacy Technician Candidates										
In-state										
Out-of-state										
TOTAL							2,896	2,372	1,336	1,069
Pharmacy Permits										
IR	651	634	636	609	621	585	584	576	573	633
RC	464	473	471	493	505	520	528	535	541	555
H	177	174	171	175	172	171	171	174	179	181
IN	46	45	38	39	19		17	18	19	27
NU	9	10	10	9	10		12	14	13	13
CH	4	4	4	7	4		8	9	11	12
OS	122	152	168	175	216	223	262	313	353	339
PE	78	104	102	120	102			95	94	0
CO	13	12	12	12	12		12	13	13	0
TOTAL	1,564	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760
Equipment Permits										
AMS							0	109	136	158
EDK							468	461	474	444

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>6/30/2005</u>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>
Pharmacists									
In-state	4,532	4,460	4,522	4,612	4,750	4,860	5,000	5,095	5,170
Out-of-state	1,686	1,915	1,975	1,964	2,029	2,098	2,179	2,258	2,588
TOTAL	6,218	6,375	6,497	6,576	6,779	6,958	7,179	7,353	7,758
Pharmacy Interns									
In-state		980	1,079	1,074	1,035	965	917	938	945
Out-of-state		109	117	67	84	153	137	128	128
TOTAL	1,154	1,089	1,196	1,141	1,119	1,118	1,054	1,066	1,073
Pharmacy Technicians									
In-state		4,552	4,587	4,780	4,733	5,363	5,722	5,509	5,752
Out-of-state		163	152	144	109	144	145	120	112
TOTAL	4,455	4,715	4,739	4,924	4,842	5,507	5,867	5,629	5,864
Pharmacy Technician Candidates									
In-state		1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658
Out-of-state		32	32	23	32	35	35	39	31
TOTAL	1,074	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695
Pharmacy Permits									
IR	729	681	620	588	592	587	591	587	575
RC	473	430	491	534	545	562	576	587	597
H	181	167	164	167	167	165	170	172	172
IN	36	35	36	37	37	27	25	24	25
NU	13	17	16	16	16	16	15	15	15
CH	12	12	12	11	12	14	12	12	12
PEN									1
NR	200	226	240	250	256	286	318	361	387
TOTAL	1,644	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784
Equipment Permits									
AMS	174	173	212	255	306	361	356	366	638
EDK	471	428	412	439	388	503	430	448	431
DME								223	378
Special Activity									41
CDTM									41
MAR									1,617
Special Work Permit							58	78	126

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>8/1/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>
ACS Animal Control Shelter	0	0	0	0	1	1	1	1
APN Advanced Practice Registered Nurse	220	346	479	607	758	889	1,015	1,103
ASC Ambulatory Surgical Center	94	94	101	106	113	90	88	85
CRX Correctional Center	0	0	0	0	0	7	6	5
DDS Dentist	2,009	2,090	2,177	2,267	2,363	2,027	2,048	1,902
DET Drug Detection Canine	19	20	20	20	22	14	12	10
DIS Distributor	236	285	322	363	400	279	288	273
DPM Podiatrist	146	147	153	161	165	139	136	118
DVM Veterinarian	817	870	936	1,000	1,065	922	901	852
DYS Dialysis Center	58	63	63	63	63	6	4	3
EMC Emergency Medical Center	17	17	17	17	18	14	16	17
EMS Emergency Medical Service	56	57	58	63	66	54	50	45
ETC Animal Euthanasia Tech - Cert	29	31	39	44	49	28	27	27
HOS Hospital	350	369	387	405	438	292	281	268
LAB Analytical Laboratory	13	13	14	14	15	12	11	12
MD Physician	12,754	13,195	13,876	14,599	15,269	12,362	11,727	10,698
MED Medical Clinic	65	73	78	88	102	80	86	82
MFR Manufacturer	31	36	43	52	58	48	50	45
MIS Other	80	74	73	58	59	20	14	12
MP Medical Psychologist	30	37	44	50	58	65	67	69
OD Optometrist	196	230	253	269	278	275	287	279
PA Physician's Assistant	153	170	194	232	272	294	326	344
PHY Pharmacy	0	0	0	0	0	1357	1,365	1,370
REP Sales Representative	54	57	65	66	88	29	20	7
RES Researcher	91	100	110	119	156	109	110	98
RHC Rural Health Clinic	15	19	20	21	23	17	12	11
SAC Substance Abuse Clinic	<u>14</u>	<u>14</u>	<u>14</u>	<u>14</u>	<u>17</u>	<u>7</u>	<u>9</u>	<u>9</u>
TOTAL	17,547	18,407	19,502	20,663	21,916	19,437	18,957	17,745

Total Credentials Under Board Management

Pharmacy Program	15,461	16,056	16,407	16,601	17,818	18,260	18,625	21,405
CDS Program	<u>17,547</u>	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>
TOTAL	33,008	34,463	35,943	37,299	39,734	37,697	37,582	39,150

New Credentials Issued

FYE 2013 ~ 4th Quarter

April 1, 2013 - June 30, 2013

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	6
AMS	X	Automated Medication System - Exempt	13
Prefix Totals			19
CDS	AMS	CDS License - Automated Medication System	9
CDS	APN	CDS License - APRN	66
CDS	DDS	CDS License - Dentist	56
CDS	DIS	CDS License - Distributor	12
CDS	DVM	CDS License - Veterinarian	23
CDS	ETC	CDS License - Animal Euthanasia Technician, Certified (AET-C)	2
CDS	HOS	CDS License - Hospital	15
CDS	MD	CDS License - Physician	230
CDS	MEX	CDS License - Medical Clinic - Exempt	1
CDS	MFR	CDS License - Manufacturer	3
CDS	MIS	CDS License - Miscellaneous / Other	1
CDS	MP	CDS License - Medical Psychologist	1
CDS	OD	CDS License - Optometrist	1
CDS	PA	CDS License - Physician Assistant	15
CDS	PHY	CDS License - Pharmacy	14
CDS	RES	CDS License - Researcher	4
Prefix Totals			453
CPT		Certified Pharmacy Technician	118
DME		Durable Medical Equipment (DME) Provider	16
EDK		Emergency Drug Kit	6
MA		Medication Administration	64
PHY	HOS	Pharmacy - Hospital Inpatient	3
PHY	IR	Pharmacy - Community ~ Independent	7
PHY	OS	Pharmacy - Nonresident	19
PHY	OSN	Pharmacy - Nonresident Nuclear	1
PHY	RC	Pharmacy - Community ~ Chain	3
Prefix Totals			33
PIC		Pharmacist-in-Charge	21
PNT		Pharmacy Intern	27
PNT	FPG	Pharmacy Intern - Foreign Pharmacy Graduate	1
Prefix Totals			28
PST		Pharmacist	90
PTC		Pharmacy Technician Candidate	368
SWP		Special Work Permit	11
Grand Totals			1227

Pending Applications

PHARMACY CREDENTIALS

Prefix	Subcat.	CredentialType	01/20/12	04/17/12	08/18/12	12/07/12	02/26/13	05/02/13	08/02/13
AMS		Automated Medication System	2	1	1	1	1	2	4
CPT		Certified Pharmacy Technician	76	72	78	95	83	62	69
DME		Durable Medical Equipment	N/A	N/A	1	2			4
EDK		Emergency Drug Kit				2	2	2	1
PHY	CH	Pharmacy - Charitable							
PHY	HOS	Pharmacy - Hospital Inpatient	4	3	3	3	4	6	8
PHY	IN	Pharmacy - Institutional	2	2	2				
PHY	IR	Pharmacy - Community ~ Independent	21	12	17	28	19	15	13
PHY	NU	Pharmacy - Nuclear							
PHY	OS	Pharmacy - Nonresident	31	37	30	41	47	45	39
PHY	PEN	Pharmacy - Penal					1	1	1
PHY	RC	Pharmacy - Community ~ Chain	6	47	4	5	3	4	5
PIC		Pharmacist-in-Charge	2		1		1		2
PNT	FPG	Pharmacy Intern - Foreign Graduate	3						2
PNT		Pharmacy Intern	61	34	86	91	44	34	66
PST		Pharmacist	220	218	260	218	247	284	335
PTC		Pharmacy Technician Candidate	469	387	377	432	342	375	334
Subtotal			897	813	860	918	794	830	883

CDS CREDENTIALS

Prefix	Subcat.	CredentialType	01/20/12	04/17/12	08/18/12	12/07/12	02/26/13	05/02/13	08/02/13
CDS	ACS	CDS - Animal Control Shelter	0						
CDS	APN	CDS - APRN	12	12	12	14	12	20	17
CDS	ASC	CDS - Ambulatory Surgical Center	1	1	1	3	1	2	3
CDS	CRX	CDS - Correctional Center			1				
CDS	DDS	CDS - Dentist			6			1	2
CDS	DET	CDS - Drug Detection / Canine	1	2	2	2	2	2	
CDS	DIS	CDS - Distributor	6	8	5	4	6	3	3
CDS	DPM	CDS - Podiatrist			1				
CDS	DVM	CDS - Veterinarian	2			1			1
CDS	DYS	CDS - Dialysis Center							
CDS	EMC	CDS - Emergency Medical Center					1	1	
CDS	EMS	CDS - Emergency Medical Service	1	1			1	1	2
CDS	ETC	CDS - Animal Euthanasia Tech, Certified			2	1	2	2	1
CDS	ETL	CDS - Animal Euthanasia Tech, Lead							
CDS	HOS	CDS - Hospital	5	7	3	2	4	4	11
CDS	HOX	CDS - Hospital - Exempt							
CDS	LAB	CDS - Laboratory							
CDS	MD	CDS - Physician	24	28	35	13	12	13	15
CDS	MED	CDS - Medical Clinic	2	1	2	4	4	2	2
CDS	MEX	CDS - Medical Clinic - Exempt						1	1
CDS	MFR	CDS - Manufacturer	1						
CDS	MIS	CDS - Miscellaneous / Other	1	1	1	1	1	2	
CDS	MP	CDS - Medical Psychologist							
CDS	OD	CDS - Optometrist	2	2	1	1	1	1	
CDS	PA	CDS - Physician Assistant	8	7	4	3	3	3	7
CDS	PHY	CDS - Pharmacy	31	75	24	32	21	18	15
CDS	PHX	CDS - Pharmacy - Exempt	1	1					
CDS	REP	CDS - Sales Representative							
CDS	RES	CDS - Researcher	3		3	4	3	2	
CDS	RHC	CDS - Rural Health Clinic							
CDS	SAC	CDS - Substance Abuse Clinic		1	2	2	2	2	
Subtotal			101	147	105	87	76	80	80

OTHER CREDENTIALS

Prefix	Subcat.	CredentialType	01/20/12	04/17/12	08/18/12	12/07/12	02/26/13	05/02/13	08/02/13
CDTM		Collaborative Drug Therapy Management	3	4	2	5			
LB		Law Book	2	2	2	1			
MA		Medication Administration	27	23	24	20	23	25	15
PMP		PMP - CDS Credential	244	301	236	240	272	289	182
PMP		PMP - MIS Credential	1	1					
PMP		PMP - PST Credential	66	69	65	50	66	53	42
SWP		Special Work Permit				50	58	58	35
Subtotal			343	400	329	366	419	425	274

TOTAL

1341 1360 1294 1371 1289 1335 1237

Individual Performance Data

	<i>Inspections</i>			<i>Investigations</i>		
	<u>CDS</u>	<u>Rx</u>	<u>Total</u>	<u>Cases Assigned</u>	<u>Audits Completed</u>	<u>Reports Submitted</u>
Aaron, Cary D. (4-18-2013)						
1st Qtr.	0	0	0	0	0	0
2nd Qtr.	0	0	0	0	0	0
3rd Qtr.	0	0	0	0	0	0
4th Qtr.	9	46	55	5	0	2
<i>Total</i>	<i>9/132</i>	<i>46/213</i>	<i>55/345</i>	<i>5</i>	<i>0</i>	<i>2</i>
Completion Rate:	7%	22%	16%			
Collins, Stephen L.						
1st Qtr	4	59	63	8	1	5
2nd Qtr	5	19	24	11	0	15
3rd Qtr	5	32	37	8	0	17
4th Qtr	5	89	94	31	0	0
<i>Total</i>	<i>19/129</i>	<i>199/310</i>	<i>218/439</i>	<i>58</i>	<i>1</i>	<i>37</i>
Completion Rate:	15%	64%	50%			
Savoie, Huey J.						
1st Qtr	1	48	49	6	1	6
2nd Qtr	10	41	51	7	0	9
3rd Qtr	10	80	90	11	1	6
4th Qtr	8	26	34	18	1	2
<i>Total</i>	<i>29/128</i>	<i>195/342</i>	<i>224/470</i>	<i>42</i>	<i>3</i>	<i>23</i>
Completion Rate:	23%	57%	48%			
Trisler, Rayland M.						
1st Qtr	6	33	39	5	1	10
2nd Qtr	16	41	57	8	0	5
3rd Qtr	4	31	35	8	0	4
4th Qtr	9	54	63	6	0	5
<i>Total</i>	<i>35/90</i>	<i>159/217</i>	<i>194/307</i>	<i>27</i>	<i>1</i>	<i>24</i>
Completion Rate:	39%	73%	63%			
Whaley, Benjamin S.						
1st Qtr	7	57	64	6	0	7
2nd Qtr	14	27	41	3	0	4
3rd Qtr	10	53	63	10	0	6
4th Qtr	6	61	67	9	0	8
<i>Total</i>	<i>37/157</i>	<i>198/315</i>	<i>235/472</i>	<i>28</i>	<i>0</i>	<i>25</i>
Completion Rate:	24%	63%	50%			
Fontenot, M. Joseph						
1st Qtr	0	0	0	3	0	1
2nd Qtr	0	0	0	0	0	2
3rd Qtr	0	0	0	0	0	1
4th Qtr	0	0	0	0	0	0
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>3</i>	<i>0</i>	<i>4</i>
Finalet, Carlos M.						
1st Qtr	0	0	0	38	0	19
2nd Qtr	0	0	0	58	0	43
3rd Qtr	0	0	0	50	0	42
4th Qtr	0	0	0	82	0	59
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>228</i>	<i>0</i>	<i>163</i>
Broussard, Malcolm J.						
1st Qtr	0	0	0	1	0	1
2nd Qtr	0	0	0	0	0	0
3rd Qtr	0	0	0	0	0	0
4th Qtr	0	0	0	0	0	0
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>1</i>	<i>0</i>	<i>1</i>
Agency Summary						
1st Qtr	18	197	215	67	2	49
2nd Qtr	45	128	173	87	0	78
3rd Qtr	29	196	225	87	1	76
4th Qtr	37	276	313	151	1	76
TOTAL	129/636	795/1397	926/2033	392	4	279
Completion Rate	20%	57%	46%			

Summary of Investigations and Adjudications

Number of Cases Pending from Prior Fiscal Year(s)	218
Number of Complaints Received during Current Fiscal Year:	392
Number of Complaints Closed during Current Fiscal Year:	355
Number of Complaints Pending at End of Fiscal Year:	255

Disposition of Closed Complaints:

Withdrawn	25	
No violations found	32	
Administrative/Field corrections	67	
Referred to another agency	3	
Administrative sanction	24	
Termination of previously imposed probationary periods	24	
Referred to Violations Committee	<u>180</u>	
	<u>355</u>	<i>Total</i>

Committee Action on Referrals:

21	Case dismissed
157	Voluntary Consent Agreement
9	Assessment
5	Denial / Refusal to Issue
3	Letter of Warning
19	Letter of Reprimand
21	Voluntary Surrender
29	Probation
22	Suspension
19	Revocation
30	Other decisions
2	Formal Hearing
1	Suspension
1	Revocation

Analysis of Adjudications by Type of Credential

	<u>PST</u>	<u>PNT</u>	<u>CPT</u>	<u>PTC</u>	<u>PHY</u>	<u>CDS</u>	<u>TOTAL</u>
Denial / Refusal to Issue	2	0	0	3	0	0	5
Assessment	2	0	0	0	7	0	9
Letter of Warning	0	0	0	0	3	0	3
Letter of Reprimand	12	0	5	0	2	0	19
Voluntary Surrender	11	1	5	1	2	1	21
Probation	16	1	3	2	6	1	29
Suspension	2	0	2	0	0	19	23
Revocation	2	0	12	3	3	0	20
TOTAL	47	2	27	9	23	21	129



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Annual Report

Fiscal Year 2012-2013

July 1, 2013

Mission

Created by the Louisiana Legislature in 1888, the mission of the Louisiana Board of Pharmacy remains unchanged over a century later: to regulate the practice of pharmacy in such a manner as to protect the public health, safety, and welfare of the citizens of Louisiana. Toward that goal, the Louisiana Pharmacy Practice Act specifically authorizes the Board to restrict the practice of pharmacy to qualified persons, as well as to control and regulate all persons and sites that sell drugs or devices or provide pharmacy care services to consumers in this state.

Membership

The Board is composed of seventeen members: two pharmacists from each of eight districts and one public member at large. The district representatives are nominated by pharmacists, appointed by the governor, and serve six year terms. The public member is selected by, and serves at the pleasure of, the governor. The current members of the Board are:

District 1	Joseph L. Adams, Richard M. Indovina, Jr.
District 2	Jacqueline L. Hall, Deborah H. Simonson
District 3	Blake P. Pitre, Richard A. Soileau
District 4	Clovis S. Burch, Rhonny K. Valentine
District 5	Carl W. Aron, T. Morris Rabb
District 6	Ronald E. Moore, Pamela G. Reed
District 7	Ryan M. Dartez, Chris B. Melancon
District 8	Brian A. Bond, Marty R. McKay
Public	Don L. Resweber

Licensure

In order to facilitate the restriction of practice to qualified persons, the Board has established educational, experiential, and examination requirements for licensure. As authorized by the legislature, the Board has contracted its high-stakes examination procedures with professional testing services.

A. *Examinations for Pharmacists*

The North American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MPJE) are administered by the National Association of Boards of Pharmacy (NABP). These computer adaptive tests are administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required on each test to qualify for pharmacist licensure. The results for all Louisiana-based NAPLEX and MPJE candidates from ULM College of Pharmacy and Xavier University – College of Pharmacy in calendar year 2012 are summarized below:

NAPLEX

	Jan – Apr		May – Aug		Sept – Dec	
	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>
Total No. of Candidates	6	13	80	120	17	21
Mean Scaled Score – School	75	77	97	95	85	83
Mean Scaled Score – State	81	81	98	98	87	87
Mean Scaled Score – National	83	83	103	103	88	88
School Pass Rate [%]	83	46	93	90	82	62
State Pass Rate	69	69	94	94	76	76
National Pass Rate	68	68	95	95	78	78

MPJE

	Jan – Apr		May – Aug		Sept – Dec	
	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>
Total No. of Candidates	4	13	126	181	87	87
Mean Scaled Score – School	82	80	83	79	80	80
Mean Scaled Score – State	81	81	81	81	80	80
Mean Scaled Score – National	80	80	82	82	81	81
School Pass Rate [%]	100	85	97	84	91	86
State Pass Rate	90	90	91	91	82	82
National Pass Rate	85	85	93	93	87	87

B. Examinations for Technicians

The Pharmacy Technician Certification Board (PTCB) administers a national certification examination; this computer adaptive test is administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required to successfully complete the examination. The Louisiana Board of Pharmacy accepts the PTCB examination score result as part of the licensure requirements for pharmacy technicians. The results for all Louisiana-based PTCB candidates for calendar year 2012 are summarized here:

No. of State Candidates	1,182
State Pass Rate [%]	69
No. of National Candidates	51,762
National Pass Rate [%]	77

C. Census Data

At the close of the fiscal year on June 30, 2013, a review of the records yielded the following census information:

	<u>2013</u>	<u>2012</u>	<u>2011</u>
• Pharmacy Program			
1. Pharmacists			
Number of active licenses	7,758	7,353	6,935
Number of licensees within the state	5,148	5,095	4,815
2. Pharmacy Interns			
Number of active registrations	1,073	1,066	1,049
3. Pharmacy technicians			
Number of active certificates	5,864	5,629	5,866
4. Pharmacy technician candidates			
Number of active registrations	1,695	1,704	1,609
5. Pharmacies			
Number of active permits	1,784	1,758	1,707
Independent retail	575	587	591
Retail chain	597	587	576
Hospital	172	172	170
Institutional	25	24	25
Nuclear	15	15	15
Charitable	12	12	12
Penal	1	1	1
Nonresident	387	361	318
6. Equipment Permits			
Emergency drug kit (EDK)	431	448	430
Automated medication systems (AMS)	638	366	356
Durable medical equipment (DME)	378	223	
7. Special Activity Credentials			
CDTM Registration	41		
Medication Administration Registration	1,617		
Special Work Permits	126	78	58
<u>Subtotal of Credentials in Pharmacy Program</u>	21,405	18,625	18,010

	<u>2013</u>	<u>2012</u>	<u>2011</u>
• CDS Program			
1. Animal Control Shelter	1	1	1
2. Advanced Practice Registered Nurse (APRN)	1,103	1,015	889
3. Ambulatory Surgical Center (ASC)	85	88	90
4. Correctional Center	5	6	7
5. Dentist	1,902	2,048	2,027
6. Drug Detection / Canine	10	12	14
7. Distributor	273	288	279
8. Podiatrist	118	136	139
9. Veterinarian	852	901	922
10. Dialysis Center	3	4	6
11. Emergency Medical Center	17	16	14
12. Emergency Medical Service	45	50	54
13. Animal Euthanasia Technician	27	27	28
14. Hospital	268	281	292
15. Laboratory	12	11	12
16. Physician	10,698	11,727	12,362
17. Medical Clinic	82	86	80
18. Manufacturer	45	50	48
19. Miscellaneous	12	14	20
20. Medical Psychologist	69	67	65
21. Optometrist	279	287	275
22. Pharmacies	1,370	1,365	1,357
23. Physician Assistant	344	326	294
24. Sales Representative	7	20	29
25. Researcher	98	110	109
26. Rural Health Clinic	11	12	17
27. Substance Abuse Clinic	9	9	7
<u>Subtotal of Credentials in CDS Program</u>	<u>17,745</u>	<u>18,957</u>	<u>19,437</u>
Total Credentials Under Management	39,150	37,582	37,447

D. New Credentials

During the past fiscal year, the Board issued 3,663 new credentials in the Pharmacy Program and 1,415 new credentials in the CDS Program. Of note within the Pharmacy Program, we issued 373 new pharmacist licenses, 266 new pharmacy intern registrations, and 625 new pharmacy technician certificates during the past fiscal year. Of note within the CDS Program, we issued new CDS licenses to 721 physicians, 224 advanced practice registered nurses, and 94 dentists.

E. Reciprocity

Persons already licensed as a pharmacist by any other state (except California) who wish to obtain a license in Louisiana must successfully complete the MPJE as well as a personal interview with the Board's Reciprocity Committee. Of the 373 new pharmacist licenses issued this past fiscal year, 163 were issued subsequent to successful completion of the reciprocity process.

Compliance

A. Enforcement

In order to control and regulate the practice of pharmacy in Louisiana, the Board employs five pharmacist compliance officers to perform routine inspections and special investigations throughout the year in all places under the Board's jurisdiction. Besides the routine inspections, site visits for permit changes, and other calls for assistance, the compliance officers completed 355 investigations during the last fiscal year: 25 of the original complaints were withdrawn, 24 resulted from termination of previously imposed probationary periods, 32 were determined to be without violation, three cases were referred to another agency, 67 resulted in field/administrative corrections, 24

resulted in administrative sanctions, and 180 cases were referred to the Board's committees. The committees took no action in 21 of their cases, issued approvals for 30 non-disciplinary petitions, and recommended voluntary consent agreements for 129 cases. Of that number, all but two accepted the proposed discipline. The remaining two respondents did not, and they were referred for formal administrative hearings.

Compliance officers coordinate other investigative activities with a wide range of agencies, including local police departments, parish sheriff departments, other state regulatory and law enforcement agencies, and federal agencies such as the Drug Enforcement Administration, the Food and Drug Administration, and the Consumer Product Safety Commission. Though the compliance officers utilize the educational approach as the fundamental mechanism to achieve compliance, certain circumstances warrant formal board action.

B. Adjudications

During the past fiscal year, the Board conducted two administrative hearings and levied formal disciplinary action against several credentials. A summary of that activity is presented here:

<i>Sanction</i>	<u>Pharmacist</u>	<u>Intern</u>	<u>Technician</u>	<u>Candidate</u>	<u>Permit</u>	<u>CDS License</u>
Assessment	2	0	0	0	7	0
Letter of Warning	0	0	0	0	3	0
Letter of Reprimand	12	0	4	0	3	0
Voluntary Surrender	11	1	5	1	2	1
Probation	16	1	2	2	6	1
Suspension	2	0	2	0	0	19
Revocation	2	0	12	3	3	0
Refused to Credential	2	0	0	3	0	0

C. Practitioner Recovery Program

The Board established its program in 1988 to assist practitioners obtain treatment for their impairment, maintain their recovery, and assist their re-entry into professional practice. As of July 1, 2013 there were 50 pharmacists, three pharmacy interns, five pharmacy technicians and two pharmacy technician candidates actively engaged in the recovery program. They surrendered their credentials while in treatment; following treatment and upon favorable recommendation by board-certified addiction medicine specialists, they applied for the reinstatement of their credentials. The Board reinstated their credentials on probation, and the licensees practice under various restrictions designed to monitor their re-entry to professional practice. In addition, the credentials for 38 pharmacists, 2 interns, 11 technicians, and 4 technician candidates were still on active suspension for impairment reasons.

Board Activity

A. Regulatory

The Board's Regulation Revision Committee is tasked with the continuous review of the Board's rules and their revision as appropriate. The committee initiated and the Board completed several regulatory projects in the previous fiscal year.

- Institutional Pharmacy, amending LAC 46:LIII.1705 and 1727;
- Interstate Remote Processing, amending LAC 46:LIII.1139 and 1143;
- Security of Prescription Department, amending LAC 46:LIII.110;
- CDS License for Nonresident Distributors, amending LAC 46:LIII.2705;
- Controlled Substances in Emergency Drug Kits, amending LAC 46:LIII.1713 and 2743;
- Prescription Monitoring Program, amending LAC 46:LIII.Chapter 29;
- Durable Medical Equipment (DME) Permit, creating a new LAC 46:LIII.Chapter 24; and
- Hospital Off-Site Satellite Pharmacies, amending LAC 46:LIII.Chapter 15.

In addition, the Board also found it necessary to adopt an Emergency Rule placing limits on the amount of drug products a pharmacy can compound without a patient-specific prescription. The Board continues to work with stakeholders to complete the rulemaking process.

The Board has several other regulatory projects underway; the progress of those projects may be monitored at the Board's website.

B. Legislative

During the 2013 regular session, the Board sponsored four bills, all of which were successful. Act 110 amended the prescription monitoring program law to authorize prescribers and dispensers to appoint and use delegates for the purpose of data retrieval from the program's database, pursuant to rules to be promulgated by the Board. Act 112 amended the definition of 'approved colleges of pharmacy' to include Board approval in addition to the previous accreditation requirement. Act 168 provides statutory authority for the Board to promulgate a rule regulating the preparation of drug products in response to purchase orders in addition to compounding preparations in response to patient-specific prescriptions. Act 282 amended the nonresident pharmacy law to specifically authorize the Board to inspect the nonresident pharmacies, to be reimbursed for their expenses for such inspections, and to require the production of certain reports issued by other agencies.

C. Operations

We have completed three years of service with our eLicense information system, and have already reaped benefits of integration of our credentialing and compliance activities. We have not yet implemented all of the modules and options and we will continue to phase those new features over time.

We have also completed three years of service with our website's content management system and its mass communication capabilities. We have increased the frequency of communications to our licensees through the use of targeted email. Through avoided postage and labor costs of mass snail mail notices, we have achieved a return of our investment and will continue our savings going forward.

Finally, the Board continued its operation of Louisiana's Prescription Monitoring Program (PMP). The monthly average of the number of prescription transactions reported to the program's database, as well as the average number of queries per day, continue to increase. Since the program is required to file an annual report to the legislature, we have appended that report to this one to facilitate its separation.

D. Physical Plant

The Board moved to its current location in May 2011. We continue to make minor improvements to the building and grounds. The separate property initially purchased in 2007 has been listed for sale. The proceeds from that sale will be used to settle the loan obligation incurred for the purchase of the office building.

Board Office

The Board currently employs 18 people on a full-time basis in a variety of professional, technical, and clerical roles; the Board also supports the local Cooperative Office Education (COE) program in Baton Rouge area high schools by hiring high school senior students on a temporary basis. The physical and mailing address of the board office is:

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700
Telephone (225) 925-6496
Telecopier (225) 925-6499

The board's website address is www.pharmacy.la.gov and general email is received at info@pharmacy.la.gov.

Conclusion

The board has had an active year on several fronts, and all of these activities have contributed to the overall mission of the board. The officers and members of the board, as well as the entire office staff, are committed to achieving our goal of protecting the public's health, safety and welfare through appropriate regulation of the practice of pharmacy in this state. We understand that public service is a privilege, and we endeavor to render that service honorably.

Prepared by:
Malcolm J Broussard
Executive Director

**Prescription Monitoring Program
Annual Report**

Fiscal Year 2012-2013

July 1, 2013

Introduction

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, operation, and evaluation of an electronic system for the monitoring of controlled substances and other drugs of concern that are dispensed within the state or dispensed by a licensed pharmacy outside the state to an address within the state. The goal of the program is to improve the state's ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner and in a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

Implementation

The Prescription Monitoring Program (PMP) was implemented in August 2008. We notified pharmacies of their requirement to report all eligible prescription transactions to the program, and further, required them to report all historical data retroactive to June 1, 2008 no later than December 31, 2008. In December 2008, the Board notified all prescribers and dispensers wishing to acquire direct access privileges of the requirement to complete the web-based orientation program prior to receiving their access privileges. The web portal to the program database was opened to queries on January 1, 2009, and the program remains fully functional.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The Board shall seek, and the advisory council shall provide, information and advice regarding: (1) which controlled substances should be monitored, (2) which drugs of concern demonstrate a potential for abuse and should be monitored, (3) design and implementation of educational courses required by the PMP law, (4) methodology to be used for analysis and interpretation of prescription monitoring information, (5) design and implementation of a program evaluation component, and (6) identification of potential additional members to the advisory council. The original legislation specifically identified the 25 organizations named to the council and further, named the leader of the organization but permitted the leader to name a designee to function in the absence of the appointee. The organizations represented on the council include the licensing agencies for the prescribers and dispensers, the professional membership organizations for the prescribers and dispensers, organizations representing federal, state, and local law enforcement agencies, as well as representatives from the legislature. The advisory council has elected its own leadership, adopted policies and procedures for its operations, and meets on a quarterly basis.

Program Metrics

The data on the following page provides summary data for the operational aspects of the program – number of prescription transactions reported to the program database, number of prescribers and dispensers registered to access the program data, the number of queries performed by those authorized prescribers and dispensers as well as law enforcement agencies and regulatory agencies.

Louisiana Board of Pharmacy
 Prescription Monitoring Program

	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>Total</u>
<i>Prescription Database:</i>							
Transactions Reported	6,015,089	11,143,865	12,116,982	12,775,367	12,990,011	6,460,342	61,501,656
<i>Access to Program Data:</i>							
New prescribers registered		1,526	721	548	574	283	3,652
New dispensers registered		728	483	361	494	314	2,380
<i>Reports from Queries by Users:</i>							
Solicited by prescribers		235,985	368,376	496,270	650,514	406,897	2,158,042
Solicited by dispensers		74,277	111,075	153,783	212,754	168,933	720,822
Solicited by law enforcement		680	889	1,230	845	622	4,266
Solicited by regulatory agencies		833	1,401	1,612	1,584	705	6,135
Average queries per day		854	1,319	1,788	2,372	3,163	1,759

Funding

It is important to note there is no legislative appropriation for the program. The program is funded through the collection of annual fees from all prescribers of controlled substances as well as all pharmacies licensed by the Board of Pharmacy. The annual fee shall not exceed \$25.

For Fiscal Year 2012-2013, the program received revenues of \$487,685. Of that amount, \$40,035 came from a one-time grant from the National Association of Boards of Pharmacy (NABP); the grant completely defrayed the cost of preparing the program's software to interface with NABP's Prescription Monitoring Program InterConnect (PMPi). The NABP PMPi is a secure network connecting state prescription monitoring programs to facilitate the sharing of PMP data across state lines. The network is still growing, but approximately half of the states now participate. During the fiscal year, the program sustained expenditures of \$323,814. Professional services from the program vendor consumed 34% of the total expenses, and staffing costs represented another 57% of that total. The remaining 9% represents operating costs such as postage, telephone, etc. With respect to the excess revenues, the Board intends to make additional investments in software enhancement to facilitate the sharing of data through other mechanisms such as health information exchanges and interfaces with professional practice management information systems.

Outlook for Next Fiscal Year

The program continues to enroll new authorized users, and the daily average number of queries continues to increase. With assistance from the licensing agencies encouraging use of the program by their licensees, we hope to improve on the current 30% registration rate, as well as the daily query rate of approximately 3,200.

Conclusion

The program has completed approximately five years of operation. Based on feedback from authorized users, it appears to represent an efficient and cost-effective use of resources. Data from the program suggests we have made some early contributions to the reduction of diversion of controlled substances. Our interstate collaborations have yielded high marks for our program design and operation. We look forward to fully developing the potential of our program to identify and inhibit the diversion of controlled substances in Louisiana.

We acknowledge the contributions from Ms. Sarah Stevens and Ms. Danielle Clausen, our Administrative Coordinators, and Mr. Joseph Fontenot, Program Manager, for their participation in the development of this report and the operation of the program.

Prepared by:
Malcolm J. Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

January 1 – April 30, 2013

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)

August 14, 2013

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	10
Current Trimester Report for Xavier College of Pharmacy	14
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: January 1, 2013 - April 30, 2013

School Name: University Louisiana Monroe

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Test Takers

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	10	100.00	81.80	3.65
School 2	34	97.06	84.26	5.87
State	72	97.22	81.90	4.34
National	3104	91.08	81.78	5.35

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Test Takers

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	11	100.00	81.45	3.64
School 2	36	97.22	84.03	5.91
State	83	93.98	81.33	4.89
National	3940	87.18	80.92	5.62

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

Test Window: January 1, 2013 - April 30, 2013

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	84	04/16/2013	05/19/2012	Y	LA
2	Pass	84	04/11/2013	05/19/2012	Y	LA
3	Pass	82	03/18/2013	05/19/2012	Y	LA
4	Pass	82	03/11/2013	05/19/2012	Y	LA
5	Pass	87	01/25/2013	05/19/2012	Y	LA
6	Pass	90	01/19/2013	05/19/2012	Y	CO
7	Pass	80	01/18/2013	05/19/2012	Y	LA
8	Pass	92	02/14/2013	05/21/2011	Y	TX
9	Pass	76	02/09/2013	05/22/2010	Y	TX
10	Pass	91	03/09/2013	05/16/2009	Y	TX
11	Pass	88	04/17/2013	05/17/2008	Y	TX
12	Pass	75	01/12/2013	05/17/2008	N	HI
13	Pass	76	01/10/2013	05/17/2008	Y	CO
14	Pass	82	02/26/2013	05/19/2007	Y	NC
15	Pass	86	01/17/2013	05/19/2007	Y	LA
16	Pass	87	01/12/2013	05/21/2005	Y	AL
17	Pass	88	03/13/2013	05/01/2005	Y	AZ
18	Pass	82	02/28/2013	05/01/2005	Y	TN
19	Pass	82	02/16/2013	07/30/2004	Y	CO
20	Pass	85	01/12/2013	05/21/2003	Y	IL
21	Pass	78	04/09/2013	05/01/2003	N	LA
22	Pass	75	02/09/2013	12/18/1999	Y	LA
23	Pass	90	04/30/2013	12/17/1999	Y	TN
24	Pass	80	02/18/2013	12/18/1998	Y	SC
25	Pass	88	02/25/2013	12/01/1998	Y	MS
26	Pass	98	02/21/2013	12/01/1998	Y	AZ
27	Pass	86	02/13/2013	12/01/1997	Y	TN
28	Pass	75	02/26/2013	12/01/1996	Y	TX
29	Pass	85	04/17/2013	08/16/1995	N	MD
30	Pass	77	03/11/2013	08/12/1995	Y	MO
31	Pass	91	04/23/2013	05/25/1995	Y	OR
32	Pass	88	04/18/2013	05/20/1995	Y	MS
33	Pass	81	02/07/2013	08/01/1992	Y	AZ
34	Pass	88	04/23/2013	08/14/1987	Y	TX
35	Pass	91	03/14/2013	08/15/1986	Y	TX
36	Pass	85	03/22/2013	05/08/1986	Y	TX
37	Pass	84	02/06/2013	12/18/1984	Y	TX
38	Pass	87	03/09/2013	05/13/1983	Y	MD
39	Pass	84	04/03/2013	08/14/1982	Y	CO
40	Pass	81	01/25/2013	05/15/1982	Y	KY
41	Pass	79	01/25/2013	05/15/1982	Y	LA
42	Pass	79	03/01/2013	08/15/1980	Y	LA
43	Pass	82	03/22/2013	05/19/1979	Y	SC
44	Pass	84	04/17/2013	05/25/1975	Y	MD

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
45	Pass	79	01/10/2013	05/25/1975	Y	IN
46	Fail	72	01/30/2013	05/25/1974	Y	TX
47	Pass	75	04/26/2013	05/25/1965	Y	MO

National Statistics for All Candidates

Mean Scaled Score: 80.92
Standard Deviation: 5.62
Range: 60 - 100
Passing Rate (%): 87.18

National Statistics for First-Time Candidates

Mean Scaled Score: 81.78
Standard Deviation: 5.35
Range: 60 - 100
Passing Rate (%): 91.08

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 3940)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	10	0.3%
65 - 69	75	2.2%
70 - 74	417	12.8%
75 - 79	1037	39.1%
80 - 84	1372	73.9%
85 - 89	788	94.0%
90 - 94	210	99.3%
95 - 100	28	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 3104)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	5	0.2%
65 - 69	29	1.1%
70 - 74	240	8.8%
75 - 79	727	32.3%
80 - 84	1158	69.6%
85 - 89	720	92.8%
90 - 94	196	99.2%
95 - 100	26	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)


University of Louisiana at Monroe

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: January 1, 2013 - April 30, 2013

School Name: Xavier University of Louisiana

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Test Takers

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	3	100.00	81.33	1.15
School 2	40	77.50	79.38	4.65
State	72	97.22	81.90	4.34
National	3104	91.08	81.78	5.35

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Test Takers

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	6	83.33	78.17	3.60
School 2	47	76.60	79.09	4.79
State	83	93.98	81.33	4.89
National	3940	87.18	80.92	5.62

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

Test Window: January 1, 2013 - April 30, 2013

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	83	04/30/2013	05/12/2012	Y	TX
2	Pass	82	04/27/2013	05/12/2012	Y	LA
3	Pass	88	04/23/2013	05/12/2012	Y	TX
4	Pass	80	03/07/2013	05/12/2012	Y	CO
5	Pass	79	02/23/2013	05/12/2012	Y	MS
6	Pass	80	02/16/2013	05/12/2012	Y	TN
7	Pass	79	02/01/2013	05/12/2012	Y	TN
8	Pass	82	01/24/2013	05/12/2012	Y	LA
9	Pass	77	03/18/2013	07/31/2011	Y	IL
10	Fail	74	04/29/2013	05/07/2011	Y	DC
11	Fail	74	04/02/2013	05/07/2011	Y	TX
12	Pass	83	03/08/2013	05/07/2011	Y	TX
13	Pass	85	02/23/2013	05/07/2011	Y	PA
14	Pass	84	04/20/2013	05/08/2010	Y	AZ
15	Pass	76	03/28/2013	05/08/2010	Y	CO
16	Fail	74	03/27/2013	05/08/2010	N	LA
17	Pass	88	03/14/2013	05/08/2010	Y	FL
18	Fail	74	03/09/2013	05/08/2010	Y	AL
19	Fail	72	03/04/2013	05/08/2010	Y	NM
20	Pass	76	01/26/2013	05/08/2010	Y	AZ
21	Pass	83	01/15/2013	05/08/2010	Y	DC
22	Pass	81	04/23/2013	05/09/2009	Y	TX
23	Fail	72	03/29/2013	05/09/2009	Y	TX
24	Pass	76	03/15/2013	12/12/2008	N	LA
25	Pass	82	01/26/2013	05/10/2008	N	OR
26	Pass	76	01/15/2013	05/10/2008	N	TN
27	Pass	80	01/14/2013	05/10/2008	Y	TN
28	Pass	79	04/30/2013	08/04/2007	N	PA
29	Fail	70	01/26/2013	08/04/2007	Y	PA
30	Pass	85	03/23/2013	05/20/2006	Y	GA
31	Pass	87	04/17/2013	05/07/2005	Y	OR
32	Pass	83	02/14/2013	05/07/2005	Y	PA
33	Pass	78	03/18/2013	05/01/2003	Y	MS
34	Pass	82	03/02/2013	05/01/2003	Y	TX
35	Pass	80	02/21/2013	05/01/2003	Y	LA
36	Fail	73	01/28/2013	08/31/2002	Y	TN
37	Pass	82	03/25/2013	05/01/2002	Y	GA
38	Pass	83	03/09/2013	05/12/2000	Y	NJ
39	Pass	79	04/25/2013	05/01/2000	Y	MS
40	Pass	78	02/23/2013	05/01/2000	Y	IL
41	Pass	83	01/25/2013	05/01/1999	Y	AZ
42	Pass	79	02/18/2013	05/09/1998	Y	TX
43	Fail	73	04/10/2013	05/01/1998	Y	WA
44	Pass	80	04/02/2013	12/16/1996	Y	PA

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
45	Pass	79	03/25/2013	12/15/1992	Y	AZ
46	Pass	82	03/16/2013	05/09/1992	N	FL
47	Pass	81	04/25/2013	05/15/1990	Y	TN
48	Fail	72	04/26/2013	05/10/1989	Y	AZ
49	Pass	80	04/25/2013	05/18/1986	Y	OK
50	Pass	83	04/24/2013	05/15/1983	N	TN
51	Fail	71	02/28/2013	06/15/1977	N	MS
52	Pass	75	02/06/2013	05/18/1975	N	LA
53	Fail	69	04/02/2013	06/01/1961	N	TX

National Statistics for All Candidates

Mean Scaled Score: 80.92
Standard Deviation: 5.62
Range: 60 - 100
Passing Rate (%): 87.18

National Statistics for First-Time Candidates

Mean Scaled Score: 81.78
Standard Deviation: 5.35
Range: 60 - 100
Passing Rate (%): 91.08

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 3940)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	10	0.3%
65 - 69	75	2.2%
70 - 74	417	12.8%
75 - 79	1037	39.1%
80 - 84	1372	73.9%
85 - 89	788	94.0%
90 - 94	210	99.3%
95 - 100	28	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 3104)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	5	0.2%
65 - 69	29	1.1%
70 - 74	240	8.8%
75 - 79	727	32.3%
80 - 84	1158	69.6%
85 - 89	720	92.8%
90 - 94	196	99.2%
95 - 100	26	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

January 1 – April 30, 2013

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


August 14, 2013

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	10
Current Trimester Report for Xavier College of Pharmacy	14
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: January 1, 2013 - April 30, 2013

School Name: University Louisiana Monroe

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	3	100.00	92.00	12.17	11.33	0.58	11.67	1.15	14.33	2.31
State	4	75.00	80.75	24.60	10.75	1.26	11.25	1.26	13.00	3.27
National	276	85.14	92.48	18.42	11.83	1.30	11.87	1.33	12.03	1.70

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	3	100.00	92.00	12.17	11.33	0.58	11.67	1.15	14.33	2.31
State	9	55.56	77.25	21.83	11.13	1.13	10.88	0.99	11.50	2.83
National	822	61.07	80.17	22.41	11.21	1.38	11.17	1.46	10.98	1.90

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2012). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2012) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.82	12.91	12.22	11.29
Mean Area 2 Scaled Score	13.83	12.83	12.18	11.22
Mean Area 3 Scaled Score	14.33	13.34	12.74	11.86
Mean Overall Scaled Score	119.72	109.26	100.15	84.05
Scaled Score Range	[114, 137]	[105, 113]	[95, 104]	[10, 94]
# Examinees per bin	3,171	3,172	3,171	3,171

In the quartile table (above), the mean overall scaled score for the bottom quartile is 84.05 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2012) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.64	10.26
Mean Area 2 Scaled Score	12.60	10.25
Mean Area 3 Scaled Score	13.15	10.81
Mean Overall Scaled Score	104.72	64.05
Scaled Score Range	[75, 137]	[10, 74]
# Examinees per bin	12,243	443

**Table 5 North American Pharmacist Licensure Examination® (NAPLEX)®
Candidate Summary Report**

Test Window: January 1, 2013 - April 30, 2013

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	86	11	11	13	01/29/2013	05/19/2012	Y
2	Pass	84	11	11	13	01/11/2013	05/19/2012	Y
3	Pass	106	12	13	17	01/02/2013	05/19/2012	Y

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 80.17
Standard Deviation: 22.41
Range: 7 - 129
Passing Rate (%): 61.07

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 92.48
Standard Deviation: 18.42
Range: 11 - 126
Passing Rate (%): 85.14

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 822)**

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	1	0.1%
10 - 14	1	0.2%
15 - 19	4	0.7%
20 - 24	4	1.2%
25 - 29	5	1.8%
30 - 34	8	2.8%
35 - 39	10	4.1%
40 - 44	17	6.2%
45 - 49	30	9.8%
50 - 54	28	13.3%
55 - 59	50	19.4%
60 - 64	42	24.6%
65 - 69	41	29.6%
70 - 74	70	38.3%
75 - 79	75	47.5%
80 - 84	73	56.5%
85 - 89	46	62.1%
90 - 94	73	71.1%
95 - 99	63	78.8%
100 - 104	49	84.9%
105 - 109	54	91.5%
110 - 114	27	94.8%
115 - 119	24	97.8%
120 - 124	14	99.5%
125 - 129	4	100.0%
130 - 134	0	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 276)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	1	0.4%
15 - 19	0	0.4%
20 - 24	0	0.4%
25 - 29	0	0.4%
30 - 34	0	0.4%
35 - 39	0	0.4%
40 - 44	2	1.1%
45 - 49	2	1.8%
50 - 54	3	2.9%
55 - 59	11	6.9%
60 - 64	4	8.4%
65 - 69	7	10.9%
70 - 74	10	14.5%
75 - 79	20	21.8%
80 - 84	29	32.4%
85 - 89	14	37.5%
90 - 94	32	49.1%
95 - 99	31	60.4%
100 - 104	29	70.9%
105 - 109	34	83.3%
110 - 114	19	90.2%
115 - 119	15	95.6%
120 - 124	10	99.3%
125 - 129	2	100.0%
130 - 134	0	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)


University of Louisiana at Monroe

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: January 1, 2013 - April 30, 2013

School Name: Xavier University of Louisiana

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	1	0.00	47.00		9.00		10.00		9.00	
State	4	75.00	80.75	24.60	10.75	1.26	11.25	1.26	13.00	3.27
National	276	85.14	92.48	18.42	11.83	1.30	11.87	1.33	12.03	1.70

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	10	40.00	68.67	18.87	10.89	1.05	10.33	0.87	10.22	1.30
State	9	55.56	77.25	21.83	11.13	1.13	10.88	0.99	11.50	2.83
National	822	61.07	80.17	22.41	11.21	1.38	11.17	1.46	10.98	1.90

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2012). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2012) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.82	12.91	12.22	11.29
Mean Area 2 Scaled Score	13.83	12.83	12.18	11.22
Mean Area 3 Scaled Score	14.33	13.34	12.74	11.86
Mean Overall Scaled Score	119.72	109.26	100.15	84.05
Scaled Score Range	[114, 137]	[105, 113]	[95, 104]	[10, 94]
# Examinees per bin	3,171	3,172	3,171	3,171

In the quartile table (above), the mean overall scaled score for the bottom quartile is 84.05 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2012) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.64	10.26
Mean Area 2 Scaled Score	12.60	10.25
Mean Area 3 Scaled Score	13.15	10.81
Mean Overall Scaled Score	104.72	64.05
Scaled Score Range	[75, 137]	[10, 74]
# Examinees per bin	12,243	443

**Table 5 North American Pharmacist Licensure Examination® (NAPLEX)®
Candidate Summary Report**

Test Window: January 1, 2013 - April 30, 2013

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	93	12	11	11	04/18/2013	05/12/2012	N
2	Fail	47	9	10	9	03/01/2013	05/12/2012	Y
3	Pass	83	12	11	10	02/21/2013	05/12/2012	N
4	Fail	69	12	10	10	01/10/2013	05/12/2012	N
5	Pass	76	11	10	10	02/20/2013	12/15/2011	N
6	Fail	69	10	10	12	01/24/2013	05/08/2010	N
7	Fail					01/17/2013	05/08/2010	N
8	Fail	45	10	10	8	03/09/2013	05/09/2008	N
9	Fail	46	11	9	10	01/18/2013	03/10/2008	N
10	Pass	90	11	12	12	01/02/2013	01/22/2001	N

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 80.17
Standard Deviation: 22.41
Range: 7 - 129
Passing Rate (%): 61.07

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 92.48
Standard Deviation: 18.42
Range: 11 - 126
Passing Rate (%): 85.14

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 822)**

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	1	0.1%
10 - 14	1	0.2%
15 - 19	4	0.7%
20 - 24	4	1.2%
25 - 29	5	1.8%
30 - 34	8	2.8%
35 - 39	10	4.1%
40 - 44	17	6.2%
45 - 49	30	9.8%
50 - 54	28	13.3%
55 - 59	50	19.4%
60 - 64	42	24.6%
65 - 69	41	29.6%
70 - 74	70	38.3%
75 - 79	75	47.5%
80 - 84	73	56.5%
85 - 89	46	62.1%
90 - 94	73	71.1%
95 - 99	63	78.8%
100 - 104	49	84.9%
105 - 109	54	91.5%
110 - 114	27	94.8%
115 - 119	24	97.8%
120 - 124	14	99.5%
125 - 129	4	100.0%
130 - 134	0	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 276)

Test Window: January 1, 2013 - April 30, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	1	0.4%
15 - 19	0	0.4%
20 - 24	0	0.4%
25 - 29	0	0.4%
30 - 34	0	0.4%
35 - 39	0	0.4%
40 - 44	2	1.1%
45 - 49	2	1.8%
50 - 54	3	2.9%
55 - 59	11	6.9%
60 - 64	4	8.4%
65 - 69	7	10.9%
70 - 74	10	14.5%
75 - 79	20	21.8%
80 - 84	29	32.4%
85 - 89	14	37.5%
90 - 94	32	49.1%
95 - 99	31	60.4%
100 - 104	29	70.9%
105 - 109	34	83.3%
110 - 114	19	90.2%
115 - 119	15	95.6%
120 - 124	10	99.3%
125 - 129	2	100.0%
130 - 134	0	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Pharmacy Technician Certification Examination (PTCE™)

January 1 – June 30, 2013

Cumulative Record (since January 2000)

August 14, 2013

Pharmacy Technician Certification Examination (PTCE™)

This computer adaptive competency assessment is administered by the Pharmacy Technician Certification Board (PTCB). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in most of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a designated testing center at any time following approval by PTCB and receipt of an Authorization to Test (ATT) document from PTCB. Individual scores are available to applicants immediately after the test; certificates are mailed to the applicant within 30 days following the examination. Summary reports are provided to the state boards on a semi-annual basis.

Table of Contents

Cumulative Report (since January 2000)

03

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	1995-1999									
<u>National Data</u>	<u>Data</u>	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Passing Score										
Average Score										
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
Louisiana Data										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Average Score										
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
<hr/>										
	2000-2002									
<u>National Data</u>	<u>Data</u>	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Passing Score										650
Average Score										702
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
Louisiana Data										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Average Score										688
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2005 Data	<u>3/11/2006</u>	<u>7/22/2006</u>	<u>9/9/2006</u>	<u>11/18/2006</u>	2000-2006 Data	<u>2/5/2007</u> <u>3/9/2007</u>	<u>4/24/2007</u> <u>5/25/2007</u>	<u>8/27/2007</u> <u>9/28/2007</u>	<u>11/26/2007</u> <u>12/31/2007</u>
<u>National Data</u>										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Passing Score		650	650	650	650	650	650	650	650	650
Average Score		688	683	683	668					
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
Louisiana Data										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Average Score		673	664	685	641					
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
<hr/>										
	2000-2007 Data	<u>2/4/2008</u> <u>3/14/2008</u>	<u>4/28/2008</u> <u>6/20/2008</u>	<u>8/18/2008</u> <u>10/10/2008</u>	<u>11/10/2008</u> <u>12/19/2008</u>	2000-2008 Data	<u>1/1/2009</u> <u>3/31/2009</u>	<u>4/1/2009</u> <u>6/30/2009</u>	<u>7/1/2009</u> <u>9/30/2009</u>	<u>10/1/2009</u> <u>12/31/2009</u>
<u>National Data</u>										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
Louisiana Data										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Average Score										
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2009 Data	1/1/2010 3/31/2010	4/1/2010 6/30/2010	7/1/2010 9/30/2010	10/1/2010 12/31/2010	2000-2010 Data	1/1/2011 3/31/2011	4/1/2011 6/30/2011	7/1/2011 9/30/2011	10/1/2011 12/31/2011
National Data										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
Louisiana Data										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Average Score										
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
<hr/>										
	2000-2011 Data	1/1/2012 3/31/2012	4/1/2012 6/30/2012	7/1/2012 9/30/2012	10/1/2012 12/31/2012	2000-2012 Data	Changed to semi-annual reports 1/1/2013 to 6/30/2013		7/1/2013 to 12/31/2013	
National Data										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448			
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581			
Passing Score	650	650	650	650	650	650	650			
Average Score										
Pass Rate	75%	78%	77%	76%	76%	75%	77%			
Louisiana Data										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622			
No. of Candidates Passing	8,298	158	269	226	168	9,119	412			
Average Score										
Pass Rate	68%	64%	73%	69%	70%	68%	66%			

LOUISIANA COMPLIANCE QUESTIONNAIRE
(For Audit Engagements of Government Entities)

August 14, 2013

Baxley & Associates, LLC
PO Box 482
Plaquemine, Louisiana 70765

In connection with your audit of our financial statements as of **June 30, 2013**, and for the **one year period including July 1, 2012 through June 30, 2013**, for the purpose of expressing an opinion as to the fair presentation of our financial statements in accordance with accounting principles generally accepted in the United States of America, to assess our system of internal control as a part of your audit, and to review our compliance with applicable laws and regulations, we confirm, to the best of our knowledge and belief, the following representations. These representations are based on the information available to us as of **July 1, 2013**.

PART I. AGENCY PROFILE

1. Name and address of the organization.
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700

2. List the population of the municipality or parish based upon the last official United States Census or most recent official census (municipalities and police juries only). Include the source of the information.
State of Louisiana – 4,533,372 [2010 U. S. Census @ www.louisiana.gov]

3. List names, addresses, and telephone numbers of entity officials. [Include elected/appointed members of the governing board, chief executive and fiscal officer, and legal counsel.]
See Appendix A.

4. Period of time covered by this questionnaire:
July 1, 2012 through June 30, 2013

5. The entity has been organized under the following provisions of the Louisiana Revised Statutes (R.S.) and, if applicable, local resolutions/ordinances.
R.S. 37:1161-1250

6. Briefly describe the public services provided:
The Board of Pharmacy regulates the practice of pharmacy to the benefit of the public's health, safety, and welfare. It accomplishes that mission through the fulfillment of two objectives: the restriction of the practice to qualified persons as evidenced by its licensure processes, and the monitoring of practitioners for compliance with all relevant laws and rules as evidenced by its disciplinary processes. Further, the Board is responsible for the issuance of all controlled dangerous substance licenses to practitioners and facilities. The Board issues and renews those credentials, and further, assesses compliance with all relevant laws and rules through inspections of healthcare facilities.

7. Expiration date of current elected/appointed officials' terms.
See Appendix A.

PART II. PUBLIC BID LAW

8. The provisions of the public bid law, R.S. Title 38:2211-2296, and, where applicable, the regulations of the Division of Administration, State Purchasing Office have been complied with.

A. All public works purchases exceeding \$100,000 have been publicly bid.

B. All material and supply purchases exceeding \$20,000 have been publicly bid.

Yes No N/A

PART III. CODE OF ETHICS LAW FOR PUBLIC OFFICIALS AND PUBLIC EMPLOYEES

9. It is true that no employees or officials have accepted anything of value, whether in the form of a service, loan, or promise, from anyone that would constitute a violation of R.S. 42:1101-1124.

Yes No N/A

10. It is true that no member of the immediate family of any member of the governing authority, or the chief executive of the governmental entity, has been employed by the governmental entity after April 1, 1980, under circumstances that would constitute a violation of R.S. 42:1119.

Yes No N/A

PART IV. LAWS AFFECTING BUDGETING

11. We have complied with the budgeting requirements of the Local Government Budget Act (R.S. 39:1301-16), R.S. 39:33, or R.S. 39:1331-1342, as applicable.

A. Local Budget Act

1. We have adopted a budget for the General Fund and all special revenue funds (R.S. 39:1305).
2. The chief executive officer, or equivalent, has prepared a proposed budget that included a budget message, a proposed budget for the General Fund and each special revenue fund, and a budget adoption instrument that specified the chief executive's authority to make budgetary amendments without approval of the governing authority. Furthermore, the proposed expenditures did not exceed estimated funds to be available during the period (R.S. 39:1305).
3. The proposed budget was submitted to the governing authority and made available for public inspection at least 15 days prior to the beginning of the budget year (R.S. 39:1306).
4. To the extent that proposed expenditures were greater than \$500,000, we have made the budget available for public inspection and have advertised its availability in our official journal. The advertisement included the date, time, and place of the public hearing on the budget. Notice has also been published certifying that all actions required by the Local Government Budget Act have been completed (R.S. 39:1307).
5. If required, the proposed budget was made available for public inspection at the location required by R.S. 39:1308.

6. All action necessary to adopt and finalize the budget was completed prior to the date required by state law. The adopted budget contained the same information as that required for the proposed budget (R.S. 39:1309).
7. After adoption, a certified copy of the budget has been retained by the chief executive officer or equivalent officer (R.S. 39:1309).
8. To the extent that proposed expenditures were greater than \$500,000, the chief executive officer or equivalent notified the governing authority in writing during the year when actual receipts plus projected revenue collections for the year failed to meet budgeted revenues by five percent or more, or when actual expenditures plus projected expenditures to year end exceeded budgeted expenditures by five percent or more (R.S. 39:1311).
9. The governing authority has amended its budget when notified, as provided by R.S. 39:1311. (Note, general and special revenue fund budgets should be amended, regardless of the amount of expenditures in the fund, when actual receipts plus projected revenue collections for the year fail to meet budgeted revenues by five percent or more; or when actual expenditures plus projected expenditures to year end exceed budgeted expenditures by five percent or more. State law exempts from the amendment requirements special revenue funds with anticipated expenditures of \$250,000 or less and exempts special revenue funds with anticipated expenditures of \$500,000 or less, and exempts special revenue funds whose revenues are expenditure-driven – primarily federal funds whose expenditures drive revenue recognition – primarily federal funds – from the requirement to amend revenues.)

Yes No N/A

B. State Budget Requirements

1. The state agency has complied with the budgetary requirements of R.S. 39:33.

Yes No N/A

C. Licensing Boards

1. The licensing board has complied with the budgetary requirements of R.S. 39:1331-1342.

Yes No N/A

PART V. ACCOUNTING, AUDITING, AND FINANCIAL REPORTING LAWS

12. We have maintained our accounting records in such a manner as to provide evidence of legal compliance and the preparation of annual financial statements to comply with R.S. 24:513 and 515, and/or 33:463.

Yes No N/A

13. All non-exempt governmental records are available as a public record and have been retained for at least three years, as required by R.S. 44:1, 44:7, 44:31, and 44:36.

Yes No N/A

14. We have filed our annual financial statements in accordance with R.S. 24:514, and 33:463 where applicable.

Yes No N/A

15. We have had our financial statements audited in a timely manner in accordance with R.S. 24:513.

Yes No N/A

PART VI. MEETINGS

16. We have complied with the provisions of the Open Meetings Law, provided in R.S. 42:1 through 42:13.

Yes No N/A

PART VII. ASSET MANAGEMENT LAWS

17. We have maintained records of our fixed assets and movable property records, as required by R.S. 24:515 and/or 39:321-332, as applicable.

Yes No N/A

PART VIII. FISCAL AGENCY AND CASH MANAGEMENT LAWS

18. We have complied with the fiscal agency and cash management requirements of R.S. 39:1211-45 and 49:301-327, as applicable.

Yes No N/A

PART IX. DEBT RESTRICTION LAWS

19. It is true we have not incurred any long-term indebtedness without the approval of the State Bond Commission, as provided by Article VII, Section 8 of the 1974 Louisiana Constitution, Article VI, Section 33 of the 1974 Louisiana Constitution, and R.S. 39:1410.60 – 1410.65.

Yes No N/A

20. We have complied with the debt limitation requirements of state law (R.S. 39:562).

Yes No N/A

21. We have complied with the reporting requirements relating to the Fiscal Review Committee of the State Bond Commission (R.S. 39:1351).

Yes No N/A

PART X. REVENUE AND EXPENDITURE RESTRICTION LAWS

22. We have restricted the collections and expenditures of revenues to those amounts authorized by Louisiana statutes, tax propositions, and budget ordinances.

Yes No N/A

23. It is true we have not advanced wages or salaries to employees or paid bonuses in violation of Article VII, Section 14 of the 1974 Louisiana Constitution, R.S. 14:138, and AG Opinion 79-729.

Yes No N/A

24. It is true that no property or things of value have been loaned, pledged, or granted to anyone in violation of Article VII, Section 14 of the 1974 Louisiana Constitution.

Yes No N/A

PART XI. QUESTIONS FOR SPECIFIC GOVERNMENTAL UNITS

Parish Governments

25. We have adopted a system of road administration that provides as follows:
- A. Approval of the governing authority of all expenditures, R.S. 48:755(A).
 - B. Development of a capital improvement program on a selective basis, R.S. 48:755.
 - C. Centralized purchasing of equipment and supplies, R.S. 48:755.
 - D. Centralized accounting, R.S. 48:755.
 - E. A construction program based on engineering plans and inspections, R.S. 48:755.
 - F. Selective maintenance program, R.S. 48:755.
 - G. Annual certification of compliance to the auditor, R.S. 48:758.
- Yes No N/A

School Boards

26. We have complied with the general statutory, constitutional, and regulatory provisions of the Louisiana Department of Education, R.S. 17:51-401.
- Yes No N/A
27. We have complied with the regulatory circulars issued by the Louisiana Department of Education that govern the Minimum Foundation Program.
- Yes No N/A
28. We have, to the best of our knowledge, accurately compiled the performance measurement data contained in the following schedules and recognize that your agreed upon procedures will be applied to such schedules and performance measurement data: [Note: Parish school boards are required to report as part of their annual financial statements measures of performance. These performance indicators are found in the supplemental schedules.]
- Schedule 1 – General Fund Instructional and Support Expenditures and Certain Local Revenues Sources
 - Schedule 2 – Education Levels of Public School Staff
 - Schedule 3 – Number and Type of Public Schools
 - Schedule 4 – Experience of Public Principals, Assistant Principals, and Full-time Classroom Teachers
 - Schedule 5 – Public School Staff Data: Average Salaries
 - Schedule 6 – Class Size Characteristics
 - Schedule 7 – Louisiana Educational Assessment Program (LEAP)
 - Schedule 8 – Graduation Exit Examination (GEE)
 - Schedule 9 – The iLEAP Tests
- Yes No N/A

Tax Collectors

29. We have complied with the general statutory requirements of R.S. 47.
- Yes No N/A

Sheriffs

30. We have complied with the state supplemental pay regulations of R.S. 33:2218.8.
Yes No N/A

31. We have complied with R.S. 33:1432 relating to the feeding and keeping of prisoners.
Yes No N/A

District Attorneys

32. We have complied with the regulations of the Louisiana Department of Social Services that relate to the Title IV-D Program.
Yes No N/A

Assessors

33. We have complied with the regulatory requirements found in Title 47 of the Louisiana Revised Statutes.
Yes No N/A

34. We have complied with the regulations of the Louisiana Tax Commission relating to the reassessment of property.
Yes No N/A

Clerks of Court

35. We have complied with R.S. 13:751-917 and applicable sections of R.S. 11:1501-1562.
Yes No N/A

Libraries

36. We have complied with the regulations of the Louisiana State Library.
Yes No N/A

Municipalities

37. Minutes are taken at all meetings of the governing authority , R.S. 42:7.1.
Yes No N/A

38. Minutes, ordinances, resolutions, budgets, and other official proceedings of the municipalities are published in the official journal, R.S. 43:141-146 and AG 86-528.
Yes No N/A

39. All official action taken by the municipality is conducted at public meetings, R.S. 42:4.1-13.
Yes No N/A

Airports

40. We have submitted our applications for funding airport construction or development to the Department of Transportation and Development as required by R.S. 2:802.
Yes No N/A
41. We have adopted a system of administration that provides for approval by the department for any expenditures of funds appropriated from the Transportation Trust Fund, and no funds have been expended without department approval, R.S. 2:810.
Yes No N/A
42. All project funds have been expended on the project and for no other purpose, R.S. 2:810.
Yes No N/A
43. We have certified to the auditor, on an annual basis, that we have expended project funds in accordance with the standards established by law, R.S. 2:811.
Yes No N/A

Ports

44. We have submitted our applications for funding port construction or development to the Department of Transportation and Development as required by R.S. 34:3452.
Yes No N/A
45. We have adopted a system of administration that provides for approval by the department for any expenditures of funds made out of state and local matching funds, and no funds have been expended without departmental approval, R.S. 34:3460.
Yes No N/A
46. All project funds have been expended on the project and for no other purpose, R.S. 34:3460.
Yes No N/A
47. We have established a system of administration the provides for the development of a capital improvement program on a selective basis, centralized purchasing of equipment and supplies, centralized accounting, and the selective maintenance and construction of port facilities based upon engineering plans and inspections, R.S. 34:3460.
Yes No N/A
48. We have certified to the auditor, on an annual basis, that we have expended project funds in accordance with the standards established by law, R.S. 34:3461.
Yes No N/A

Sewerage Districts

49. We have complied with the statutory requirements of R.S. 33:3881-4159.10.
Yes No N/A

Waterworks Districts

50. We have complied with the statutory requirements of R.S. 33:3811-3837.

Yes No N/A

Utility Districts

51. We have complied with the statutory requirements of R.S. 33:4161-4546.21.

Yes No N/A

Drainage and Irrigation Districts

52. We have complied with the statutory requirements of R.S. 38:1601-1707 (Drainage Districts), R.S. 38:1751-1921 (Gravity Drainage Districts), R.S. 38:1991-2048 (Levee and Drainage Districts), or R.S. 38:2101-2123 (Irrigation Districts), as appropriate.

Yes No N/A

Fire Protection Districts

53. We have complied with the statutory requirements of R.S. 40:1491-1509.

Yes No N/A

Other Special Districts

54. We have complied with those specific statutory requirements of state law applicable to our district.

Yes No N/A

The previous responses have been made to the best of our belief and knowledge.

President: _____
Carl W. Aron

Date

Secretary: _____
Brian A. Bond

Date

Roster of Board Members & Executive Staff

Carl W. Aron
1209 N. 18th Street
Monroe, LA 71201-5495
318.323.1232
July 28, 2014

Brian A. Bond
PO Box 1154
Jena, LA 71342-1154
318.992.2665
June 30, 2018

Clovis S. Burch
1849 Line Avenue
Shreveport, LA 71101
318.865.0234
August 24, 2016

Ryan M. Dartez
509 Jefferson Street
Lafayette, LA 70501
337.235.4578
August 24, 2016

Jacqueline L. Hall
5781 Eastover Drive
New Orleans, LA 70128-2172
504.861.5033
July 28, 2014

Richard M. Indovina, Jr.
1001 Moss Lane
River Ridge, LA 70123
504.473.3180
August 24, 2016

Marty R. McKay
9049 Hwy. 165 South
Woodworth, LA 70506
318.776.5649
July 28, 2014

Chris B. Melancon
550 Catholique Road
Carencro, LA 70520
337.896.8434
June 30, 2018

Diane M. Milano
4803 Hessmer Avenue
Metairie, LA 70002-1531
504.889.2300
June 30, 2019

Ronald E. Moore
13906 Hootsell Court
Baton Rouge, LA 70816
225.241.2993
July 28, 2014

Blake P. Pitre
301 Roberta Grove Blvd.
Houma, LA 70363-5465
985.693.7496
June 30, 2018

T. Morris Rabb
1531 Frenchman's Bend Road
Monroe, LA 71203-8797
318.329.4641
June 30, 2018

Pamela G. Reed
14133 Kimbleton Avenue
Baton Rouge, LA 70817
225.753.1061
August 24, 2016

Donald L. Resweber
1379 Burton Plantation Highway
St. Martinville, LA 70582
337.654.3900
Pleasure of the Governor

Deborah H. Simonson
1516 Jefferson Highway
New Orleans, LA 70121
504.842.2246
August 24, 2016

Richard A. Soileau
805 Center Street
New Iberia, LA 70560
337.365.6721
July 28, 2014

Rhonny K. Valentine
116 Jefferson Street
Mansfield, LA 71052
318.872.5300
June 30, 2018

Malcolm J. Broussard
Executive Director
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

Carlos M. Finalet, III
General Counsel
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

M. Joseph Fontenot
Asst. Executive Director
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

Kelley L. Villeneuve
Office Manager
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Roster of Agency Publications

Minutes of Board Meetings and Administrative Hearings

The board generally meets on a calendar quarter basis. The minutes for a board meeting are approved at the next regular meeting and then posted on the board's website. These documents exist in electronic form only; they are not commercially printed.

Newsletters

The board publishes a quarterly newsletter in a collaborative effort with the National Association of Boards of Pharmacy (NABP) Foundation. Both parties contribute content for the newsletter, which is published in January, April, July, and October. This newsletter is published commercially and then mailed to all of the board's licensees with active pharmacy credentials. An electronic copy of the newsletter is also posted on the board's website.

Bulletins

As the need arises, the board may publish a bulletin for all of its licensees or some portion thereof. These documents may be mailed, or in the alternative, may be distributed by email. Electronic copies of these documents are posted on the board's website.

Guidance Documents

As the need arises, the board may publish compliance policy guidance documents on certain topics for its licensees. These documents may be mailed, or in the alternative, may be distributed by email. Electronic copies of these documents are posted on the board's website.

Laws & Regulations

The board publishes a compilation of the laws and rules relevant to pharmacy practice in Louisiana. This publication exists in electronic form only and is posted on the board's website.

Directory of Government Agencies & Private Organizations

As a service to its licensees, the board publishes a directory of government agencies and private organizations with some connection to the education, practice, and regulation of the pharmacy profession. The publication exists in electronic form only and is posted on the board's website.

Annual Reports

The board publishes an annual report on its activities. The report exists in electronic form only and is posted on the board's website. The board also submits a comprehensive annual financial report to the legislative auditor.

Commissioned Reports

From time to time, the legislature requests the board's assistance on certain pharmacy-related issues in public health and safety. When requested, the board will prepare commissioned reports for submission to the legislature. These documents exist in electronic form only and are posted on the board's website.

Prescription Monitoring Program (PMP)

The program vendor published an implementation guide for dispensers of prescriptions for controlled substances describing how to set up their accounts to facilitate the reporting of their eligible prescription activity to the program database. The guides were last updated 09-21-2010.

The board also posts the minutes from the PMP Advisory Council's quarterly meetings on the board's website.

Inventory of Agency Publications

(Revised 06-30-2013)

Minutes of Board Meetings & Administrative Hearings

2013 – Jan. 29, Mar. 6-7
2012 – Feb. 1-2, May 2-3, Aug. 22-23, Dec. 12-13.
2011 – Feb. 16-17, May 4-5, Aug. 17, Nov. 16-17.
2010 – Feb. 3, May 5-6, Aug. 11-12, Nov. 9-10.
2009 – Feb. 11-12, May 6-7, Aug. 5-6, Nov. 18-19.
2008 – Feb. 21-22, May 7-8, Aug. 6-7, Nov. 13.
2007 – Mar. 6-7, May 9-10, Aug. 15-16, Nov. 14-15.
2006 – Feb. 15-16, May 17-18, Aug. 15-16, Oct. 5-6, Nov. 9, Dec. 6-7.
2005 – Feb. 17, May 11-12, Aug. 17-18, Nov. 9.
2004 – Feb. 11-12, May 5-6, July 29, Aug. 18-19, Nov. 17-18.
2003 – Feb. 11-12, Feb. 19-20, May 22-23, Aug. 20-21, Nov. 19-20.
2002 – Feb. 20-21, May 8-9, Aug. 21, Nov. 20-21.
2001 – Feb. 8, May 16-17, Aug. 15-16, Nov. 14-15.
2000 – Feb. 10, Apr. 26-27, Aug. 16-17, Nov. 28-29.

For meeting minutes prior to 2000, please contact the board office for assistance.

Newsletters

This document is published in January, April, July, and October. Electronic copies for every year from 2000 forward are posted on the website. Editions from 1999 to 1982 are available in the board office.

Bulletins

<i>Issue No.</i>	<i>Date of Issue</i>	<i>Title</i>
13-02	05-01-2013	Law Book Update No. 6 (total replacement of all printed pages)
13-01	01-07-2013	Notice of Emergency Rule & Delayed Publication of 2013 Law Book
12-01	01-01-2012	Law Book Update No. 5 (total replacement of all printed pages)
11-01	01-31-2011	Law Book Update No. 4 (total replacement of all printed pages)
10-01	08-15-2010	New Laws – New Rules – New Website – New Licensure System
09-03	09-15-2009	Immunization Information & Emergency Order
09-02	07-25-2009	New Laws – New Controlled Substances
09-01	04-15-2009	Expedited Partner Therapy
08-03	08-15-2008	PMP, New Laws, & New Rules
08-02	04-07-2008	Technician Renewal Process
08-01	03-10-2008	Board Member Elections and CDTM
07-01	08-15-2007	New Laws & Rules
06-04	11-20-2006	Notice of Regulatory Activity re Project 2006-3
06-03	09-01-2006	Repeal of Certified Pharmacist Preceptor Program
06-02	09-01-2006	Law Book Update No. 3 (total replacement of all printed pages)
06-01	01-30-2006	Notice of Regulatory Activity re §705 and 907 of Board Rules
05-04	08-15-2005	Recent Changes in Pharmacy and Related Laws
05-03	03-04-2005	Electronic Transmission of Prescriptions
05-02	01-31-2005	Prescriptive Authority for Physician Assistants & Medical Psychologists
05-01	01-01-2005	Law Book Update No. 2
04-03	12-15-2004	New Regulation and Other Important Information
04-02	09-15-2004	Law Book Update No. 1
04-01	09-04-2004	Recent Changes in Pharmacy Laws

Guidance Documents

<i>Date of Issue</i>	<i>Title</i>
08-01-2012	Act 651 of 2012 Legislature – Pharmacist Immunizations in Health Professional Shortage Areas
08-01-2010	Act 287 Of 2010 Legislature & Pharmacist Immunization Recordkeeping
08-01-2010	Medication Disposal Programs
08-01-2010	Prescribers with Authority for Controlled Substances
05-01-2009	Buprenorphine in Treatment of Opiate Addiction
10-15-2008	Medication Guides (MedGuides®)

Laws & Regulations

The current edition of this electronic reference was published April 15, 2013. The following previous editions are still available: 01-01-2012 and 01-01-2011.

Directory of Government Agencies & Private Organizations

The current edition of this electronic reference was published April 15, 2013.

Annual Reports

Once approved by the board, typically during their summer session, these electronic reports are posted on the board's website. The reports from 2001 forward are posted on the website. The comprehensive annual financial reports audited by the legislative auditor are available from the board office.

Commissioned Reports

The following special reports were commissioned by the Louisiana Legislature, and are posted on the board's website:

<i>Date of Issue</i>	<i>Title</i>
02-01-2012	Administration of Immunizations in Louisiana, issued in response to Senate Resolution 122 of 2011 Legislature
02-01-2012	Legislative Workgroup on Electronic Prescribing, issued in response to House Resolution 108 and Senate Resolution 81 of 2011 Legislature
03-11-2009	Generic Substitution for Epilepsy Medication, issued in response to House Concurrent Resolution 198 of 2008 Legislature
07-14-2008	Prescription Monitoring Program Update, issued in response to Senate Concurrent Resolution 102 of 2008 Legislature
01-24-2006	Final Report of Prescription Monitoring Program Task Force, issued in response to House Concurrent Resolution 98 of 2005 Legislature
04-20-2005	Recycling of Unused Previously Dispensed Prescription Drugs, issued in response to House Concurrent Resolution 292 of 2004 Legislature

Prescription Monitoring Program (PMP)

Minutes from the meetings of the PMP Advisory Council (and its predecessor PMP Task Force) are posted on the board's website:

2013 – Jan. 9, Apr. 10
2012 – Jan. 11, Apr. 11, Jul. 11, Oct. 10.
2011 – Jan. 12, Apr. 13, Jul. 13, Oct. 12.
2010 – Jan. 13, Apr. 14, Jul. 14, Oct. 13.
2009 – Jan. 7, Apr. 8, Jul. 8, Oct. 14.
2008 – Jan. 16, Apr. 16, Jul. 9, Oct. 29.
2007 – Jan. 10, Apr. 11.
2006 – Jan. 24.
2005 – Jan. 12, Mar. 16, May 18, Aug. 4, Oct. 26, Nov. 30.

The following PMP-related guidance documents are posted on the board's website:

Date of Issue

Title

09-21-2010

Dispenser's Implementation Guide

09-21-2010

Dispensing Dentist's Implementation Guide



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



Legislative Brief

2013-0606 @ 1800

Regular Session of the 2013 Louisiana Legislature
Convened 2013-0408 @ 1200 – Adjourned 2013-0606 @ 1800

Last Items Reviewed						
HB 729	HR 227	HCR 188	HSR 11	HCSR 6		
SB 262	SR 207	SCR 131	SSR 1	SCSR 1	Acts 439	
Total = 1,763				Items on Watch List = 25		

House of Representatives

Bills

HB 10 Pearson Administration of Criminal Justice
Adds certain hallucinogenic substances to the list of Schedule I controlled dangerous substances.
05-23-2013 Signed as **Act 7**; effective 08-01-2013.

This measure added 27 newly identified hallucinogenic substances to Schedule I of the Louisiana Controlled Substances Law. Since we include the controlled substance law in the pharmacy law book, passage of this bill will require an update of the law book.

HB 15 Mack Administration of Criminal Justice
Adds certain compounds to the Schedule I classification of controlled dangerous substances.
05-23-2013 Signed as **Act 8**; effective 08-01-2013.

This measure added new compounds to the list of stimulants as well as new compounds to the list of synthetic cannabinoids, both in Schedule I of the Louisiana Controlled Substances Law. Since we include the controlled substances law in the pharmacy law book, passage of this bill will require an update of the law book.

HB 355 LeBas Health & Welfare
Provides relative to access to state prescription monitoring program information.
06-05-2013 Signed as **Act 110**; effective 08-01-2013.

This measure was sponsored by the Board at the request of the Prescription Monitoring Program Advisory Council. It authorizes prescribers and dispensers to appoint delegates for the purpose of retrieving data from the PMP database, subject to rules to be developed by the Board.

HB 390 LeBas Health & Welfare
Clarifies definition relative to colleges of pharmacy.
06-05-2013 Signed as **Act 112**; effective 08-01-2013.

This measure was sponsored by the Board to expand the definition of approved colleges of

pharmacy to include the new requirement of Board approval. The previous law required ACPE accreditation as part of the definition but not Board approval.

HB 391 LeBas Health & Welfare
Clarifies powers and duties of Louisiana Board of Pharmacy relative to nonresident pharmacies.
06-14-2013 Signed as **Act 282**; effective 08-01-2013.

This measure was sponsored by the Board to give the agency specific authority to inspect pharmacies located in other states and licensed to conduct business in this state, and further, to require the production of certain reports issued by other state boards of pharmacy, the DEA, or the FDA. Finally, the law authorizes the Board to recoup its expenses incurred in the inspection of nonresident pharmacies, in addition to the pharmacy permit fees.

HB 674 LeBas
Provides relative to pharmacy-generated drugs.
06-07-2013 Signed as **Act 168**; effective 08-01-2013.

This measure was sponsored by the Board to provide statutory authority for the Board to promulgate a rule that will allow pharmacies to make drug products without the necessity of a patient-specific prescription – a practice sometimes referred to ‘compounding for office use’ or ‘compounding for practitioner administration.’ The new law will require the Board to revise its rules for that practice.

Concurrent Resolutions

HCR 129 Broadwater House & Governmental Affairs
Directs each public body that has a custodian of public records to make the identity and contact information of the custodian available to the public.
06-06-2013 Filed with Secretary of State.

This measure will require the Board to include the identity and contact information for the Board's custodian of public records on the Board's website.

Study Resolutions

HSR 1 Honore
Requests a study of the feasibility and effectiveness of legalizing marijuana possession and use.
05-01-2013 Request approved.

This measure requests the House Committee on Administration of Criminal Justice to consult and work with at least ten other named organizations (including the Board of Pharmacy) to study this issue and report their findings prior to the beginning of the 2014 Regular Session. In their study, the resolution specifically requested consideration of the following factors: (1) Determining how the legalization of marijuana would affect the health, safety and welfare of the citizens of Louisiana; (2) Determining the impact legalization would have on drug-free workplace policies and procedures; (3) Determining the effect that legalization would have on existing criminal laws, including the Uniform Controlled Dangerous Substances Law, the habitual offender law, as well as provisions prohibiting the operation of a vehicle while intoxicated; (4) Determining the regulations needed for the licensing of retailers to sell marijuana; and (5) Determining the product labeling, quality control, and taxing regulations needed.

HSR 6 Hill
Requests a study of the feasibility and practicality of limiting the sale of products containing dextromethorphan.
06-06-2013 Request approved.

This measure requests the House Committee on Health and Welfare study the feasibility and practicality of limiting the sale of products containing dextromethorphan and report its findings to the House of Representatives prior to the 2014 Regular Session. The resolution requests the committee to consult with at least ten named organizations, including the Board of Pharmacy.

Senate

Bills

SB 187 F. Thompson Agriculture, Forestry, Aquaculture, & Rural Development
Provides relative to veterinarians and the Prescription Monitoring Program.
05-23-2013 Signed as **Act 27**; effective 05-23-2013.
This measure seeks to remove veterinarians from participation in the Prescription Monitoring Program.

Resolutions

SR 196 Mills
Expresses condolences on the death of Howard B. Bolton, Sr.
06-05-2013 Filed.
06-06-2013 Passed Senate (38-0);
Signed by Senate President; Sent to Secretary of State.

Roster of Colleges and Schools of Pharmacy
Status of Accreditation by ACPE

<u>NABP #</u>	<u>Name</u>	<u>City</u>	<u>State</u>	<u>Status</u>
045	Albany College of Pharmacy	Albany	NY	Full
108	Appalachian College of Pharmacy <i>(formerly University of Appalachia)</i>	Oakwood	VA	Full
001	Auburn University - Harrison School of Pharmacy	Auburn	AL	Full
110	Belmont University - College of Pharmacy	Nashville	TN	Full
017	Butler University - College of Pharmacy	Indianapolis	IN	Full
094	California Northstate University - College of Pharmacy	Rancho Cordova	CA	Full
075	Campbell University - College of Pharmacy	Buies Creek	NC	Full
	Cedarville University - School of Pharmacy	Cedarville	OH	Candidate
111	Chicago State University - College of Pharmacy	Chicago	IL	Full
	Concordia University - School of Pharmacy	Mequon	WI	Candidate
036	Creighton University - School of Pharmacy	Omaha	NE	Full
019	Drake University - College of Pharmacy	Des Moines	IA	Full
055	Duquesne University - Mylan School of Pharmacy	Pittsburgh	PA	Full
	D'Youville College - School of Pharmacy	Buffalo	NY	Candidate
105	East Tennessee State University - Bill Gatton College of Pharmacy	Johnson City	TN	Full
	Fairleigh Dickinson University - School of Pharmacy	Florham Park	NJ	Candidate
028	Ferris State University - College of Pharmacy	Big Rapids	MI	Full
011	Florida A&M University - College of Pharmacy	Tallahassee	FL	Full
083	Hampton University - School of Pharmacy	Hampton	VA	Full
096	Harding University - College of Pharmacy	Searcy	AR	Full
010	Howard University - College of Pharmacy	Washington	DC	Full
	Husson University - School of Pharmacy	Bangor	ME	Candidate
015	Idaho State University - College of Pharmacy	Pocatello	ID	Full
088	Lake Erie College of Osteopathic Medicine - School of Pharmacy	Erie	PA	Full
300	Lebanese American University - School of Pharmacy	Byblos	Lebanon	Full
112	Lipscomb University - College of Pharmacy	Nashville	TN	Full
089	Loma Linda University - School of Pharmacy	Loma Linda	CA	Full
042	Long Island University - Arnold & Marie Schwartz College of Pharmacy	Brooklyn	NY	Full
	Manchester University - College of Pharmacy	Fort Wayne	IN	Candidate
	Marshall University - School of Pharmacy	Huntington	WV	Candidate
026	MCPHS University - School of Pharmacy @ Boston <i>(formerly Massachusetts College of Pharmacy & Health Sciences)</i>	Boston	MA	Full

Roster of Colleges and Schools of Pharmacy
Status of Accreditation by ACPE

085	MCPHS University - School of Pharmacy @ Worcester <i>(formerly Massachusetts College of Pharmacy & Health Sciences)</i>	Worcester	MA	Full
013	Mercer University - College of Pharmacy	Atlanta	GA	Full
082	Midwestern University - College of Pharmacy @ Glendale	Glendale	AZ	Full
077	Midwestern University - College of Pharmacy @ Chicago	Chicago	IL	Full
047	North Dakota State University - College of Pharmacy	Fargo	ND	Full
101	Northeast Ohio Medical University - College of Pharmacy <i>(formerly Northeastern Ohio University Colleges of Medicine & Pharmacy)</i>	Rootstown	OH	Full
027	Northeastern University - School of Pharmacy	Boston	MA	Full
	Notre Dame of Maryland University - School of Pharmacy <i>(formerly College of Notre Dame of Maryland)</i>	Baltimore	MD	Candidate
076	Nova Southeastern University - College of Pharmacy	Fort Lauderdale	FL	Full
048	Ohio Northern University - College of Pharmacy	Ada	OH	Full
049	Ohio State University - College of Pharmacy	Columbus	OH	Full
054	Oregon State University - College of Pharmacy	Corvallis	OR	Full
103	Pacific University - School of Pharmacy	Hillsboro	OR	Full
086	Palm Beach Atlantic University - Lloyd L Gregory School of Pharmacy	West Palm Beach	FL	Full
	Philadelphia College of Osteopathic Medicine - School of Pharmacy	Suwanee	GA	Candidate
	Presbyterian College - School of Pharmacy	Clinton	SC	Candidate
018	Purdue University - College of Pharmacy	West Lafayette	IN	Full
	Regis University - School of Pharmacy	Denver	CO	Full
	Roosevelt University - College of Pharmacy	Schaumburg	IL	Candidate
	Rosalind Franklin University - College of Pharmacy	North Chicago	IL	Candidate
087	Roseman University - College of Pharmacy <i>(formerly Univ of Southern Nevada - College of Pharmacy)</i>	Henderson	NV	Full
038	Rutgers, the State University of New Jersey - Ernest Mario School of Pharmacy	Piscataway	NJ	Full
002	Samford University - McWhorter School of Pharmacy	Birmingham	AL	Full
081	Shenandoah University - Bernard J Dunn School of Pharmacy	Winchester	VA	Full
104	South Carolina College of Pharmacy	Charleston	SC	Full
	South College - School of Pharmacy	Knoxville	TN	Candidate
063	South Dakota State University - College of Pharmacy	Brookings	SD	Full
091	South University - School of Pharmacy	Savannah	GA	Full
099	Southern Illinois University - Edwardsville School of Pharmacy	Edwardsville	IL	Full
052	Southwestern Oklahoma State University - College of Pharmacy	Weatherford	OK	Full

Roster of Colleges and Schools of Pharmacy
Status of Accreditation by ACPE

100	St. John Fisher College - Wegmans School of Pharmacy	Rochester	NY	Full
043	St. John's University - College of Pharmacy	Jamaica	NY	Full
033	St. Louis College of Pharmacy	St. Louis	MO	Full
044	State University of New York (SUNY) at Buffalo - School of Pharmacy	Amherst	NY	Full
093	Sullivan University - College of Pharmacy	Louisville	KY	Full
057	Temple University - School of Pharmacy	Philadelphia	PA	Full
106	Texas A&M University - Irma Lerma Rangel College of Pharmacy	Kingsville	TX	Full
065	Texas Southern University - College of Pharmacy	Houston	TX	Full
078	Texas Tech University - School of Pharmacy	Amarillo	TX	Full
095	Thomas Jefferson University - School of Pharmacy	Philadelphia	PA	Full
113	Touro New York College of Pharmacy	New York City	NY	Full
097	Touro University - California College of Pharmacy	Vallejo	CA	Full
114	Union University - School of Pharmacy	Jackson	TN	Full
003	University of Arizona - College of Pharmacy	Tucson	AZ	Full
004	University of Arkansas for Medical Sciences - College of Pharmacy	Little Rock	AR	Full
090	University of California, San Diego -Skaggs School of Pharmacy	San Diego	CA	Probation
005	University of California, San Francisco - School of Pharmacy	San Francisco	CA	Full
109	University of Charleston - School of Pharmacy	Charleston	WV	Full
050	University of Cincinnati - James L Winkle College of Pharmacy	Cincinnati	OH	Full
008	University of Colorado - Skaggs School of Pharmacy	Aurora	CO	Full
009	University of Connecticut - School of Pharmacy	Storrs	CT	Full
102	University of Findlay - College of Pharmacy	Findlay	OH	Full
012	University of Florida - College of Pharmacy	Gainesville	FL	Full
014	University of Georgia - College of Pharmacy	Athens	GA	Full
098	University of Hawaii at Hilo - Daniel K Inouye College of Pharmacy	Hilo	HI	Full
066	University of Houston - College of Pharmacy	Houston	TX	Full
016	University of Illinois at Chicago - College of Pharmacy	Chicago	IL	Full
020	University of Iowa - College of Pharmacy	Iowa City	IA	Full
021	University of Kansas - School of Pharmacy	Lawrence	KS	Full
022	University of Kentucky - College of Pharmacy	Lexington	KY	Full
023	University of Louisiana at Monroe - College of Pharmacy	Monroe	LA	Full
025	University of Maryland - School of Pharmacy	Baltimore	MD	Full
	University of Maryland - Eastern Shore School of Pharmacy	Princess Anne	MD	Full
029	University of Michigan - College of Pharmacy	Ann Arbor	MI	Full

Roster of Colleges and Schools of Pharmacy
Status of Accreditation by ACPE

031	University of Minnesota - College of Pharmacy	Minneapolis	MN	Full
032	University of Mississippi - School of Pharmacy	Oxford	MS	Full
034	University of Missouri at Kansas City - School of Pharmacy	Kansas City	MO	Full
035	University of Montana - Skaggs School of Pharmacy	Missoula	MT	Full
037	University of Nebraska - College of Pharmacy	Omaha	NE	Full
	University of New England - College of Pharmacy	Portland	ME	Full
039	University of New Mexico - College of Pharmacy	Albuquerque	NM	Full
046	University of North Carolina - Eshelmann School of Pharmacy	Chapel Hill	NC	Full
	University of North Texas - College of Pharmacy	Fort Worth	TX	Precandidate
053	University of Oklahoma - College of Pharmacy	Oklahoma City	OK	Full
058	University of Pittsburgh - School of Pharmacy	Pittsburgh	PA	Full
059	University of Puerto Rico - School of Pharmacy	San Juan	PR	Full
060	University of Rhode Island - College of Pharmacy	Kingston	RI	Full
	University of Saint Joseph - School of Pharmacy <i>(formerly St. Joseph College)</i>	Hartford	CT	Full
	University of South Florida - School of Pharmacy	Tampa	FL	Candidate
007	University of Southern California - School of Pharmacy	Los Angeles	CA	Full
064	University of Tennessee - College of Pharmacy	Memphis	TN	Full
067	University of Texas at Austin - College of Pharmacy	Austin	TX	Full
107	University of the Incarnate Word - Feik School of Pharmacy	San Antonio	TX	Full
006	University of the Pacific - Thomas J Long School of Pharmacy	Stockton	CA	Full
056	University of the Sciences - Philadelphia College of Pharmacy	Philadelphia	PA	Full
051	University of Toledo - College of Pharmacy	Toledo	OH	Full
068	University of Utah - College of Pharmacy	Salt Lake City	UT	Full
070	University of Washington - School of Pharmacy	Seattle	WA	Full
073	University of Wisconsin at Madison - School of Pharmacy	Madison	WI	Full
074	University of Wyoming - School of Pharmacy	Laramie	WY	Full
069	Virginia Commonwealth University - School of Pharmacy	Richmond	VA	Full
071	Washington State University - College of Pharmacy	Pullman	WA	Full
030	Wayne State University - Eugene Applebaum College of Pharmacy	Detroit	MI	Full
072	West Virginia University - School of Pharmacy	Morgantown	WV	Full
	Western New England University - College of Pharmacy	Springfield	MA	Candidate
084	Western University of Health Sciences - College of Pharmacy	Pomona	CA	Full
080	Wilkes University - Nesbitt College of Pharmacy	Wilkes-Barre	PA	Full

Roster of Colleges and Schools of Pharmacy
Status of Accreditation by ACPE

092	Wingate University - School of Pharmacy	Wingate	NC	Full
024	Xavier University of Louisiana - College of Pharmacy	New Orleans	LA	Full

Accreditation Status

Precandidate A new program that has no students enrolled but that meets the eligibility criteria for accreditation may be granted Precandidate accreditation status. The granting of Precandidate status indicates that a college or school's planning for the Doctor of Pharmacy program has taken into account ACPE standards and guidelines and suggests reasonable assurances of moving to the next step, that of Candidate status. Granting of Precandidate status brings no rights or privileges of accreditation. Full public disclosure by the college or school of pharmacy of the terms and conditions of this accreditation status is required.

Candidate Once students have enrolled in a new program, but the program has not had a graduating class, the program may be granted Candidate status. The granting of Candidate status denotes a developmental program that is expected to mature in accord with stated plans and within a defined time period. Reasonable assurances are expected to be provided that the program may become accredited as programmatic experiences are gained, generally, by the time the first class has graduated. Graduates of a class designated as having Candidate status have the same rights and privileges as graduates of an accredited program.

Full The professional degree program of a college or school of pharmacy is granted initial or full accreditation if it has been demonstrated to the satisfaction of ACPE that the program complies with accreditation standards, including the appropriateness of the program's mission and goals, the adequacy of resources and organization to meet the mission and goals, outcomes which indicate that the mission and goals are being met, and the reasonable assurance of the continued compliance with standards.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



August 14, 2013

**Agenda Item 11 – Request for Opinion from BioScrip®:
Addition of Medications by Non-Pharmacy Practitioners to Parenteral Preparations
Previously Compounded by Pharmacies**

This request comes from BioScrip, a home infusion company, pursuant to their inquiry to the La. State Board of Nursing. The issue relates to that board's previous declaration in 1987 that the addition of drugs by home health nurses to parenteral solutions as beyond their scope of practice. That 1987 ruling referenced the La. Board of Pharmacy's rules relative to compounding. BioScrip recently requested an updated opinion from the La. State Board of Nursing, and that board's staff advised the petitioner of their belief the current membership of the nursing board would uphold the 1987 nursing board opinion since the pharmacy board's definition of compounding has not changed in the interim. BioScrip now comes to the Board of Pharmacy.

While their desired outcome is easily surmised, their specific request to the pharmacy board is not clear. The Board of Pharmacy cannot opine as to the valid scope of practice for nurses. The pharmacy board does have long-standing laws and rules relative to compounding, and those rules include standards for pharmacy licensees performing that activity. The pharmacy board may only establish standards for its licensees. Since the activity of compounding medication is legally authorized for other professions besides pharmacy, the pharmacy board can only address the standards for its own licensees and not for any other licensees. While nurses do not have the legal authority to compound medications, they do have authority to administer medications.

The 1987 opinion of the nursing board acknowledged the authority of the pharmacy board to regulate the compounding of medications. As part of that general conversation between the nursing and pharmacy boards, the pharmacy board acknowledged the preparation of medication for immediate administration was an activity appropriate for a nurse, assuming the nurse's education and training for that activity was documented and available for review (an assumption commonly stated by the nursing board in its various opinions).

In lieu of disturbing a long-standing opinion from the nursing board that was predicated on a legal definition of compounding which remains unchanged, it may be reasonable for the pharmacy board to consider whether the addition of short stability drugs by home health nurses to parenteral nutrition solutions within one hour of the time of administration of the parenteral solution is an activity properly construed as preparation of the medication for administration, and further, that such activity may be appropriate for a nurse, subject to the opinion of the nursing board.

Staff recommends taking the current request for an opinion under advisement, then directing staff to consult with the staff of the nursing board for the development of a draft opinion on the issue, then docketing the drafted opinion for approval by the board.

Respectfully submitted,
Malcolm J Broussard
Executive Director

A Petition to the Louisiana State Board of Pharmacy

3388 Brentwood Drive, Baton Rouge, LA 70809-1700

Requestor:

National Home Infusion Association (NHIA)

Petition presented on behalf of NHIA by NHIA Standards Committee Member Marc Stranz, PharmD,
National Vice President of Clinical Services, BioScrip

NHIA Contact: *Nancy Kramer, Vice President of Clinical Affairs, National Home Infusion Association*

Nancy.kramer@nhia.org Telephone: (513) 515-9440

NHIA

100 Daingerfield Rd

Alexandria, VA 22314

Petition: NHIA, representing home infusion pharmacies doing business in the State of Louisiana, respectfully requests an opinion from the Louisiana State Board of Pharmacy regarding the addition of medications by non-pharmacy practitioners to parenteral preparations previously compounded by pharmacies, when performed in accordance with United States Pharmacopeial (USP) Standards, and when a sterile product pharmacy is not available to perform such immediate-use compounding.ⁱ

Background

- In 1987, the Louisiana State Board of Nursing published an opinion that declared the addition of short stability medications to total parenteral nutrition (TPN, now commonly referred to only as “PN”) solution in the home to be beyond the scope of practice for registered nurses (RNs) (*see Attachment A for a copy of this original position statement*).
- When formulating this opinion, the Louisiana State Board of Nursing notes that input was sought from the Louisiana State Board of Pharmacy regarding which licensed professionals in the state of Louisiana were permitted by current Board of Pharmacy regulations to compound sterile products. The Louisiana State Board of Pharmacy at that time confirmed that only licensed pharmacists in the state of Louisiana were permitted by state pharmacy regulation to compound sterile medications, and that the addition of medications to a bag of parenteral nutrition in a patient’s home exceeded the scope of practice for a registered nurse.
- Certain additives, which are essential to the health and well-being of patients receiving PN as their sole source of nutrition, are not stable for more than 24 hours after addition to parenteral nutrition.
 - They include multivitamins, heparin, and the H₂ blockers.ⁱⁱ
 - In home infusion pharmacy, compounded parenteral nutrition solution is stable (USP <797>) for 9 days, and most patients receive seven days of product with each delivery to their home.^{iii, iv}

- Since adding these short stability drugs to the parenteral nutrition in the pharmacy is not good practice, the addition must be done in the home on the day of infusion by trained patients or by the home health nurse if necessary.
- Since the publication of the 1987 opinion by the Louisiana State Board of Nursing, home infusion providers in the State of Louisiana have had to develop methods for teaching patients how to make these critical nutrient additions to their PN bags without the hands-on demonstration by a home infusion nurse.
 - Many providers utilize “practice bags” to demonstrate this procedure, and patients return-demonstrate with a practice bag until they demonstrate competency and are able to safely add these medications to their own PN solution.

Current Situation

- In early 2013, NHIA member pharmacies including BioScrip (524 Elmwood Park Blvd, Suite 110, Jefferson, LA 70123) reported that certified Home Health Agencies (HHAs) were declining to provide nursing services for patients who were newly prescribed PN therapy in the home, citing the 1987 Louisiana State Board of Nursing Opinion as their rationale. These HHAs are contending that this opinion also prohibits nurses from teaching patients how to add medications to their PN solution.
- If a nurse is unable to participate in the teaching of patients that are prescribed PN therapy in their home and who need to learn how to add short-stability medications to their PN each day, then substantial numbers of Louisiana patients are no longer candidates for home PN and may require extended stays in hospitals or skilled facilities in order to safely receive this life-sustaining therapy.
- In order for NHIA to petition the Louisiana State Board of Nursing for a reconsideration of their 1987 opinion, we were advised by Cynthia York, RN, MSN, CGRN, Director, Practice and Credentialing Department, Louisiana State Board of Nursing, to first “seek a formal opinion from the Louisiana State Board of Pharmacy.”
 - The above quote attributed to Ms. York is derived from her May 31st email response (*Attachment B*) to an email/letter sent by BioScrip Vice President of Nursing Kathy Puglise (*Attachment C*), requesting a reversal of the 1987 opinion.
 - In that email response, Ms. York notes that the Louisiana opinion rendered in 1987 was based on the Louisiana State Board of Pharmacy’s rules/regulations pertaining to compounding.

Support for this Petition

USP Chapter <797>

- USP Chapter <797> outlines the standards of practice for the safe and effective preparation of sterile products. A hallmark of these standards is the scope of personnel to whom they apply, which includes nurses – USP describes this scope as follows:
 - “The standards in this chapter are intended to apply to all persons who prepare compounded sterile preparations (CSPs) and all places where CSPs are prepared (e.g., hospitals and other healthcare institutions, patient treatment clinics, pharmacies, physicians’ practice facilities, and other locations and facilities in which CSPs are prepared, stored, and transported). Persons who perform sterile compounding include pharmacists, nurses, pharmacy technicians, and physicians.”^v

- Further, USP Chapter <797> includes an immediate-use compounding provision that is intended only for those situations where there is a need for emergency or immediate patient administration of a CSP, such as in the case of a short-stability drug. This provision requires that the administration of such immediate-use preparations begin within one hour of the compounding.

The Joint Commission®

- The Joint Commission® (TJC) publishes Home Care Accreditation Standards which include standards pertaining to medication management (MM). These standards specifically address the role of compounding in relation to drugs with short stability as follows:
 - “Standard MM 4.20, EP 1: When an on-site, licensed pharmacy is available, only the pharmacy compounds or admixes all sterile medications, IV admixtures, or other drugs except in emergencies or when not feasible (for example, when the product stability is short).”^{vi}

American Society for Parenteral and Enteral Nutrition (ASPEN)

- The American Society for Parenteral and Enteral Nutrition (ASPEN) is a professional society dedicated to improving patient care by advancing the science and practice of clinical nutrition and metabolism. The need for patients to add short stability medications to PN is recognized by ASPEN and other clinical standards bodies in published guidelines and clinical research, and is also noted in a letter sent from ASPEN to the Louisiana Board of Nursing (*Attachment D*).^{vii}

Infusion Nurses Society (INS)

- The Infusion Nurses Society recognizes situations in which nurses may need to perform compounding of parenteral solutions and medications in Standard 20 of the Infusion Nursing Standards of Practice.^{viii}
 - These standards note that compounding shall be performed in accordance with state and federal regulations as well as USP Standards, and shall be performed under the direction of the pharmacy.
 - INS has also submitted a letter to the Louisiana Board of Nursing, requesting a reversal of the 1987 opinion (*Attachment E*).

Conclusion

We appreciate your consideration of this petition for a formal opinion from the Louisiana State Board of Pharmacy regarding the addition of medications by non-pharmacy practitioners to parenteral preparations previously compounded by pharmacies, when such addition is performed in accordance with United States Pharmacopeial (USP) Standards, and when a sterile product pharmacy is not available to perform such immediate-use compounding.

Attachments

- A. Original 1987 Louisiana Board of Nursing Position Statement
- B. Attachment B: LA BON CYork Response May 2013
- C. Attachment C: KPuglise Letter to LA BON May 2013
- D. Attachment D: ASPEN Letter to LA BON 7-4-2013
- E. Attachment E: INS Letter to LA BON 7-18-2013

REFERENCES

- ⁱ United States Pharmacopeial Convention. Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Official June 1, 2008.
- ⁱⁱ Bing CM, Nowobilski-Vasilios A. Extended stability for parenteral drugs. 5th ed. Bethesda, MD: American Society of Health System Pharmacists; 2013.
- ⁱⁱⁱ Bing CM, Nowobilski-Vasilios A. Extended stability for parenteral drugs. 5th ed. Bethesda, MD: American Society of Health System Pharmacists; 2013.
- ^{iv} United States Pharmacopeial Convention. Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Official June 1, 2008.
- ^v United States Pharmacopeial Convention. Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Official June 1, 2008. Introduction: 35.
- ^{vi} The Joint Commission, Comprehensive Accreditation Manual for Home Care, 2013.
- ^{vii} Kovacevich DS, Frederick A, Kelly D, Nishikawa R, Young L. ASPEN Standards for Specialized Nutrition Support: Home Care Patients. Nutrition in Clinical Practice 20:579-590, October 2005.
- ^{viii} Infusion Nurses Society, Infusion Nursing Standards of Practice. Journal of Infusion Nursing, 2011. 34(1S):S27.

September 24, 1987

Frances Dixon, RN, CNA
Vice President
Southern Regional Nursing Associates, Inc.
132 1/2 Phyllis Court
River Ridge, LA 70123

Dear Ms. Dixon:

At its regular meeting on September 22, 1987, the Board of Nursing deliberated on your request for an official opinion of the Board regarding registered nurses adding medications to TPN solution prior to administration in the home. After due deliberation, the Board adopted the following opinion.

.33

In reference to Agenda Item 2 a, it is not within the realm of the practice of a registered nurse to add medications to TPN solution prior to administration.

The members of the Board appreciated the opportunity to discuss this matter with you. Additionally, they appreciated the input from the Board of Pharmacy.

Sincerely,

Sister Lucie Leonard, MSN, RN
Nursing Practice Consultant

cc: Howard B. Bolton, Executive Director, Louisiana Board of Pharmacy
Henry E. Gowland, Jr., Pharmacy Inspector

From: Cynthia York [yorkc@lsbn.state.la.us]
Sent: Friday, May 31, 2013 9:35 PM
To: Kathy Puglise
Subject: FW: Scope of Practice

Ms. Puglise:

Thank you for contacting the Louisiana State Board of Nursing.

I have reviewed your request as well as the opinion rendered by the nursing board back in 1987. It appears the opinion was rendered based on the Louisiana State Board of Pharmacy's rules/regulations as it pertains to compounding.

The pharmacy board's current rules define compounding as: *the preparation, mixing, assembling, packaging, or labeling of a drug or device by a pharmacist for his patient as the result of a practitioner's prescription drug order or initiative based on the practitioner/patient/pharmacist relationship in the course of professional practice, or including the preparation of drugs or devices in anticipation of prescription orders to be received by the compounding pharmacist based on routine, regularly observed prescribing patterns. Compounding does not include the compounding of drug products that are essentially copies of a commercially available product.*

It is board staff's opinion that the board members would uphold the opinion rendered in 1987. If you wish to speak directly with the board members, I encourage you to complete the petition for declaratory statement/opinion which may be located on our website under practice at www.lsbn.state.la.us. Please mail the completed petition and supporting documents to my attention and I will be glad to assist you through the process. I would recommend that prior to doing so, you seek a formal opinion from the Louisiana State Board of Pharmacy.

Sincerely,

Cynthia York, RN, MSN, CGRN
Director, Practice and Credentialing Department
Louisiana State Board of Nursing
Phone: 225-755-7519
Fax: 225-755-7581

From: Kathy Puglise [<mailto:kpuglise@bioscrip.com>]
Sent: Friday, May 31, 2013 7:03 PM
To: Practice_Department
Cc: Corporate Clinical Services; Dave Evans; Nancy Kramer
Subject: Scope of Practice

Dear Ms. York,

Please see attached for review. Thank you in advance for your time.

Kathy Puglise, MSN/ED, BSN, RN, CRNI
Vice President of Infusion Nursing
BioScrip, Inc.
5365 Robin Hood Road, Suite 200, Norfolk, VA 23513
(757) 855-4255 (Work) (757) 323-9663 (Cell)

E-MAIL DISCLOSURE STATEMENT

You are hereby advised that this transmission, including any attachment(s), has originated from the Louisiana State Board of Nursing and may contain privileged and/or confidential information, including protected health information, individually identifiable health information or other information which may be protected under state and/or federal law. This transmission, including any attachment(s), is meant only for the exclusive use of the intended recipient(s) named above. If you are not the intended recipient of this transmission, be aware that any unauthorized review, dissemination, distribution, duplication or other use of this transmission, including any attachment(s), is strictly prohibited. If you have received this transmission in error, you are asked to please notify both the sender and the administrator (lsbn@lsbn.state.la.us) and to destroy all copies of this transmission. The foregoing shall apply whether this transmission has been received in electronic or documentary format.

Any views or opinions expressed in the foregoing e-mail are solely those of the author and may not reflect those of the Louisiana State Board of Nursing or its staff.

CONFIDENTIALITY NOTICE: This e-mail and any files transmitted with it are confidential and are intended solely for the use of the individual or entity to which they are addressed. This communication may also contain material protected and governed by the Health Insurance and Portability and Accountability Act (HIPAA). If you are not the intended recipient of this e-mail and the information it contains or if you are not the employee or agent responsible for delivering this e-mail and the information it contains to the intended recipient, be advised that you have received this e-mail in error and that any use, dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. If you have received this e-mail in error, please contact the sender of this message.

This message has been checked for all known viruses by the MessageLabs Virus Scanning Service for BioScrip, Inc.



May 31, 2013

Louisiana State Board of Nursing
Attn: Ms. Cindy York
17373 Perkins Road
Baton Rouge, LA 70810

Dear Ms. York,

At its regular meeting on September 22, 1987, the Louisiana State Board of Nursing (the "Board") deliberated and issued an official opinion stating that adding medications to Total Parenteral Nutrition (TPN a/k/a PN) solution prior to administration is not within the scope of practice for a Registered Nurse (RN).¹

Since the Board's 1987 determination, alternate-site healthcare, specifically home infusion care, has grown tremendously. Today, there are more than 40,000 patients in the United States that receive PN therapy in the home care setting. Collaborative care teams consisting of physicians, pharmacists, RNs, and registered dietitians manage PN patients in their homes in order to meet each patient's individualized needs to achieve positive patient outcomes.

As a result of advancements in health care that have allowed patients to be managed at home safely and effectively on PN, the Louisiana Board of Nursing opinion regarding the addition of medications to PN no longer reflects the current standards of nursing practice. For example, the need for patients to add short stability medications to PN is recognized by ASPEN and other clinical standards bodies.² Nevertheless, and despite the fact that patient safety and protection are top priorities in the administration of health care,³ the current Louisiana rules restrict home infusion RNs from adding medication to a bag of PN, which inhibits proper patient education.

¹ The American Society for Parenteral and Enteral Nutrition (ASPEN) now refers to TPN as Parenteral Nutrition (PN), which will be used throughout this letter.

² Common additives may include, but are not limited to, multivitamins, macronutrients, antiemetics, insulin, or proton pump inhibitors; Reference: Kovacevich DS, Frederick A, Kelly D, Nishikawa R, Young L. ASPEN Standards for Specialized Nutrition Support: Home Care Patients. *Nutrition in Clinical Practice* 20:579-590, October 2005..

³ Home health nurses and infusion nurses must be knowledgeable and competent in the provision of care according to organizational policies and procedures and the standards of practice set forth by the infusion Nurses Society (INS). The INS standards of practice states that:³

The scope of practice for each type of personnel involved with the delivery of infusion therapy shall be organized to support patient safety and protection and shall clearly define the roles, responsibilities, range of services and accountability for all levels of personnel involved with the delivery of infusion therapy.

As a method of public protection, nurses shall be competent in the safe delivery of infusion therapy and shall be responsible and accountable for attaining and maintaining competence with infusion therapy.



Proper patient and caregiver education should include the nurse explaining and demonstrating how to add medications to the PN bag, and ensuring that the patient/caregiver is knowledgeable and competent in adding such medications to the PN bag independently through return demonstrations. The Board's restriction on RN scope of practice not only limits their care of home-based PN patients, but also the demonstration aspect of patient/caregiver education, which can place patients' safety at risk as they learn how to self-administer PN therapy in their home.

Accordingly, I respectfully request that the Board reconsider and revise its 1987 opinion and find that it is within the scope of practice for an RN to add medications to PN solution prior to administration, as well as to teach a patient and or caregiver how to add such medications to PN solution as part of their self-care regimen that allows the receipt of this life-sustaining therapy in the home setting.

Please contact me should you have any questions or concerns. I can be reached at telephone number (757) 855-4255 (O) or (757) 323-9663 (C) or email kpuglise@bioscrip.com.

Regards,

Kathy Puglise MSN ED, BSN, RN, CRNI®

Kathy Puglise, MSN/ED, BSN, RN, CRNI®
Vice President of Infusion Nursing
BioScrip, Inc.



July 4, 2013

Louisiana State Board of Nursing
Attn: Ms. Cindy York
17373 Perkins Road
Baton Rouge, LA 70810

Dear Ms. York,

On behalf of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), the A.S.P.E.N. Public Policy Committee in conjunction with the A.S.P.E.N. Nutrition Support Nurses Practice Section would like to support change to the 1987 ruling by the Louisiana State Board of Nursing on adding medications to Parenteral Nutrition (PN).

This ruling, where adding medications to PN by Registered Nurses falls outside of the scope of practice is no longer current practice and can impede patient education and delivery of much need PN solutions. A.S.P.E.N. would like to share two documents with you all for consideration

1. *The Future of Nursing: Leading Change, Advancing Health* Committee on the Robert Wood Johnson Foundation Initiative on the Future of Nursing, at the Institute of Medicine; Institute of Medicine (see attached). The conclusion to this report reads: "Now is the time to eliminate the outdated regulations and organizational and cultural barriers that limit the ability of nurses to practice to the full extent of their education, training, and competence. The U.S. is transforming its health care system to provide quality care leading to improved health outcomes, and nurses can and should play a significant role." We believe the nurse is a key healthcare professional leading to the success and growth of home parenteral nutrition as patient and caregiver educators of sterile admixture in the home, reducing length of stay in the hospital as a cost effective alternative to quality care.
2. *Standards for Specialized Nutrition Support: Home Care Patients* American Society for Parenteral and Enteral Nutrition Board of Directors and the Standards for Specialized Nutrition Support Task Force: Debra S. Kovacevich, RN, MPH; Annie Frederick, RD, CNSD; Darlene Kelly, MD, PhD; Reid Nishikawa, PharmD, BCNSP; and Lorraine Young, MS, RD, CNSD. *Nutrition in Clinical Practice* 20:579-590, October 2005. Standard 15. Additives to PN Formulations states:
"15.2. All additions to a PN formulation such as multivitamins shall be made by the patient or caregiver in a designated clean area as instructed by the home care provider. Parenteral multivitamins should be added immediately before starting the PN infusion." As the nurse is teaching the patient or caregiver in the home to perform this task, she must be able to demonstrate this skill or perform it when the patient or caregiver is unable.

Based on these standards and statements, we respectfully request that the Board reconsider its 1987 ruling and allow registered nurses to add medications to PN prior to administration. It is up to the home infusion agency to provide oversight and measure competency for its nursing staff to be able to safely perform this task. Please contact Peggi Guenter, PhD, RN at peggig@aspen.nutr.org with any communication or questions on this issue. Thank you for your consideration of our request.

Sincerely,
Jay Mirtallo, MS, RPh, BCNSP, FASHP, FASPEN
Chairman, A.S.P.E.N. Public Policy Committee
Silver Spring, MD

1973 • 2013



Setting the Standard for Infusion Care®

for **40** years

July 18, 2013

Cynthia York, RN, MSN, CGRN
Director, Practice and Credentialing Department
Louisiana State Board of Nursing
17373 Perkins Road
Baton Rouge, LA 70810

Dear Ms. York,

On behalf of the Infusion Nurses Society (INS), I would like to express our support for changing the 1987 ruling by the Louisiana State Board of Nursing on adding medications to Parenteral Nutrition (PN).

As patients transition from hospital to the home setting and are receiving long-term, life-sustaining therapies such as PN, it is critical that the care is provided safely and in a timely manner. Home infusion nurses, educated and trained, are best equipped to teach patients how to provide self-care in a safe manner.

While patients are taught to add medications to PN, it is imperative that Registered Nurses (RNs), teaching and caring for these patients, have the same authorization to perform these patient care procedures. Current nursing practice has evolved to address the changing patient care needs with attention to the patient's care setting. RNs, educated and deemed competent, can properly and safely add medications to PN and support the patient should he or she be unable to perform the procedure.

A great deal of recent literature on health care reinforces the need to expand the RN's scope of practice in all health care settings. Please consider the following:

1. Infusion Nurses Society. *Infusion Nursing Standards of Practice*. 2011; 34(1S): The *Infusion Nursing Standards of Practice* provides nurses with standards that guide safe, competent practice. Of note, Standard 20: "Compounding of Parenteral Solutions and Medications" supports the collaborative practice between nursing and pharmacy as it relates to compounding: "The nurse shall perform compounding under the direction of the pharmacy..."^(p.527)
2. Mary Alexander, MA, RN, CRNI®, CAE, FAAN; Ann Corrigan, MS, RN, CRNI®; Lisa Gorski, MS, HHCNS-BC, CRNI®, FAAN; Judy Hankins, BSN, CRNI®; Roxanne Perucca, MS, CRNI®, eds. *Infusion Nursing: An Evidence-Based Approach*. St. Louis, MO: Saunders/Elsevier; 2010: "The nurse's role in IV drug administration is determined by the health care setting. In the

315 Norwood Park South
Norwood, MA 02062
(781) 440-9408
(781) 440-9409 Fax
ins1.org

inpatient setting, the nurse may be responsible for drug preparation and administration, whereas home care usually requires the nurse to educate the patient or family in self-administration techniques.”^(p.266)

3. *Infusion Nursing: An Evidence-Based Approach*: “The most critical factor in the success of [home parenteral nutrition] may be the adequate education of the patient and caregiver by the clinician. Reduced complications and improved clinical outcomes have both been shown when repeated education of the patient in the home setting is emphasized....In the first phase of education, the patient and caregiver observe the procedure being performed by the nurse. In the second phase, the patient or caregiver performs the procedure under nursing supervision. The goal is for the learner to demonstrate proficiency in each phase of the procedure.”^(pp.345,346)
4. Julie A. Fairman, PhD, RN; John W. Rowe, MD; Susan Hassmiller, PhD; RN; Donna E. Shalala, PhD. *New England Journal of Medicine*. 2011; 364:193-196: “This is a critical time to support an expanded, standardized scope of practice for nurses. Economic forces, demographics, the gap between supply and demand, and the promised expansion of care necessitate changes in primary care delivery....The challenge will be for all health care professionals to embrace these changes and come together to improve US health care.”^(p.196)

The RN’s role in PN administration and patient education is essential to ensuring positive outcomes. INS respectfully requests that Registered Nurses be permitted to add medications to PN before administration by changing the 1987 ruling of the Louisiana State Board of Nursing.

Please do not hesitate to contact me with any questions about this issue.

Sincerely,



Mary Alexander, MA, RN, CRNI®, CAE, FAAN
Chief Executive Officer



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
www.pharmacy.la.gov



August 14, 2013

Agenda Item 12: Announcements

- | | |
|------------------|---|
| Aug. 27 | Public Hearing |
| Aug. 28-29 | Violations Committee Informal Conference |
| Aug. 31 – Sep. 5 | FIP World Congress – Dublin, IE |
| Sep. 2 | Labor Day – Board office closed |
| Sep. 8-11 | NABP-AACP District 6 Annual Meeting – Boulder, CO |
| Sept. 26 | Reciprocity Interviews |
| Sep. 29 – Oct. 2 | MALTAGON Conference – Asheville, NC |
| Oct. 5 | LSHP MidYear Meeting – Shreveport, LA |
| Oct. 9 | Louisiana Pharmacy Congress
PMP Advisory Council |
| Oct. 10 | Drug Policy Board |
| Oct. 21-22 | ASPMP Annual Meeting – Kansas City, MO |
| Oct. 22-25 | NASCSA Annual Meeting – Kansas City, MO |
| Oct. 24 | Reciprocity Interviews |
| Nov. 5 | Finance, Reinstatement, & Impairment Committees |
| Nov. 6 | Reciprocity Committee & Board Meeting |
| Nov. 7 | Administrative Hearing |